Part 4 : Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations by C. Callaway et al.
S84
Introduction
The International Liaison Committee on Resuscitation 
(ILCOR) Advanced Life Support (ALS) Task Force per-
formed detailed systematic reviews based on the recom-
mendations of the Institute of Medicine of the National 
Academies1 and using the methodological approach pro-
posed by the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) Working Group.2 
Questions to be addressed (using the PICO [population, 
intervention, comparator, outcome] format)3 were priori-
tized by ALS Task Force members (by voting). Prioritization 
criteria included awareness of significant new data and new 
controversies or questions about practice. Questions about 
topics no longer relevant to contemporary practice or where 
little new research has occurred were given lower prior-
ity. The ALS Task Force prioritized 42 PICO questions for 
review. With the assistance of information specialists, a 
detailed search for relevant articles was performed in each 
of 3 online databases (PubMed, Embase, and the Cochrane 
Library).
By using detailed inclusion and exclusion criteria, arti-
cles were screened for further evaluation. The reviewers for 
each question created a reconciled risk of bias assessment 
for each of the included studies, using state-of-the-art tools: 
Cochrane for randomized controlled trials (RCTs),4 Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS)-2 
for studies of diagnostic accuracy,5 and GRADE for obser-
vational studies that inform both therapy and prognosis 
questions.6
GRADE evidence profile tables7 were then created to facil-
itate an evaluation of the evidence in support of each of the 
critical and important outcomes. The quality of the evidence 
(or confidence in the estimate of the effect) was categorized as 
high, moderate, low, or very low,8 based on the study method-
ologies and the 5 core GRADE domains of risk of bias, incon-
sistency, indirectness, imprecision, and other considerations 
(including publication bias).9
These evidence profile tables were then used to cre-
ate a written summary of evidence for each outcome (the 
consensus on science statements). Whenever possible, 
consensus-based treatment recommendations were then 
created. These recommendations (designated as strong or 
weak) were accompanied by an overall assessment of the 
evidence and a statement from the task force about the val-
ues, preferences, and task force insights that underlie the 
recommendations. Further details of the methodology that 
underpinned the evidence evaluation process are found in 
“Part 2: Evidence Evaluation and Management of Conflicts 
of Interest.”
The task force preselected and ranked outcome measures 
that were used as consistently as possible for all PICO ques-
tions. Longer-term, patient-centered outcomes were consid-
ered more important than process variables and shorter-term 
outcomes. For most questions, we used the following hier-
archy starting with the most important: long-term survival 
with neurologically favorable survival, long-term survival, 
short-term survival, and process variable. In general, long-
term was defined as from hospital discharge to 180 days or 
longer, and short-term was defined as shorter than to hospital 
discharge. For certain questions (eg, related to defibrillation 
or confirmation of tracheal tube position), process variables 
such as termination of fibrillation and correct tube placement 
were important. A few questions (eg, organ donation) required 
unique outcomes.
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With Treatment Recommendations (CoSTR) statements in this 
Part are organized in the approximate sequence of interventions 
for a patient: defibrillation, airway, oxygenation and ventilation, 
circulatory support, monitoring during cardiopulmonary resus-
citation (CPR), drugs during CPR, and special circumstances. 
We also include statements for postresuscitation care, prognos-
tication of neurologic outcome, and organ donation.
Defibrillation Strategies for Ventricular Fibrillation (VF) 
or Pulseless Ventricular Tachycardia (pVT)
•	 Biphasic waveform (ALS 470)
•	 Pulsed biphasic waveform (ALS 470)
•	 First-shock energy (ALS 470)
•	 Single shock versus stacked shocks (ALS 470)
•	 Fixed versus escalating defibrillation energy levels 
(ALS 470)
•	 Recurrent VF (ALS 470)
Airway, Oxygenation, and Ventilation
•	 Oxygen dose during CPR (ALS 889)
•	 Basic versus advanced airway (ALS 783)
•	 Supraglottic airways (SGAs) versus tracheal intubation 
(ALS 714)
•	 Confirmation of correct tracheal tube placement 
(ALS 469)
•	 Ventilation rate during continuous chest compressions 
(ALS 808)
Circulatory Support During CPR
•	 Impedance threshold device (ITD) (ALS 579)
•	 Mechanical CPR devices (ALS 782)
•	 Extracorporeal CPR (ECPR) versus manual or mechani-
cal CPR (ALS 723)
Physiological Monitoring During CPR
•	 End-tidal carbon dioxide (ETCO2) to predict outcome of 
cardiac arrest (ALS 459)
•	 Monitoring physiological parameters during CPR (ALS 656)
•	 Ultrasound during CPR (ALS 658)
Drugs During CPR
•	 Epinephrine versus placebo (ALS 788)
•	 Epinephrine versus vasopressin (ALS 659)
•	 Epinephrine versus vasopressin in combination with epi-
nephrine (ALS 789)
•	 Standard-dose epinephrine (SDE) versus high-dose epi-
nephrine (HDE) (ALS 778)
•	 Timing of administration of epinephrine (ALS 784)
•	 Steroids for cardiac arrest (ALS 433)
•	 Antiarrhythmic drugs for cardiac arrest (ALS 428)
Cardiac Arrest in Special Circumstances
•	 Cardiac arrest during pregnancy (ALS 436)
•	 Lipid therapy for cardiac arrest (ALS 834)
•	 Opioid toxicity (ALS 441)
•	 Cardiac arrest associated with pulmonary embolism 
(PE) (ALS 435)
•	 Cardiac arrest during coronary catheterization (ALS 479)
Postresuscitation Care
•	 Oxygen dose after return of spontaneous circulation 
(ROSC) in adults (ALS 448)
•	 Postresuscitation ventilation strategy (ALS 571)
•	 Postresuscitation hemodynamic support (ALS 570)
•	 Postresuscitation antiarrhythmic drugs (ALS 493)
•	 Targeted temperature management (ALS 790)
•	 Timing of induced hypothermia (ALS 802)
•	 Prevention of fever after cardiac arrest (ALS 879)
•	 Postresuscitation seizure prophylaxis (ALS 431)
•	 Seizure treatment (ALS 868)
•	 Glucose control after resuscitation (ALS 580)
•	 Prognostication in comatose patients treated with 
hypothermic targeted temperature management (TTM) 
(ALS 450)
•	 Prognostication in the absence of TTM (ALS 713)
•	 Organ donation (ALS 449)
The 2010 CoSTR statements10,11 that have not been 
addressed in 2015 are listed under the relevant section.
Summary of ALS Treatment Recommendations
The systematic reviews showed that the quality of evidence for 
many ALS interventions is low or very low, and this led to pre-
dominantly weak recommendations. For some issues, despite 
a low quality of evidence, the values and preferences of the 
task force led to a strong recommendation. This was espe-
cially so when there was consensus that not doing so could 
lead to harm. In addition, treatment recommendations were 
left unchanged unless there were compelling reasons not to 
do so. The rationale for any change is addressed in the values, 
preferences, and insights that follow treatment recommenda-
tions. The most important developments and recommenda-
tions in ALS since the 2010 ILCOR review are as follows:
Defibrillation strategies for VF or pVT:
•	 There were no major developments since 2010. We sug-
gest if the first shock is not successful and the defibrilla-
tor is capable of delivering shocks of higher energy, it is 
reasonable to increase the energy for subsequent shocks.
Airway, oxygenation, and ventilation:
•	 We suggest using the highest possible inspired oxygen 
concentration during CPR.
•	 There was equipoise between the choice of an advanced 
airway or a bag-mask device for airway management 
during CPR, and the choice between a SGA or tracheal 
tube as the initial advanced airway during CPR.
•	 The role of waveform capnography during ALS was 
emphasized, including its use to confirm and to continu-
ously monitor the position of a tracheal tube during CPR.
Circulatory support during CPR:
•	 We recommend against the routine use of the ITD in 
addition to conventional CPR but could not achieve 
consensus for or against the use of the ITD when 
used together with active compression-decompression 
(ACD) CPR.
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•	 We suggest against the routine use of automated 
mechanical chest compression devices but suggest they 
are a reasonable alternative to use in situations where 
sustained high-quality manual chest compressions are 
impractical or compromise provider safety.
•	 We suggest ECPR is a reasonable rescue therapy for 
select patients with cardiac arrest when initial con-
ventional CPR is failing in settings where this can be 
implemented.
Physiological monitoring during CPR:
•	 Physiological measurement in addition to clinical signs 
and electrocardiographic monitoring has the potential to 
help guide interventions during ALS.
•	 We have not made a recommendation for any particu-
lar physiological measure to guide CPR, because the 
available evidence would make any estimate of effect 
speculative.
•	 We recommend against using ETCO2 cutoff values alone 
as a mortality predictor or for the decision to stop a 
resuscitation attempt.
•	 We suggest that if cardiac ultrasound can be performed 
without interfering with standard advanced cardiovascu-
lar life support (ACLS) protocol, it may be considered 
as an additional diagnostic tool to identify potentially 
reversible causes.
Drugs during CPR:
•	 We suggest SDE (defined as 1 mg) be administered to 
patients in cardiac arrest after considering the observed 
benefit in short-term outcomes (ROSC and admission to 
hospital) and our uncertainty about the benefit or harm 
on survival to discharge and neurologic outcome. Our 
statement is not intended to change current practice until 
there are high-quality data on long-term outcomes.
•	 We suggest the use of amiodarone in adult patients with 
refractory VF/pVT to improve rates of ROSC. Our state-
ment is not intended to change current practice until 
there are high-quality data on long-term outcomes.
Cardiac arrest in special circumstances:
•	 The systematic review found very-low-quality evi-
dence for specific interventions for ALS in the pregnant 
woman. We suggest delivery of the fetus by perimortem 
cesarean delivery for women in cardiac arrest in the sec-
ond half of pregnancy.
•	 The lack of comparative studies led to the task force 
being unable to make any evidence-based treatment 
recommendation about the use of intravenous (IV) lipid 
emulsion to treat toxin-induced cardiac arrest.
•	 We recommend the use of naloxone by IV, intramuscu-
lar, subcutaneous, intraosseous (IO), or intranasal routes 
in respiratory arrest associated with opioid toxicity but 
make no recommendation regarding the modification of 
standard ALS in opioid-induced cardiac arrest.
Postresuscitation care:
•	 We recommend avoiding hypoxia in adults with ROSC 
after cardiac arrest.
•	 We suggest avoiding hyperoxia in adults with ROSC 
after cardiac arrest.
•	 We suggest the use of 100% inspired oxygen until the 
arterial oxygen saturation or the partial pressure of arte-
rial oxygen can be measured reliably in adults with 
ROSC after cardiac arrest.
•	 We suggest maintaining Paco2 within a normal physi-
ological range as part of a post-ROSC bundle of care.
•	 We suggest hemodynamic goals (eg, mean arterial pres-
sure [MAP], systolic blood pressure [SBP]) be consid-
ered during postresuscitation care and as part of any 
bundle of postresuscitation interventions.
•	 We recommend selecting and maintaining a constant 
target temperature between 32°C and 36°C for those 
patients in whom temperature control is used.
•	 We recommend TTM as opposed to no TTM for adults 
with out-of-hospital cardiac arrest (OHCA) with an initial 
shockable rhythm who remain unresponsive after ROSC.
•	 We suggest TTM as opposed to no TTM for adults with 
OHCA with an initial nonshockable rhythm who remain 
unresponsive after ROSC.
•	 We suggest TTM as opposed to no TTM for adults with 
in-hospital cardiac arrest (IHCA) with any initial rhythm 
who remain unresponsive after ROSC.
•	 We suggest that if TTM is used, duration should be at 
least 24 hours.
•	 We recommend against routine use of prehospital cool-
ing with rapid infusion of large volumes of cold IV fluid 
immediately after ROSC.
•	 We suggest prevention and treatment of fever in persis-
tently comatose adults after completion of TTM between 
32°C and 36°C.
•	 We suggest against routine seizure prophylaxis in post–
cardiac arrest patients.
•	 We recommend the treatment of seizures in post–cardiac 
arrest patients.
•	 We suggest no modification of standard glucose man-
agement protocols for adults with ROSC after cardiac 
arrest.
•	 Comatose patients treated with TTM:
 ◦ We suggest against the use of clinical criteria alone 
before 72 hours after ROSC to estimate prognosis.
 ◦ We suggest prolonging the observation of clinical 
signs when interference from residual sedation or 
paralysis is suspected, so that the possibility of incor-
rectly predicting poor outcome is minimized.
 ◦ We recommend that the earliest time to prognosticate 
a poor neurologic outcome is 72 hours after ROSC, 
and should be extended longer if the residual effect 
of sedation and/or paralysis confounds the clinical 
examination.
 ◦ We suggest that multiple modalities of testing (clini-
cal exam, neurophysiological measures, imaging, or 
blood markers) be used to estimate prognosis instead 
of relying on single tests or findings.
•	 We recommend that all patients who have restoration of 
circulation after CPR and who subsequently progress to 
death be evaluated for organ donation.
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Defibrillation Strategies for VF or pVT
The task force restricted its review to new studies since the 
2010 CoSTR12,13 and topics not reviewed in 2010. There are 
no major differences between the recommendations made in 
2015 and those made in 2010. The PICO questions have been 
grouped into (1) waveforms, (2) first-shock energy, (3) single 
shock versus 3 shocks, (4) fixed versus escalating energy lev-
els, and (5) refibrillation. In reviewing these, shock success is 
usually defined as termination of VF 5 seconds after the shock.
Consensus on science and treatment recommendations 
for the use of automated external defibrillators can be found 
in “Part 3: Adult Basic Life Support and Automated External 
Defibrillation,” and for infants or children requiring defibril-
lation in “Part 6: Pediatric Basic Life Support and Pediatric 
Advanced Life Support.”
Biphasic Waveform (ALS 470)
Among adults who are in VF or pVT in any setting (P), does 
any specific defibrillation strategy, such as biphasic waveform 
(I), compared with standard management (or other defibril-
lation strategy), such as monophasic waveform (C), change 
survival with favorable neurologic/functional outcome at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; survival 
only at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC; termination of arrhythmia (O)?
Introduction
All newly manufactured defibrillators currently deliver shocks 
using biphasic waveforms. Although it has not been shown 
conclusively in randomized clinical studies that biphasic 
defibrillators save more lives than monophasic defibrillators, 
biphasic defibrillators achieve higher first-shock success rates 
at lower energy levels and appear to cause less postshock 
myocardial dysfunction.12,13
Consensus on Science
No new randomized trials of biphasic waveforms since 2010 
were identified.
Treatment Recommendation
We recommend that a biphasic waveform (biphasic truncated 
exponential [BTE] or rectilinear-biphasic [RLB]) is used 
for both atrial and ventricular arrhythmias in preference to a 
monophasic waveform (strong recommendation, very-low-
quality evidence). In the absence of biphasic defibrillators, 
monophasic defibrillators are acceptable.
Values, Preferences, and Task Force Insights
In making this strong recommendation, we place a high value 
on the reported higher first-shock success rate for termina-
tion of fibrillation with a biphasic waveform, the potential for 
less postshock myocardial dysfunction, and the existing 2010 
CoSTR.12,13 The task force acknowledges that many emer-
gency medical services (EMS) systems and hospitals around 
the world continue to use older monophasic devices.
Pulsed Biphasic Waveform (ALS 470)
Among adults who are in VF or pVT in any setting (P), does 
any specific defibrillation strategy, such as pulsed bipha-
sic waveform (I), compared with standard management (or 
other defibrillation strategy) (C), change survival with favor-
able neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 30 
days, 60 days, 180 days, and/or 1 year; ROSC; termination of 
arrhythmia (O)?
Introduction
The pulsed biphasic waveform that is used in clinical practice 
had not previously been reviewed in 2010. The single pub-
lished study14 of this waveform used a non–impedance com-
pensated waveform (ie, the current delivered is not adjusted 
for the impedance of the chest), whereas the waveform in 
clinical use is an impedance-compensated waveform (ie, the 
current delivered is adjusted for the impedance of the chest).
Consensus on Science
For the critical outcome of survival to hospital discharge, 
very-low-quality evidence (downgraded for very serious risk 
of bias and serious indirectness) from 1 cohort study (ie, no 
control group)14 with a total of 104 patients that used a 130 
J-130 J-180 J pulsed biphasic waveform protocol documented 
a survival rate of 9.8%. This compares with a weighted aver-
age BTE survival rate of 33.1% at 150 to 200 J.14
For the important outcome of termination of fibrillation, 
the same very-low-quality evidence (downgraded for very 
serious risk of bias and serious indirectness) from 1 cohort 
study14 with a total of 104 patients documented first-shock 
termination rates at 130 J of 90.4% with a pulsed biphasic 
waveform, comparable with BTE waveforms (weighted aver-
age 91.8%) at 150 to 200 J.14
Treatment Recommendation
We recommend following the manufacturer’s instructions for 
first and subsequent shock energy levels for the pulsed bipha-
sic waveform (strong recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this strong recommendation, we have placed a high 
value on following the manufacturer’s guidance in the absence 
of high-quality data to suggest otherwise. The available very-
low-quality data showing the efficacy of a non–impedance 
compensated pulsed biphasic waveform do not enable direct 
comparison with other biphasic waveforms. In addition, no 
clinical studies attest to the efficacy of this waveform in its 
current impedance-compensated form.
First-Shock Energy (ALS 470)
Among adults who are in VF or pVT in any setting (P), does 
any specific defibrillation strategy, such as specific first-shock 
energy level (I), compared with standard management (or 
other defibrillation strategy), such as a different first-shock 
energy level (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 days, 180 
days, and/or 1 year; ROSC; termination of arrhythmia (O)?
Introduction
In 2010, it was concluded that it was reasonable to start at a 
selected energy level of 150 to 200 J for a BTE waveform, and 
no lower than 120 J for an RLB waveform for defibrillation of 
 by guest on N
ovem
ber 29, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
S88  Circulation  October 20, 2015
VF/pVT cardiac arrest, acknowledging that the evidence was 
limited.12,13
Consensus on Science
For the important outcome of termination of VF/pVT, low-
quality evidence (downgraded for imprecision and risk of 
bias, respectively) from a post hoc report from an RCT and 
a cohort study showed a first-shock success rate of 73 of 86 
(85%) and 79 of 90 (87.8%), respectively, when using a 120 J 
initial shock with an RLB waveform.15,16
Treatment Recommendations
We recommend an initial biphasic shock energy of 150 J or 
greater for BTE waveforms, and 120 J or greater for RLB 
waveforms (strong recommendation, very-low-quality evi-
dence). If a monophasic defibrillator is used, we recommend 
an initial monophasic shock energy of 360 J (strong recom-
mendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making these strong recommendations, the working group 
was keen to acknowledge manufacturer’s instructions and rec-
ognize that evidence for the optimal first-shock energy level 
was lacking. We also considered that although monophasic 
defibrillators are no longer manufactured, they are still used 
in many countries.
Single Shock Versus Stacked Shocks (ALS 470)
Among adults who are in VF or pVT in any setting (P), does 
any specific defibrillation strategy, such as a single shock (I), 
compared with standard management (or other defibrilla-
tion strategy), such as 3 stacked shocks (C), change survival 
with favorable neurologic/functional outcome at discharge, 
30 days, 60 days, 180 days, and/or 1 year; survival only at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; ROSC; 
termination of arrhythmia (O)?
Introduction
In 2010, it was recommended that when defibrillation was 
required, a single shock should be provided with immediate 
resumption of chest compressions after the shock.12,13 This 
recommendation was made for 2 reasons: (1) in an attempt to 
minimize perishock interruptions to chest compressions, and 
(2) because it was thought that with the greater efficacy of 
biphasic shocks, if a biphasic shock failed to defibrillate, a fur-
ther period of chest compressions could be beneficial. It was 
acknowledged that there was no clinical evidence to support 
improved outcomes from this strategy.
Consensus on Science
For the critical outcome of survival to 1 year, we have identi-
fied low-quality evidence (downgraded for serious risk of bias 
and serious indirectness) from 1 RCT enrolling 845 OHCA 
patients showing no difference in single versus 3 stacked 
shocks (odds ratio [OR], 1.64; 95% confidence interval [CI], 
0.53–5.06).17
For the critical outcome of survival to hospital dis-
charge, we have identified low-quality evidence (downgraded 
for serious risk of bias and serious indirectness) from 1 RCT 
enrolling 845 OHCA patients showing no difference in single 
versus 3 stacked shocks (OR, 1.29; 95% CI, 0.85–1.96).17
For the critical outcome of survival to hospital 
 admission, we have identified very-low-quality evidence 
(downgraded for serious risk of bias and serious indirectness) 
from 1 RCT enrolling 845 OHCA patients showing no dif-
ference in single versus 3 stacked shocks (OR, 1.02; 95% CI, 
0.78–1.34).17
For the critical outcome of ROSC, we have identified low-
quality evidence (downgraded for serious risk of bias and seri-
ous indirectness) from 1 RCT enrolling 845 OHCA patients 
showing no difference in single versus 3 stacked shocks (OR, 
0.94; 95% CI, 0.72–1.23).17
For the important outcome of recurrence of VF (refibril-
lation), we have identified low-quality evidence (downgraded 
for serious risk of bias, serious indirectness, and serious 
imprecision) from 1 RCT enrolling 136 OHCA patients show-
ing no difference in single versus 3 stacked shocks (OR, 1.00; 
95% CI, 0.47–2.13).18
Treatment Recommendation
We recommend a single-shock strategy when defibrillation is 
required (strong recommendation, low-quality evidence).
Values, Preferences, and Task Force Insights
In making this strong recommendation, the task force has placed 
a greater value on not changing current practice and minimiz-
ing interruptions in chest compressions whilst acknowledg-
ing that studies since 2010 have not shown that any specific 
shock strategy is of benefit for any survival end point. There is 
no conclusive evidence that a single-shock strategy is of ben-
efit for ROSC or recurrence of VF compared with 3 stacked 
shocks, but in view of the evidence suggesting that outcome is 
improved by minimizing interruptions to chest compressions, 
we continue to recommend single shocks. The task force is 
aware that there are some circumstances (eg, witnessed, moni-
tored VF cardiac arrest with defibrillator immediately avail-
able) when 3 rapid stacked shocks could be considered.
Fixed Versus Escalating Defibrillation Energy 
Levels (ALS 470)
Among adults who are in VF or pVT in any setting (P), does 
any specific defibrillation strategy, such as fixed shock energy 
level (I), compared with standard management (or other defi-
brillation strategy), such as escalating shock energy level (C), 
change survival with favorable neurologic/functional outcome 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; sur-
vival only at discharge, 30 days, 60 days, 180 days, and/or 
1 year; ROSC; termination of arrhythmia (O)?
Introduction
In 2010, we recommended that for second and subsequent 
biphasic shocks, the same initial energy level was acceptable, 
but that it was reasonable to increase the energy level when 
possible (ie, with manual defibrillators).12,13
Consensus on Science
For the critical outcome of survival with favorable neuro-
logic outcome at hospital discharge, we identified very-low-
quality evidence (downgraded for serious risk of bias, serious 
imprecision, and serious indirectness) from 1 RCT enrolling 
221 OHCA patients showing no benefit of one strategy over 
the other (OR, 0.78; 95% CI, 0.34–1.78).19
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For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded 
for serious risk of bias, serious imprecision, and serious indi-
rectness) from 1 RCT enrolling 221 OHCA patients showing 
no benefit of one strategy over the other (OR, 1.06; 95% CI, 
0.52–2.16).19
For the critical outcome of ROSC, we have identified 
very-low-quality evidence (downgraded for serious risk of 
bias, serious imprecision, and serious indirectness) from 1 
RCT enrolling 221 OHCA patients showing no benefit of one 
strategy over the other (OR, 1.095; 95% CI, 0.65–1.86).19
Treatment Recommendation
We suggest if the first shock is not successful and the defi-
brillator is capable of delivering shocks of higher energy, it is 
reasonable to increase the energy for subsequent shocks (weak 
recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we have considered that an 
escalating shock energy may prevent the risk of refibrillation 
(see ALS 470). We also consider this to be in line with current 
practices where rescuers will escalate shock energy if initial 
defibrillation attempts fail and the defibrillator is capable of 
delivering a higher shock energy.
Recurrent VF (Refibrillation) (ALS 470)
Among adults who are in VF or pVT in any setting (P), does 
any specific defibrillation strategy (I), compared with standard 
management (or other defibrillation strategy) (C), improve 
termination of refibrillation (O)?
Introduction
Refibrillation is common and occurs in the majority of patients 
after initial first-shock termination of VF.20 Refibrillation was 
not specifically addressed in 2010 guidelines. Distinct from 
refractory VF, defined as fibrillation that persists after 1 or 
more shocks, recurrence of fibrillation is usually defined as 
recurrence of VF during a documented cardiac arrest, occur-
ring after initial termination of VF while the patient remains 
under the care of the same providers (usually out-of-hospital).
Consensus on Science
For the important outcome of termination of refibrillation, 
low-quality evidence (downgraded for serious risk of bias) 
from 2 observational studies16,21 with a total of 191 cases of 
initial fibrillation showed termination rates of subsequent 
refibrillation were unchanged when using fixed 120 or 150 J 
shocks, respectively, and another observational study20 (down-
graded for confounding factors) with a total of 467 cases of 
initial fibrillation showed termination rates of refibrilla-
tion declined when using repeated 200 J shocks, unless an 
increased energy level (360 J) was selected.
Treatment Recommendation
We suggest an escalating defibrillation energy protocol to 
prevent refibrillation (weak recommendation, low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this weak recommendation, we considered the 
lack of studies showing myocardial injury from biphasic 
waveforms, making it reasonable to consider increasing defi-
brillation energy levels when delivering shocks for refibril-
lation if the energy dose delivered by the defibrillator can be 
increased. It is unclear from current studies whether repeated 
episodes of VF are more resistant to defibrillation and require a 
higher energy level or whether a fixed energy level is adequate.
Defibrillation Knowledge Gaps
•	 Considering that defibrillation is one of the few inter-
ventions that improves outcome from cardiac arrest, 
high-quality studies of optimal defibrillation strategies 
are sparse.
•	 The dose response curves for defibrillation of shockable 
rhythms is unknown and the initial shock energy, subse-
quent shock energies, and maximum shock energies for 
each waveform are unknown. In particular, the strategy 
of delivering shock energy at maximum defibrillation 
output to improve current defibrillation efficacy rates 
remains unanswered.
•	 Studies of optimal defibrillation energies for refibrilla-
tion are contradictory, and it remains unclear whether 
refibrillation is a different form of fibrillation that 
requires the same or higher energy levels for successful 
termination of fibrillation.
•	 The selected energy is a poor comparator for assess-
ing different waveforms, as impedance compensation 
and subtleties in waveform shape result in a different 
transmyocardial current between devices for any given 
selected energy. The optimal energy levels may ulti-
mately vary between different manufacturers and associ-
ated waveforms.
•	 We would encourage manufacturers to undertake high-
quality clinical trials to support their defibrillation 
strategy recommendations. Caution is also urged in 
attributing the outcomes observed to any one portion of 
the elements of bundled care.
•	 The task force did not address the topic of hands-on defi-
brillation strategies, its efficacy, and safety, although we 
realize it is a topic of interest for future studies.
2010 CoSTR Defibrillation Topics Not  
Reviewed in 2015
•	 CPR before defibrillation
•	 Self-adhesive defibrillation pads compared with paddles
•	 Placement of paddles/pads
•	 Size of paddles/pads
•	 Composition of conductive material
•	 Biphasic compared with monophasic defibrillation 
waveform
•	 Multiphasic compared with biphasic defibrillation 
waveform
•	 Waveforms, energy levels, and myocardial damage
•	 Shock using manual versus semiautomatic mode
•	 Cardioversion strategy in atrial fibrillation
•	 Pacing (eg, transcutaneous, transvenous, needle, and fist)
•	 Implantable cardioverter-defibrillator or pacemaker
•	 Predicting success of defibrillation and outcome (VF 
waveform analysis)
 by guest on N
ovem
ber 29, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
S90  Circulation  October 20, 2015
•	 Defibrillation in the immediate vicinity of supplemen-
tary oxygen
•	 Algorithm for transition from shockable to nonshock-
able rhythm
Airway, Oxygenation, and Ventilation
The use of supplementary oxygen (when it is available) dur-
ing CPR is accepted practice, but in other circumstances (eg, 
acute myocardial infarction), there is increasing evidence that 
administration of high-concentration oxygen may be harmful.
The optimal strategy for managing the airway has yet to be 
determined, but several observational studies have challenged 
the premise that tracheal intubation improves outcomes. 
Options for airway management can be categorized broadly 
into bag-mask ventilation with simple airway adjuncts, SGAs, 
and tracheal intubation. In this section, we present the evi-
dence for the use of oxygen and airway devices during CPR, 
for how to confirm correct tracheal tube placement, and for 
ventilation rate once an advanced airway device (either a tra-
cheal tube or SGA) has been inserted.
Oxygen Dose During CPR (ALS 889)
In adults with cardiac arrest in any setting (P), does admin-
istering a maximal oxygen concentration (eg, 100% by face 
mask or closed circuit) (I), compared with no supplementary 
oxygen (eg, 21%) or a reduced oxygen concentration (eg, 
40%–50%) (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Introduction
It has generally been considered appropriate to administer 
100% oxygen, whenever available, during cardiac arrest; how-
ever, in some other medical emergencies, the use of 100% is 
now being challenged.
Consensus on Science
There are no adult human studies that directly compare 
maximal inspired oxygen with any other inspired oxygen 
concentration.
For the critical outcome of survival to hospital discharge 
with favorable neurologic outcome (Cerebral Performance 
Category [CPC] 1 or 2), we identified very-low-quality evi-
dence (downgraded for very serious risk of bias, very serious 
indirectness, and serious imprecision) from 1 observational 
study22 enrolling 145 OHCA patients who had a Pao2 mea-
sured during CPR that showed no difference between an 
intermediate Pao2 and low Pao2 (11/83 [13.3%] versus 1/32 
[3.1%]; relative risk [RR], 4.2; 95% CI, 0.57–31.52; P=0.16), 
or between a high Pao2 and low Pao2 (7/30 [23.3%] versus 
1/32 [3.1%]; RR, 7.45; 95% CI, 0.98–57.15; P=0.053).
For the important outcome of ROSC, we identified very-
low-quality evidence (downgraded for very serious risk of 
bias, very serious indirectness, and serious imprecision) 
from 1 observational study22 enrolling 145 OHCA patients 
who had a Pao2 measured during CPR that showed improved 
ROSC in those with a higher Pao2: intermediate Pao2 versus 
low Pao2 (47/83 [56.6%] versus 7/32 [21.9%]; RR, 2.59; 95% 
CI, 1.31–5.12; P=0.006); high Pao2 versus low Pao2 (25/30 
[83.3%] versus 7/32 [21.9%]; RR, 3.81; 95% CI, 1.94–7.48; 
P=0.0001); high Pao2 versus intermediate Pao2 (25/30 [83.3%] 
versus 47/83 [56.6%]; RR, 1.47; 95% CI, 1.15–1.88; P=0.002).
In the single identified study,22 all patients had tracheal 
intubation and received 100% inspired oxygen during CPR. 
The worse outcomes associated with a low Pao2 during CPR 
could be an indication of illness severity.
Treatment Recommendation
We suggest the use of the highest possible inspired oxygen 
concentration during CPR (weak recommendation, very-low-
quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we have considered the lim-
ited available evidence and the need to correct tissue hypoxia 
during CPR, and see no reason to change the current treatment 
recommendation.
Knowledge Gaps
•	 The optimal arterial or tissue oxygen targets during CPR 
are unknown.
•	 A method of reliably monitoring oxygen targets during 
CPR has not been established.
•	 The feasibility of controlling inspired oxygen concentra-
tion during CPR remains unclear.
•	 Prospective clinical trials may be warranted to explore 
different inspired oxygen concentrations during CPR.
•	 The role and feasibility of alternatives to oxygen/air 
mixtures during CPR are unknown.
Basic Versus Advanced Airway (ALS 783)
Among adults who are in cardiac arrest in any setting (P), does 
insertion of an advanced airway (tracheal tube or SGA) (I), 
compared with basic airway (bag-mask device with or with-
out oropharyngeal airway) (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 days, 
180 days, and/or 1 year; survival only at discharge, 30 days, 
60 days, 180 days, and/or 1 year; ROSC; CPR parameters; 
development of aspiration pneumonia (O)?
Introduction
The optimal approach to managing the airway during cardiac 
arrest has been unclear, and several recent observational stud-
ies have challenged the assumption that advanced airways are 
necessarily superior to basic airway techniques.
Consensus on Science
All Advanced Airways (I) Versus Bag-Mask Device (C)
For the critical outcome of 1-year survival, we have identi-
fied very-low-quality evidence (downgraded for very serious 
risk of bias, indirectness and imprecision, and serious incon-
sistency) from 1 observational study of 1278 OHCAs show-
ing a similar unadjusted rate of survival with insertion of an 
advanced airway (tracheal tube, esophageal obturator airway 
[EOA] or laryngeal mask airway [LMA]) compared with a 
bag-mask device (3.7% versus 5.6%; OR, 0.65; 95% CI, 
0.4–1.1).23
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For the critical outcome of favorable neurologic survival 
at 1 month, we have identified very-low-quality evidence 
(downgraded for very serious risk of bias and indirectness, 
and serious inconsistency) from 1 observational study of 
648 549 OHCAs showing a lower unadjusted rate of survival 
with insertion of an advanced airway (tracheal tube, LMA, 
laryngeal tube, or Combitube) compared with management 
with a bag-mask device (1.1% versus 2.9%; OR, 0.38; 95% 
CI, 0.36–0.39).24 When adjusted for all known variables, the 
OR was 0.32 (95% CI, 0.30–0.33).
For the critical outcome of favorable neurologic survival 
to hospital discharge, we have identified very-low-quality 
evidence (downgraded for very serious risk of bias and indi-
rectness, and serious inconsistency) from 1 observational 
study of 10 691 OHCAs showing a lower unadjusted rate of 
survival with insertion of an advanced airway (tracheal tube, 
LMA, laryngeal tube, or Combitube) compared with manage-
ment with a bag-mask device (5.3% versus 18.6%; OR, 0.25; 
95% CI, 0.2–0.3).25 In an analysis of 3398 propensity-matched 
patients from the same study, the OR for favorable neuro-
logic survival at hospital discharge (bag-mask device versus 
advanced airway) adjusted for all variables was 4.19 (95% CI, 
3.09–5.70).
For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded for 
very serious risk of bias and indirectness, and serious incon-
sistency) from 2 observational studies: 1 of 10 691 OHCAs 
showed a lower unadjusted rate of survival with insertion of 
an advanced airway (tracheal tube or LMA) compared with 
a bag-mask device (7.7% versus 21.9%; OR, 0.30; 95% CI, 
0.3–0.3)25; 1 of 5278 OHCAs showed a similar unadjusted 
rate of survival with insertion of an advanced airway (tracheal 
tube or LMA) compared with a bag-mask device (6.6% versus 
7.0%; OR, 0.94; 95% CI, 0.7–1.3).26
Tracheal Intubation (I) Versus Bag-Mask Device (C)
For the critical outcome of favorable neurologic survival 
at 1 month, we have identified very-low-quality evidence 
(downgraded for very serious risk of bias and indirectness, and 
serious inconsistency) from 1 observational study of 409 809 
OHCAs showing a lower unadjusted rate of survival with 
tracheal intubation compared with a bag-mask device (1.0% 
versus 2.9%; OR, 0.35; 95% CI, 0.31–0.38).24 In an analysis 
of 357 228 propensity-matched patients from the same study, 
the OR for favorable neurologic survival at 1 month (tracheal 
intubation versus bag-mask device) adjusted for all variables 
was 0.42 (95% CI, 0.34–0.53).
For the critical outcome of survival at 1 month, we have 
identified very-low-quality evidence (downgraded for very 
serious risk of bias and indirectness, and serious inconsis-
tency) from 2 observational studies. One of 409 809 OHCAs 
showed a lower unadjusted rate of survival with tracheal intu-
bation compared with a bag-mask device (4.2% versus 5.3%; 
OR, 0.77; 95% CI, 0.74–0.81).24 In an analysis of 357 228 
propensity-matched patients from the same study, the OR 
for survival at 1 month (tracheal intubation versus bag-mask 
device) adjusted for all variables was 0.88 (95% CI, 0.79–
0.98). Another study of 10 783 OHCAs also showed a lower 
unadjusted rate of survival with tracheal intubation compared 
with a bag-mask device (3.6% versus 6.4%; OR, 0.54; 95% 
CI, 0.5–0.7).27
For the critical outcome of favorable neurologic survival 
to hospital discharge, we have identified very-low-quality 
evidence (downgraded for very serious risk of bias and indi-
rectness, and serious inconsistency) from 1 observational 
study of 7520 OHCAs showing a lower unadjusted rate of 
survival with tracheal intubation compared with a bag-mask 
device (5.4% versus 18.6%; OR, 0.25; 95% CI 0.2–0.3).25
For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded 
for very serious risk of bias, indirectness, and imprecision, 
and serious inconsistency) from 6 observational studies. One 
observational study of 7520 OHCAs showed a lower unad-
justed rate of survival with tracheal intubation compared with 
a bag-mask device (8.3% versus 21.9%; OR, 0.25; 95% CI, 
0.2–0.3).25 One study of 4887 OHCAs showed a similar unad-
justed rate of survival with insertion of a tracheal tube com-
pared with a bag-mask device (8.0% versus 7.0%; OR, 1.16; 
95% CI, 0.7–1.9).26 Among 496 propensity-matched OHCAs 
in the same study, the OR for survival to discharge (tracheal 
intubation versus bag-mask device) was 1.44 (95% CI, 0.66–
3.15).26 One observational study of 1158 OHCAs showed a 
lower unadjusted rate of survival with tracheal intubation com-
pared with a bag-mask device (3.7% versus 10.8%; OR, 0.32; 
95% CI, 0.2–0.6).28 One observational study of 8651 OHCAs 
showed a lower unadjusted rate of survival with tracheal intu-
bation compared with a bag-mask device (3.7% versus 9.1%; 
OR, 0.41; 95% CI, 0.3–0.5).29 One observational study of 
1142 OHCAs showed a lower unadjusted rate of survival with 
tracheal intubation compared with a bag-mask device (6.3% 
versus 28.6%; OR, 0.17; 95% CI, 0.1–0.2).30
Supraglottic Airways (I) Versus Bag-Mask Device (C)
For the critical outcome of favorable neurologic survival at 
1 month, we have identified very-low-quality evidence (down-
graded for very serious risk of bias and indirectness, and serious 
inconsistency) from 1 observational study of 607 387 OHCAs 
showing a lower unadjusted rate of survival with insertion 
of an SGA (LMA, laryngeal tube, or Combitube) compared 
with a bag-mask device (1.1% versus 2.9%; OR, 0.38; 95% 
CI, 0.37–0.40).24 In an analysis of 357 228 propensity-matched 
patients from the same study, the OR for favorable neurologic 
survival at 1 month (SGA versus bag-mask device) adjusted 
for all variables was 0.36 (95% CI, 0.33–0.40).
For the critical outcome of favorable neurologic survival 
to hospital discharge, we have identified very-low-quality 
evidence (downgraded for very serious risk of bias and indi-
rectness, and serious inconsistency) from 1 observational 
study of 5039 OHCAs showing a lower unadjusted rate of sur-
vival with an SGA compared with a bag-mask device (5.2% 
versus 18.6%; OR, 0.24; 95% CI, 0.2–0.3).25
For the critical outcome of survival to hospital dis-
charge, we have identified very-low-quality evidence 
(downgraded for very serious risk of bias, indirectness, and 
imprecision, and serious inconsistency) from 2 observational 
studies. One observational study of 5039 OHCAs showed a 
lower unadjusted rate of survival with an SGA compared with 
a bag-mask device (6.7% versus 21.9%; OR, 0.26; 95% CI, 
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0.2–0.3).25 Another study of 262 OHCAs also showed a lower 
unadjusted rate of survival with an SGA compared with a bag-
mask device (0.0% versus 10.7%).28
Laryngeal Mask Airway (I) Versus Bag-Mask Device (C)
For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded for 
very serious risk of bias, indirectness, and imprecision, and seri-
ous inconsistency) from 1 observational study of 5028 OHCAs 
showing a similar unadjusted rate of survival with insertion of 
an LMA compared with a bag-mask device (5.6% versus 7.0%; 
OR, 0.80; 95% CI, 0.5–1.2).26 Among 772 propensity-matched 
OHCAs in the same study, the OR for survival to discharge 
(LMA versus bag-mask device) was 0.45 (95% CI, 0.25–0.82).26
Treatment Recommendation
We suggest using either an advanced airway or a bag-mask 
device for airway management during CPR (weak recommenda-
tion, very-low-quality evidence) for cardiac arrest in any setting.
Values, Preferences, and Task Force Insights
In the absence of sufficient data obtained from studies of IHCA, 
it is necessary to extrapolate from data derived from OHCA.
The type of airway used may depend on the skills and 
training of the healthcare provider. Tracheal intubation may 
result in unrecognized esophageal intubation and increased 
hands-off time in comparison with insertion of an SGA or a 
bag-mask device. Both a bag-mask device and an advanced 
airway are frequently used in the same patient as part of a 
stepwise approach to airway management, but this has not 
been formally assessed.
Knowledge Gaps
•	 There are no RCTs of initial airway management during 
cardiac arrest.
•	 The type and duration of training required for each 
device is unknown.
•	 During cardiac arrest, is a stepwise approach to airway 
management commonly used? It is not clear how this 
can be studied rigorously.
SGAs Versus Tracheal Intubation (ALS 714)
Among adults who are in cardiac arrest in any setting (P), 
does SGA insertion as first advanced airway (I), compared 
with insertion of a tracheal tube as first advanced airway (C), 
change survival with favorable neurologic/functional outcome 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; sur-
vival only at discharge, 30 days, 60 days, 180 days, and/or 
1 year; ROSC; CPR parameters; development of aspiration 
pneumonia (O)?
Introduction
SGAs are generally considered easier to insert than tracheal 
tubes are, and their use in cardiac arrest has been increasing.
Consensus on Science
SGAs (Combitube, LMA, Laryngeal Tube) Versus Tracheal 
Intubation
For the critical outcome of favorable neurologic survival, 
we have identified very-low-quality evidence (downgraded 
for very serious concerns about risk of bias, inconsistency, 
and indirectness) from 1 observational study of 5377 OHCAs 
showing no difference between tracheal intubation and inser-
tion of a SGA (adjusted OR, 0.71; 95% CI, 0.39–1.30),31 from 
1 observational study of 281 522 OHCAs showing higher rates 
of favorable neurologic outcome between insertion of an SGA 
and tracheal intubation (OR, 1.11; 95% CI, 1.0–1.2),24 and 
from 2 studies showing higher rates of favorable neurologic 
outcome between tracheal intubation and insertion of an SGA 
(8701 OHCAs: adjusted OR, 1.44; 95% CI, 1.10–1.8825 and 
10 455 OHCAs: adjusted OR, 1.40; 95% CI, 1.04–1.89).32
SGAs (EOA and LMA) Versus Tracheal Intubation
For the critical outcome of neurologically favorable 1-month 
survival, we have identified very-low-quality evidence (down-
graded for very serious risk of bias, inconsistency, indirect-
ness, and imprecision) from 1 observational study of 138 248 
OHCAs that showed higher rates of neurologically favorable 
1-month survival with tracheal intubation compared with 
insertion of an EOA or LMA (OR, 0.89; 95% CI, 0.8–1.0).33
For the critical outcome of 1-month survival, we have 
identified very-low-quality evidence (downgraded for very 
serious concerns about risk of bias, inconsistency, indirect-
ness, and imprecision) from 1 observational study that showed 
no difference in 1-month survival between tracheal intubation 
and insertion of an EOA of an LMA (OR, 0.75; 95% CI, 0.3–
1.9)23 and very-low-quality evidence (downgraded for very 
serious risk of bias, inconsistency, indirectness, and impre-
cision) from another observation study that showed higher 
1-month survival with tracheal intubation compared with 
insertion of an EOA of an LMA (OR, 1.03; 95% CI, 0.9–1.1).33
LMA (I) Versus Tracheal Intubation (C)
For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded 
for very serious risk of bias, inconsistency, indirectness, and 
imprecision) from 1 observational study of 641 OHCAs that 
showed lower rates of survival to hospital discharge with 
insertion of an LMA compared with tracheal tube (OR, 0.69; 
95% CI, 0.4–1.3).26
Esophageal Gastric Tube Airway (I) Versus Tracheal 
Intubation (C)
For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded for 
very serious risk of bias and imprecision) from 1 RCT enroll-
ing 175 OHCAs showing no difference between esophageal 
gastric tube airway and tracheal intubation (OR, 1.19; 95% 
CI, 0.5–3.0).34
Combitube (I) Versus Tracheal Intubation (C)
For the critical outcome of survival to hospital discharge, 
we have identified very-low-quality evidence (downgraded 
for very serious risk of bias, inconsistency, indirectness, and 
imprecision) from 1 RCT enrolling 173 OHCAs that showed 
no difference between Combitube and tracheal intubation 
(OR, 2.38; 95% CI, 0.5–12.1)35 and very-low-quality evidence 
from 1 observational study of 5822 OHCAs that showed no 
difference between tracheal intubation by paramedics, and 
Combitube insertion by emergency medical technicians 
(adjusted OR, 1.02; 95% CI, 0.79–1.30).36
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Treatment Recommendation
We suggest using either an SGA or tracheal tube as the initial 
advanced airway during CPR (weak recommendation, very-
low-quality evidence) for cardiac arrest in any setting.
Values, Preferences, and Task Force Insights
In the absence of sufficient data obtained from studies of 
IHCA, it is necessary to extrapolate from data derived from 
OHCA.
The type of airway used may depend on the skills and 
training of the healthcare provider. Tracheal intubation 
requires considerably more training and practice. Tracheal 
intubation may result in unrecognized esophageal intubation 
and increased hands-off time in comparison with insertion of 
an SGA. Both an SGA and tracheal tube are frequently used 
in the same patients as part of a stepwise approach to airway 
management, but this has not been formally assessed.
Knowledge Gaps
•	 There are no RCTs of initial airway management during 
cardiac arrest.
•	 The type and duration of training required for each 
device is unknown.
•	 During the management of cardiac arrest, is a stepwise 
approach to airway management commonly used? It is 
not clear how this can be studied rigorously.
Confirmation of Correct Tracheal Tube Placement 
(ALS 469)
Among adults who are in cardiac arrest, needing/with an 
advanced airway during CPR in any setting (P), does use of 
devices (eg, waveform capnography, CO2 detection device, 
esophageal detector device, or tracheal ultrasound) (I), com-
pared with not using devices (C), change placement of the tra-
cheal tube in the trachea and above the carina, or success of 
intubation (O)?
Introduction
Unrecognized esophageal intubation is a serious complica-
tion of attempted tracheal intubation during CPR. There are 
several potential methods for confirming correct placement of 
a tracheal tube: capnography and detection of CO2, use of an 
esophageal detection device, and tracheal ultrasound.
Consensus on Science
Waveform Capnography
For the important outcome of detection of correct placement 
of a tracheal tube during CPR, we identified very-low-qual-
ity evidence (downgraded for risk of bias and indirectness) 
from 1 observational study37 showing that the use of waveform 
capnography compared with no waveform capnography in 
153 critically ill patients (51 with cardiac arrest) decreased the 
occurrence of unrecognized esophageal intubation on hospital 
arrival from 23% to 0% (OR, 29; 95% CI, 4–122).
For the important outcome of detection of correct place-
ment of a tracheal tube during CPR, we identified low-
quality evidence (downgraded for serious risk of bias and 
imprecision) from 3 observational studies38–40 with 401 patients 
and 1 randomized study41 including 48 patients that showed 
that the specificity for waveform capnography to detect cor-
rect tracheal placement was 100% (95% CI, 87%–100%). The 
sensitivity was 100% in 1 study38,39 when waveform capnog-
raphy was used in the prehospital setting immediately after 
intubation, and esophageal intubation was less common than 
the average (1.5%). The sensitivity was between 65% and 
68% in the other 3 studies39–41 when the device was used in 
OHCA patients after intubation in the emergency department 
(ED). The difference may be related to prolonged resuscita-
tion with compromised or nonexistent pulmonary blood flow. 
Based on the pooled sensitivity/specificity from these studies 
and assumed esophageal intubation prevalence of 4.5%, the 
false-positive rate (FPR) of waveform capnography was 0% 
(95% CI, 0%–0.6%).
Colorimetric CO2 Detection Devices
For the important outcome of detection of correct placement 
of a tracheal tube during CPR, we identified very-low-qual-
ity evidence (downgraded for risk of bias and indirectness) 
from 7 observational studies38,42–47 including 1119 patients 
that evaluated the diagnostic accuracy of colorimetric CO2 
devices. The specificity was 97% (95% CI, 84%–99%), the 
sensitivity was 87% (95% CI, 85%–89%), and the FPR was 
0.3% (95% CI, 0%–1%).
Esophageal Detection Devices
For the important outcome of detection of correct placement 
of a tracheal tube during CPR, we identified very-low-quality 
evidence (downgraded for risk of bias, indirectness, inconsis-
tency, and a strong suspicion of publication bias) from 4 obser-
vational studies39,40,43,48 including 228 patients, low-quality 
evidence (downgraded for risk of bias and indirectness) from 
1 randomized study41 including 48 patients, and very-low-
quality evidence (downgraded for risk of bias, indirectness, 
inconsistency, and a strong suspicion of publication bias) from 
1 observational study50 including 168 patients that evaluated 
esophageal detection devices. The pooled specificity was 92% 
(95% CI, 84%–96%), the pooled sensitivity was 88% (95% 
CI, 84%–192%), and the FPR was 0.2% (95% CI, 0%–0.6%). 
Low-quality evidence (downgraded for risk of bias and sus-
pected publication bias) from 1 observational study41 showed 
no statistically significant difference between the performance 
of a bulb (sensitivity 71%, specificity 100%)- and a syringe 
(sensitivity 73%, specificity 100%)-type esophageal detection 
devices in the detection of tracheal placement of a tracheal tube.
Ultrasound for Tracheal Tube Detection
For the important outcome of detection of correct placement 
of a tracheal tube during CPR, we identified low-quality 
evidence (downgraded for suspicion of publication bias and 
indirectness) from 3 observational studies51–53 including 254 
patients in cardiac arrest that evaluated the use of ultrasound 
to detect tracheal tube placement. The pooled specificity was 
90% (95% CI, 68%–98%), the sensitivity was 100% (95% CI, 
98%–100%), and the FPR was 0.8% (95% CI, 0.2%–2.6%).
Treatment Recommendations
We recommend using waveform capnography to confirm and 
continuously monitor the position of a tracheal tube during 
CPR in addition to clinical assessment (strong recommenda-
tion, low-quality evidence).
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We recommend that if waveform capnography is not 
available, a nonwaveform CO2 detector, esophageal detector 
device, or ultrasound in addition to clinical assessment is an 
alternative (strong recommendation, low-quality evidence).
Values, Preferences, and Task Force Insights
In making these strong recommendations, and despite the 
low-quality evidence, we place a high value on avoiding 
unrecognized esophageal intubation. The mean incidence of 
unrecognized esophageal intubation in cardiac arrest was 4.3% 
(range, 0%–14%) in the 11 studies we assessed. Unrecognized 
esophageal placement of an advanced airway is associated 
with a very high mortality. We, therefore, place value on rec-
ommending devices with a low FPR (ie, the device indicates 
tracheal placement but the tube is in the esophagus).
In addition, waveform capnography is given a strong rec-
ommendation, because it may have other potential uses dur-
ing CPR (eg, monitoring ventilation rate, assessing quality 
of CPR).
Knowledge Gaps
•	 The evidence is limited on the value of CO2 devices after 
prolonged cardiac arrest.
•	 There are very few studies comparing the practical 
implications (cost, timeliness) of these devices.
•	 The use of ultrasound requires further studies.
Ventilation Rate During Continuous Chest 
Compression (ALS 808)
Among adults with cardiac arrest with a secure airway receiv-
ing chest compressions (in any setting, and with standard tidal 
volume) (P), does a ventilation rate of 10 breaths/min (I), 
compared with any other ventilation rate (C), change survival 
with favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Introduction
Hyperventilation during CPR has been shown to be harmful, 
but once an advanced airway has been placed, the optimal 
ventilation rate remains uncertain.
Consensus on Science
We did not identify any evidence to address the critical out-
comes of survival with favorable neurologic/functional out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival at discharge, 30 days, 60 days, 180 days, and/or 1 year.
We identified very-low-quality evidence (downgraded for 
very serious risk of bias and indirectness, and serious incon-
sistency and imprecision) from 10 animal studies54–63 and 1 
human observational study64 that does not enable us to esti-
mate with confidence the effect of a ventilation rate of 10/
min compared with any other rate for the important outcome 
of ROSC.
Treatment Recommendation
We suggest a ventilation rate of 10 breaths/min in adults 
with cardiac arrest with a secure airway receiving continuous 
chest compressions (weak recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we have valued the need to 
suggest a ventilation rate that is already in use. We note that 
the Australian and New Zealand Committee on Resuscitation 
(ANZCOR) currently recommends a ventilation rate of 6 to 
10 breaths/min and would see no reason for this to change. We 
did not assess effect of tidal volume and any other ventilation 
variables during CPR and have therefore not addressed these 
in the treatment recommendation.
Knowledge Gaps
•	 Ventilation rates lower than 10/min need to be assessed 
during ALS.
•	 We do not know the ideal tidal volume and any other 
ventilation variables during CPR.
2010 CoSTR Topics Not Reviewed in 2015
•	 Oropharyngeal and nasopharyngeal adjuncts
•	 Monitoring ventilator parameters during CPR
•	 Thoracic impedance to confirm airway placement
•	 Cricoid pressure
•	 Automatic ventilators versus manual ventilation 
during CPR
Circulatory Support During CPR
The ALS Task Force reviewed the evidence for 3 technolo-
gies for which there have been significant developments since 
2010: (1) the ITD, (2) automated mechanical chest compres-
sion devices, and (3) ECPR. All are already in use in some 
settings, have strong proponents for their use, and have cost 
implications for their implementation such that there was 
considerable debate in reaching a consensus on science and 
treatment recommendation. In addition, some studies of these 
technologies had support and involvement of device manufac-
turers. Some of this debate is presented in the narrative that 
follows each treatment recommendation.
Impedance Threshold Device (ALS 579)
Among adults who are in cardiac arrest in any setting (P), does 
use of an inspiratory ITD during CPR (I), compared with no 
ITD (C), change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/or 1 
year; survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; ROSC (O)?
Introduction
The ITD is designed to reduce the intrathoracic pressure dur-
ing the decompression phase of chest compression. There is 
some evidence the ITD increases blood flow during CPR. The 
ITD has been studied during conventional CPR and during 
ACD CPR.
Consensus on Science
ITD Plus Conventional CPR (I) Versus  
Conventional CPR (C)
For the critical outcome of neurologically favorable survival 
at hospital discharge (assessed with modified Rankin Scale 
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[mRS] score of 3 or less), there was 1 RCT65 of high quality in 
8718 OHCAs that was unable to demonstrate a clinically sig-
nificant benefit from the addition of the ITD to conventional 
CPR (RR, 0.97; 95% CI, 0.82–1.15).
For the critical outcome of survival to hospital dis-
charge, there was 1 RCT65 of high quality in 8718 OHCAs 
that was unable to demonstrate a clinically significant benefit 
from the addition of the ITD to conventional CPR (RR, 1; 
95% CI, 0.87–1.15).
ITD Plus ACD CPR (I) Versus ACD CPR (C)
For the critical outcome of neurologically favorable sur-
vival, there were no studies identified that compared the use 
of ITD with ACD CPR with ACD CPR in cardiac arrests.
For the critical outcome of survival to hospital discharge, 
there were 2 RCTs66,67 of very low quality (downgraded for 
serious imprecision and very serious indirectness because of 
pre-2000 resuscitation practices) that that were unable to dem-
onstrate a clinically significant benefit from the addition of the 
ITD to ACD CPR in a total of 421 OHCAs (RR, 0.91; 95% CI, 
0.07–12.766 and RR, 1.25; 95% CI, 0.5–3.1).67
ITD Plus ACD CPR (I) Versus Conventional CPR (C)
For the critical outcome of neurologically favorable survival 
(CPC ≤2) at 12 months, there was 1 publication reporting 
results from a randomized study68 of very low quality (down-
graded for very serious risk of bias and serious imprecision) 
in 2738 OHCAs that was unable to demonstrate a clinically 
significant benefit from the addition of the ITD to ACD CPR 
(when compared with conventional CPR: RR, 1.34; 95% CI, 
0.97–1.85).
For the critical outcome of neurologically favorable sur-
vival at hospital discharge, there was 1 RCT68 that incorpo-
rated the presumed cardiac etiology subset published in 201169 
of very low quality (downgraded for very serious risk of 
bias, serious inconsistency, and serious imprecision) in 2738 
OHCAs that was unable to demonstrate a clinically significant 
benefit (using CPC ≤2) from the addition of the ITD to ACD 
CPR (when compared with conventional CPR: RR, 1.28; 95% 
CI, 0.98–1.69). Similar data (neurologically intact survival 
at hospital discharge) were also reported that used mRS of 
3 or less, and were unable to demonstrate a clinically signifi-
cant benefit (lower CI was 3 more/1000 in Frascone [number 
needed to treat, NNT, of 333] and 6 more/1000 [NNT of 167] 
in Aufderheide).68,69
For the critical outcome of survival to 12 months, there 
were 2 publications reporting results from a single randomized 
study,68 which incorporated the presumed cardiac etiology 
subset published in 2011,69 of very low quality (downgraded 
for very serious risk of bias and serious imprecision) in 2738 
OHCAs that was unable to demonstrate a clinically signifi-
cant benefit from the addition of the ITD to ACD CPR (when 
compared with conventional CPR): Frascone: RR, 1.39 
(95% CI, 1.04–1.85; lower CI was 2 more/1000; NNT, 500); 
Aufderheide: RR, 1.49 (95% CI, 1.05–2.12; lower CI was 4 
more/1000; NNT, 250).
For the critical outcome of survival to hospital dis-
charge, there were 3 publications reporting results from 2 
randomized studies69,70 (which incorporated the presumed 
cardiac etiology subset published in Aufderheide69) of very 
low quality (downgraded for very serious risk of bias, seri-
ous indirectness, and serious imprecision) in a total of 2948 
OHCAs that were unable to demonstrate a clinically signifi-
cant benefit from the addition of the ITD to ACD CPR (when 
compared with conventional CPR): Frascone: RR, 1.17 (95% 
CI, 0.94–1.45); Aufderheide: RR, 1.26 (95% CI, 0.96–1.66); 
Wolcke: RR, 1.41 (95% CI, 0.75–2.66).
Treatment Recommendation
We recommend against the routine use of the ITD in addition 
to conventional CPR (strong recommendation, high-quality 
evidence).
A consensus recommendation could not be reached for the 
use of the ITD when used together with ACD CPR.
Values, Preferences, and Task Force Insights
In making a recommendation against the routine use of the 
ITD alone, we place a higher value on not allocating resources 
to an ineffective intervention over any yet-to-be-proven ben-
efit for critical or important outcomes.
Because of the concern about allocating resources to an 
intervention with equivocal benefit for critical or important 
outcomes, a consensus recommendation could not be reached 
for ITD combined with ACD CPR. The task force thought that 
the decision on use of the ITD plus ACD combination should 
be left to individual Council guidelines.
Public comments posted online were reviewed and con-
sidered by the task force, specifically regarding the use of 
the ITD and ACD CPR combination and the task force’s 
interpretation of the data from 2 publications from the same 
study68,69 using the GRADE process, and how the data from 
these studies had been analyzed and interpreted. The task 
force received feedback from the investigator(s) of this 
study in the public commenting period and in an open ses-
sion. In addition, it considered an editorial on the analysis 
of this study71 and discussed the publications68,69 and their 
clinical significance in its closed sessions. The NNTs were 
discussed and the use of the CI closest to unity as a measure 
of study precision. It was also noted that the critical and 
important endpoints for this and the other ALS PICO ques-
tions were agreed a priori and posted for public comment-
ing before searches took place, hence the difference in our 
hierarchy of outcomes compared with the actual primary 
and secondary outcomes reported in the study that made 
up the 2 publications. The task force appreciated the chal-
lenges of studying a combined intervention and conducting 
a large cardiac arrest study. There was also discussion of the 
involvement of the manufacturer in the design and report-
ing of the study and that sponsorship of drug and device 
studies by manufacturers can lead to more favorable results 
and conclusions.72 There was considerable debate on this 
topic in both closed and open task force sessions such that 
a consensus could not be achieved by the task force on a 
treatment recommendation for the use of the ITD when used 
together with ACD CPR.
Knowledge Gaps
•	 Optimal compression and ventilation rates for ITD CPR 
and ACD plus ITD CPR may or may not be different 
from those for conventional CPR.
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•	 The independent effects of ITD and ACD CPR are 
uncertain.
•	 Effectiveness studies should examine other geographical 
settings and populations.
Mechanical CPR Devices (ALS 782)
Among adults who are in cardiac arrest in any setting (P), do 
automated mechanical chest compression devices (I), com-
pared with standard manual chest compressions (C), change 
survival with favorable neurologic/functional outcome at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; survival 
only at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC (O)?
Introduction
Providing high-quality manual CPR is tiring, and there is evi-
dence that CPR quality deteriorates with time. Mechanical 
CPR devices may enable the delivery of high-quality CPR for 
a sustained period, but at the time of writing the 2010 CoSTR, 
their impact on outcome was unclear.
Consensus on Science
For the critical outcome of survival to 1 year, we identified 
moderate-quality evidence (downgraded for serious risk of 
bias) from 1 cluster RCT73 using the Lund University Cardiac 
Arrest System (LUCAS) device showing no benefit or harm 
when compared with manual chest compressions (5.4% ver-
sus 6.2%; RR, 0.87; 95% CI, 0.68–1.11).
For the critical outcomes of survival at 180 days with 
good neurologic outcome and survival at 30 days with 
favorable neurologic outcome, we identified moderate-
quality evidence (downgraded for serious risk of bias) from 
1 RCT74 using a LUCAS device and enrolling 2589 OHCA 
patients that did not show benefit or harm when compared 
with manual chest compressions at 180 days (8.5% versus 
7.6%; RR, 1.11; 95% CI, 0.86–1.45) or 30 days (7.3% versus 
8.1%; RR, 1.11; 95% CI, 0.84–1.45).
For the critical outcome of survival to 180 days, we iden-
tified moderate-quality evidence (downgraded for serious risk 
of bias) from 1 RCT74 using a LUCAS device enrolling 2589 
OHCA patients showing no benefit or harm when compared 
with manual chest compressions where quality of chest com-
pressions in the manual arm was not measured (8.5% versus 
8.1%; RR, 1.06; 95% CI, 0.81–1.41).
For the critical outcome of survival to hospital discharge 
with favorable neurologic outcome (defined as CPC 1–2 
or mRS 0–3), we have identified moderate-quality evidence 
(downgraded for serious risk of bias) from 3 RCTs enroll-
ing 7582 OHCA patients showing variable results.74–76 One 
study75 (n=767) showed harm with the use of a load-distribut-
ing band mechanical chest compression device compared with 
manual chest compressions (7.5% of patients in the control 
group versus 3.1% in the intervention group; P=0.006; RR, 
0.41; 95% CI, 0.21–0.79). Two other RCTs74,76 (n=6820), one 
using a load-distributing band and the other using a LUCAS, 
did not show benefit or harm when compared with manual 
chest compressions: load-distributing band study: 4.14% 
survival in the intervention group versus 5.25% for manual 
compressions (RR, 0.79; 95% CI, 0.60–1.03); LUCAS: 8.31% 
intervention versus 7.76% manual compressions (RR, 1.07; 
95% CI, 0.83–1.39).
For the critical outcome of survival to hospital discharge, 
we identified moderate-quality evidence (downgraded for 
serious risk of bias) from 5 RCTs74–78 enrolling 7734 OHCA 
patients and 150 IHCA patients showing heterogeneous 
results. One study of patients with IHCAs77 (n=150) showed 
benefit with use of a piston device compared with manual 
chest compressions (32.9% versus 14.7%; P=0.02; RR, 2.21; 
95% CI, 1.17–4.17). Two other RCTs74,78 of LUCAS did not 
show benefit or harm (9.0% versus 9.15%; RR, 0.98; 95% CI, 
0.77–1.25 and 8.0% versus 9.72%; RR, 0.82; 95% CI, 0.29–
2.33, respectively, for LUCAS versus manual compressions). 
One large RCT76 (n=4231) using a load-distributing band 
device showed equivalence when compared with high-quality 
manual chest compressions (9.34% versus 10.93%; RR, 0.85; 
95% CI, 0.71–1.02).
For the critical outcome of survival to 30 days, we identi-
fied moderate-quality evidence (downgraded for serious risk 
of bias) from 2 RCTs73,74 (n=7060) using the LUCAS device 
showing no benefit or harm when compared with manual 
chest compressions and where quality of compressions in the 
manual arm was not measured (6.3% versus 6.85%; RR, 0.92; 
95% CI, 0.73–1.16 and 8.82% versus 8.07%; RR, 1.02; 95% 
CI, 0.97–1.31, respectively).
For the important outcome of ROSC, we identified low-
quality evidence (downgraded for serious risk of bias and 
serious inconsistency) from 7 RCTs enrolling 11 638 cardiac 
arrest patients (IHCA and OHCA).73,74,76–80 Two studies77,79 
(n=167) showed benefit with mechanical chest compression 
devices compared with manual compressions: 14.29% ver-
sus 0% (RR, not applicable) and 55.26% versus 37.84% (RR, 
1.46; 95% CI, 1.02–2.08), respectively. One study76 (n=4231) 
showed harm with mechanical devices; however, there was no 
adjustment for interim analyses: 28.59% versus 32.32% (RR, 
0.88; 95% CI, 0.81–0.97). Four studies73,74,78,80 (n=7240) did 
not show benefit or harm when compared with manual chest 
compressions: 47.06% versus 17.75% (RR, 2.67; 95% CI, 
0.85–8.37), 31.60% versus 31.39% (RR, 1.01; 95% CI, 0.92–
1.10), 35.38% versus 34.60% (RR, 1.02; 95% CI, 0.92–1.14), 
and 40.54% versus 31.94% (RR, 1.27; 95% CI, 0.82–1.96), 
respectively.
Treatment Recommendations
We suggest against the routine use of automated mechanical 
chest compression devices to replace manual chest compres-
sions (weak recommendation, moderate-quality evidence).
We suggest that automated mechanical chest compression 
devices are a reasonable alternative to high-quality manual 
chest compressions in situations where sustained high-qual-
ity manual chest compressions are impractical or compro-
mise provider safety (weak recommendation, low-quality 
evidence).
Values, Preferences, and Task Force Insights
The task force placed value on ensuring high-quality chest 
compressions with adequate depth, rate, and minimal inter-
ruptions, regardless of whether they are delivered by machine 
or human. The task force also considered that application of 
a mechanical chest compression device without a focus on 
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minimizing interruptions in compressions and delay to defi-
brillation could cause harm.
In making a recommendation for mechanical compres-
sion devices for use in some settings, we place value on the 
results from a large, high-quality RCT76 showing equivalence 
between very-high-quality manual chest compressions and 
mechanical chest compressions delivered with a load-distrib-
uting band in a setting with rigorous training and CPR quality 
monitoring. Also, the task force acknowledges the existence 
of situations where sustained high-quality manual chest com-
pressions may not be practical. Examples include CPR in a 
moving ambulance where provider safety is at risk, the need 
for prolonged CPR where provider fatigue may impair high-
quality manual compressions (eg, hypothermic arrest), and 
CPR during certain procedures (eg, coronary angiography or 
preparation for ECPR).
Our task force agreed that there was an adequate amount 
of data generated from RCTs for the systematic review to 
exclude observational studies. We agreed that despite the 
availability of several observational studies comparing man-
ual and mechanical chest compressions, the inherent risk of 
bias related to patient selection, group allocation, and uncon-
trolled confounders supports a decision to exclude them from 
the process of developing this CoSTR statement.
We conducted a universal literature search for RCTs 
studying any type of automated mechanical chest compres-
sion device. Prior to initiating the review, we planned to parse 
the data by device type if an effect specific to device was 
observed in the analysis. Although we did not undertake a for-
mal analysis by device, there were no obvious device-specific 
effects observed.
The task force did consider some data that are not included 
in the evidence profile tables or CoSTR statement. Specifically, 
the PARAMEDIC (prehospital randomized assessment of 
a mechanical compression device in cardiac arrest) study73
 
showed an association between mechanical chest compres-
sions and worse survival with good neurologic outcome (CPC 
1–2) at 3 months (adjusted OR, 0.72; 95% CI, 0.52–0.99). 
This was not included in our consensus on science, because 
survival with good neurologic outcome at 90 days was not an 
a priori outcome identified by the group.
After assessing the evidence, there was much debate over 
the ultimate wording of our recommendation. Some mem-
bers thought a weak recommendation supporting mechani-
cal chest compression devices as a reasonable alternative to 
manual chest compressions was most appropriate, whereas 
others thought a recommendation against the routine use of 
mechanical chest compression devices was more appropri-
ate. There was general agreement that the bulk of evidence 
reviewed suggests no significant difference or equivalence 
between mechanical and manual chest compressions related 
to critical and important clinical outcomes. The task force 
weighed this with the data from a few studies suggesting a 
negative association between mechanical chest compression 
and outcomes as well as the potential resource implications 
associated with implementation of mechanical devices in any 
setting. With these factors in mind, the task force concluded 
that available clinical evidence did not support a recommen-
dation for broad and universal implementation of mechanical 
chest compression devices across all clinical settings in favor 
of high-quality manual chest compressions.
Public comments provided online were reviewed by the 
task force. Comments suggested that we consider special cir-
cumstances where mechanical chest compressions may be 
more practical than the continued provision of high-quality 
chest compression and circumstances where provider safety 
might be improved with the use of mechanical versus man-
ual chest compressions. Delivery of manual compressions in 
a moving ambulance by an unrestrained provider was seen 
as a particularly unsafe situation. Mechanical devices may 
allow providers to remain seated and restrained in this situ-
ation while chest compressions continue. Accordingly, we 
have included a treatment recommendation to address these 
situations not directly addressed in the literature reviewed but 
deemed to represent reasonable situations for the use of this 
technology.
Knowledge Gaps
•	 Are mechanical chest compression devices superior to 
manual chest compressions in special situations such as 
the moving ambulance, prolonged CPR, or during proce-
dures such as coronary angiography?
•	 Are there certain subgroups of patients who may benefit 
differentially from mechanical or manual chest com-
pressions (eg, shockable versus nonshockable initial 
rhythm)?
•	 Is one type of mechanical chest compression device 
superior to another with respect to important clinical 
outcomes?
ECPR Versus Manual or Mechanical  
CPR (ALS 723)
Among adults who are in cardiac arrest in any setting (P), does 
the use of ECPR techniques (including extracorporeal mem-
brane oxygenation or cardiopulmonary bypass) (I), compared 
with manual CPR or mechanical CPR (C), change survival 
with favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Introduction
Extracorporeal techniques require vascular access and a cir-
cuit with a pump and oxygenator and can provide a circu-
lation of oxygenated blood to restore tissue perfusion. This 
has the potential to buy time for restoration of an adequate 
spontaneous circulation and treatment of reversible underly-
ing conditions. This is commonly called extracorporeal life 
support (ECLS), and more specifically ECPR when done dur-
ing cardiac arrest. These techniques are increasingly being 
used for OHCA. We considered ECLS for IHCA and OHCA 
separately.
Consensus on Science
ECPR for IHCA
For the critical outcome of favorable functional survival 
at 180 days or 1 year after IHCA, we identified very-low-
quality evidence (downgraded for risk of bias from selection 
of cases for ECPR, crossover in treatments, and imprecision) 
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from 2 non-RCTs,81,82 comparing 144 patients treated with 
ECPR to 434 patients treated with conventional CPR. At 180 
days, favorable outcome increased with ECPR (RR, 3.78; 
95% CI, 2.26–6.31), even in propensity-matched samples.82 
At 1 year, favorable outcome was not different with ECPR 
(RR, 1.72; 95% CI, 0.74–4.01).
For the critical outcome of survival to 30, 180 days, 
or 1 year after IHCA, we identified very-low-quality evi-
dence (downgraded for risk of bias from selection of cases 
for ECPR, crossover in treatments, and imprecision) from 2 
non-RCTs,81,82 comparing 144 patients treated with ECPR 
to 434 patients treated with conventional CPR. These stud-
ies found improved survival at 30 days (RR, 2.25; 95% CI, 
1.28–3.96) and 180 days (RR, 2.81; 95% CI, 1.79–4.39 
and RR, 2.50; 95% CI, 1.31–4.80), but not 1 year (RR, 
1.92; 95% CI, 0.88–4.15). A propensity-matched sample 
found improved survival at 180 days82 (RR, 3.20; 95% CI, 
1.25–8.18).
For the important outcome of favorable functional 
survival at hospital discharge after IHCA, we identified 
very-low-quality evidence (downgraded for risk of bias from 
selection of cases for ECPR, crossover in treatments, and 
imprecision) from 2 non-RCTs,81,82 comparing 144 patients 
treated with ECPR to 434 patients treated with conventional 
CPR. These studies found improved favorable outcome with 
ECPR (RR, 2.23; 95% CI, 1.11–4.52 and adjusted RR, 3.63; 
95% CI, 2.18–6.02), even in propensity-matched samples 
(RR, 4.67; 95% CI, 1.41–15.41).82
For the important outcome of survival to hospital dis-
charge after IHCA, we identified very-low-quality evi-
dence (downgraded for risk of bias from selection of cases 
for ECPR, crossover in treatments, and imprecision) from 2 
non-RCTs,81,82 comparing 144 patients treated with ECPR 
to 434 patients treated with conventional CPR. These stud-
ies found improved survival to hospital discharge in the entire 
cohort (RR, 2.33; 95% CI, 1.23–4.38 and RR, 2.81; 95% CI, 
1.85–4.26). One of these studies found improved survival to 
hospital discharge in propensity-matched samples (RR, 3.17; 
95% CI, 1.36–7.37).82
ECPR for OHCA
For the critical outcome of favorable functional survival at 
30, 90, or 180 days after OHCA, we identified very-low-
quality evidence from 2 non-RCTs (downgraded for risk of 
bias for selection of cases for ECPR and imprecision), com-
paring 311 patients treated with ECPR to 312 patients treated 
with conventional CPR.83,84 One study reported increased 
favorable outcome with ECPR at 30 days (RR, 7.92; 95% CI, 
2.46–25.48) and 180 days (RR, 4.34; 95% CI, 1.71–11.00).84 
The other study reported increased favorable outcome at 90 
days (RR, 5.48; 95% CI, 1.52–19.84), but this association was 
not present in the propensity-matched sample (RR, 3.50; 95% 
CI, 0.81–15.16).83
For the critical outcome of survival to 30, 90, or 180 
days after OHCA, we identified very-low-quality evidence 
(downgraded for risk of bias from selection of cases for ECPR 
and imprecision) from 2 non-RCTs, comparing 311 patients 
treated with ECPR to 312 patients treated with conventional 
CPR.83,84 One study reported increased survival with ECPR 
at 30 days (RR, 3.94; 95% CI, 2.24–6.92) and 180 days (RR, 
5.42; 95% CI, 2.65–11.09),84 and the other study reported 
increased survival with ECPR at 90 days (RR, 6.17; 95% CI, 
2.37–16.07), even in a propensity-matched sample (RR, 4.50; 
95% CI, 1.08–18.69).83
For the important outcome of favorable functional sur-
vival at hospital discharge after OHCA, we identified no 
comparative studies.
For the important outcome of survival to hospital dis-
charge after OHCA, we identified very-low-quality evi-
dence (downgraded for risk of bias from selection of cases 
for ECPR and imprecision) from 1 non-RCT comparing 53 
patients treated with ECPR to 109 patients treated with con-
ventional CPR.83 Survival to hospital discharge was higher in 
patients treated with ECPR (RR, 4.99; 95% CI, 2.21–11.30), 
though not in propensity matched samples (RR, 3.00; 95% CI, 
0.92–9.74).
Treatment Recommendation
We suggest ECPR is a reasonable rescue therapy for selected 
patients with cardiac arrest when initial conventional CPR is 
failing in settings where this can be implemented (weak rec-
ommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making this weak recommendation, we note that the 
published series used selected patients for ECPR and that 
guidelines for clinical practice should apply to similar popula-
tions. Published comparative studies are limited by the bias 
created when experienced clinicians select the best candi-
dates to receive ECPR, perhaps using unmeasured variables. 
We acknowledge that ECPR is a complex intervention that 
requires considerable resource and training that is not univer-
sally available, but put value on an intervention that may be 
successful in individuals where usual CPR techniques have 
failed. In addition, ECPR can buy time for another treatment 
such as coronary angiography and percutaneous coronary 
intervention (PCI). 
Knowledge Gaps
•	 Controlled clinical trials are needed to assess the effect 
of ECPR versus traditional CPR on clinical outcomes in 
patients with cardiac arrest.
•	 What is the optimal flow rate for ECPR in the treatment 
for cardiac arrest?
•	 Which subgroups of patients can benefit most from a 
strategy of ECPR?
•	 What type of patients should be considered for ECPR?
•	 What role, if any, should prehospital ECPR play in 
resuscitating patients from OHCA?
•	 What is the optimal target temperature for patients on 
ECPR after cardiac arrest?
•	 What are reliable prognostic factors for patients treated 
with ECPR after cardiac arrest?
2010 CoSTR Topics Not Reviewed in 2015
•	 Interposed abdominal compression CPR
•	 ACD CPR
•	 Open-chest CPR
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Physiological Monitoring During CPR
The ability to monitor real-time physiological variables and 
obtain ultrasound images during CPR, in addition to clinical 
signs and electrocardiographic monitoring, has the potential 
to enable rescuers to tailor ALS interventions. Strategies for 
physiological monitoring include the use of ETco
2
, arterial 
pressure, central venous pressure (enabling monitoring of 
coronary perfusion pressure and aortic diastolic pressure), and 
cerebral oximetry (regional cerebral oxygenation).
ETCO2 to Predict Outcome of Cardiac  
Arrest (ALS 459)
Among adults who are in cardiac arrest in any setting (P), does 
any ETCO2 level value, when present (I), compared with any 
ETCO2 level below that value (C), change survival with favor-
able neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 30 
days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Introduction
ETCO2 is the partial pressure of CO2 at the end of an exhaled 
breath. It reflects cardiac output (CO) and pulmonary blood 
flow, as CO2 is transported by the venous system to the right 
side of the heart and then pumped to the lungs by the right ven-
tricle. During CPR, ETCO2 values are low, reflecting the low 
CO generated by chest compression. Although ETCO2 val-
ues higher than 10 mm Hg have been correlated to ROSC,85–89 
there is uncertainty if any ETCO2 value measured during CPR 
can reliably predict survival or survival with good neurologic 
outcome.
Consensus on Science
We did not identify any evidence to address the critical out-
come of neurologically intact survival.
For the critical outcome of survival at discharge, we have 
identified low-quality evidence (downgraded for serious risk 
of bias and serious imprecision) from 1 observational study 
enrolling 127 patients90 showing a correlation with initial 
ETCO2 10 mm Hg (1.33 kPa) or greater when compared with 
less than 10 mm Hg (OR, 11.4; 95% CI, 1.4–90.2).
For the critical outcome of survival at discharge, we have 
identified low-quality evidence (downgraded for serious risk 
of bias and serious imprecision) from 1 observational study 
enrolling 127 patients90 showing a correlation with 20 minutes 
of ETCO2 20 mm Hg (2.67 kPa) or greater when compared 
with less than 20 mm Hg (OR, 20.0; 95% CI, 2.0–203.3).
For the important outcome of ROSC, we have identified 
moderate-quality evidence (downgraded for serious risk of 
bias) from 3 observational studies enrolling 302 patients90–92 
showing a correlation with initial ETCO2 10 mm Hg or greater 
when compared with less than 10 mm Hg (OR, 10.7; 95% CI, 
5.6–20.3).
For the important outcome of ROSC, we have identified 
very-low-quality evidence (downgraded for very serious risk 
of bias, serious inconsistency, and serious imprecision) from 
3 observational studies enrolling 367 patients90,93,94 showing 
correlation with 20 minutes ETCO2 10 mm Hg or greater 
when compared with less than 10 mm Hg (OR, 181.6; 95% 
CI, 40.1–822.6).
Treatment Recommendations
We recommend against using ETCO2 cutoff values alone as a 
mortality predictor or for the decision to stop a resuscitation 
attempt (strong recommendation, low-quality evidence).
We suggest that an ETCO2 10 mm Hg or greater measured 
after tracheal intubation or after 20 minutes of resuscitation 
may be a predictor of ROSC (weak recommendation, low-
quality evidence).
We suggest that an ETCO2 10 mm Hg or greater measured 
after tracheal intubation or an ETCO2 20 mm Hg or greater 
measured after 20 minutes of resuscitation may be a predictor 
of survival to discharge (weak recommendation, moderate-
quality evidence).
Values, Preferences, and Task Force Insights
In making the strong recommendations against using a spe-
cific ETCO2 cutoff value alone as a mortality predictor or for 
the decision to stop a resuscitation attempt, we have put a 
higher value on not relying on a single variable (ETCO2) and 
cutoff value when their usefulness in actual clinical practice, 
and variability according to the underlying cause of cardiac 
arrest, has not been established and there are considerable 
knowledge gaps.
The task force was concerned that the etiology (eg, 
asphyxia, PE) of cardiac arrest could affect ETCO2 values, 
and that there was a risk of self-fulfilling prophecy if specific 
threshold values were followed. There was concern about the 
accuracy of ETCO2 values measured during CPR. During 
open discussions there were requests that the ILCOR recom-
mendation be far more prescriptive to prevent futile and pro-
longed resuscitation attempts.
Knowledge Gaps
•	 The effects on ETCO2 of timing, etiology of arrest, ven-
tilation rate, and chest compression quality are not fully 
understood.
•	 The role of ETCO2 with a bag-mask device or SGA 
requires further study.
•	 Are ETCO2 values measured during CPR accurate?
•	 The ETCO2 cutoff values to reliably predict short- and 
long-term outcomes is not known.
Monitoring Physiological Parameters During CPR 
(ALS 656)
Among adults who are in cardiac arrest in any setting (P), 
does the use of physiological feedback regarding CPR qual-
ity (eg, arterial lines, ETCO2 monitoring, Spo2 waveforms, 
or others) (I), compared with no feedback (C), change sur-
vival with favorable neurologic/functional outcome at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; survival 
only at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC; change in physiologic values by modifications in 
CPR (O)?
Introduction
Several physiological variables such as ETCO2, coronary per-
fusion pressure, aortic diastolic pressure, and cerebral oxim-
etry measurements have been used to assess and guide the 
quality of CPR.
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Consensus on Science
We found no studies that addressed the critical and important 
outcomes.
For the outcome of change in physiologic values by 
modifications in CPR, we identified 13 observational studies 
that provided very-low-quality evidence (downgraded for seri-
ous risk of bias, serious inconsistency, serious indirectness, 
and serious imprecision) comparing different CPR techniques 
(standard, lower sternal, active compression-decompression, 
intra-abdominal compression, mechanical thumper, ITD, band 
chest compression, load-distributing band, vest CPR) with the 
use of physiologic monitoring (arterial line, ETCO2, oxygen 
saturation as measured by pulse oximetry (Spo2), coronary 
perfusion pressure, cerebral oximetry, near-infrared spec-
troscopy) in 469 subjects.66,80,95–105 Differences were detected 
between different CPR techniques, although this was not con-
sistent across different modalities. Given the heterogeneity of 
CPR techniques used across studies, data could not be pooled. 
There were no studies that were found that used physiologic 
feedback to evaluate CPR quality.
Treatment Recommendation
We make no treatment recommendation for any particular 
physiological measure to guide CPR, because the available 
evidence would make any estimate of effect speculative.
Values, Preferences, and Task Force Insights
In making no recommendation, we have placed high value 
on the lack of evidence and the need for further studies in 
this area.
Knowledge Gaps
•	 Studies of the effect of using physiologic feedback to 
evaluate CPR quality and modifications in CPR tech-
nique are required.
•	 Studies that measure the effect of physiological monitor-
ing to guide resuscitation on ROSC and survival with 
good neurologic outcome are required.
Ultrasound During CPR (ALS 658)
Among adults who are in cardiac arrest in any setting (P), does 
use of ultrasound (including echocardiography or other organ 
assessments) during CPR (I), compared with conventional CPR 
and resuscitation without use of ultrasound (C), change survival 
with favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Introduction
Ultrasound has been increasingly used as a diagnostic and 
prognostic tool for critically ill patients, particularly in inten-
sive care units (ICUs).106 Specific protocols for evaluation dur-
ing CPR enable assessment of myocardial contractility and may 
help identify potentially treatable causes, such as hypovolemia, 
pneumothorax, pulmonary thromboembolism, or restrictive 
pericardial effusion, without interfering in patient care.107
Consensus on Science
For the critical outcome of survival, we identified 1 obser-
vational study.108 The evidence was downgraded for very 
high risk of bias (significant confounding, selection bias) and 
imprecision (small sample size). Therefore, we concluded that 
the data do not provide enough evidence to address the PICO 
question.
For the important outcome of ROSC, we identified very-
low-quality evidence (downgraded for imprecision [small 
sample size] and very high risk of bias [no information about 
randomization allocation, lack of blinding, lack of blinding in 
outcome assessors]) from 1 RCT investigating the use of car-
diac ultrasound during ACLS, compared with no use of car-
diac ultrasound during ACLS in adult patients with pulseless 
electrical activity arrest.109 This study enrolled 100 patients in 
a convenience sample and reported ROSC for at least 10 sec-
onds in 34% of patients in the ultrasound group versus 28% in 
the group with no ultrasound (P=0.52).
Treatment Recommendations
We suggest that if cardiac ultrasound can be performed with-
out interfering with standard ACLS protocol, it may be con-
sidered as an additional diagnostic tool to identify potentially 
reversible causes (weak recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this recommendation we have placed a higher 
value on the potential harm from interruptions in chest com-
pressions. There is currently inadequate evidence to evalu-
ate whether there is any benefit of cardiac ultrasound during 
ACLS. Although this was not specifically part of the ques-
tion, the task force discussed the importance of the need for an 
individual trained in ultrasound during resuscitation to mini-
mize interruption in chest compression. The task force agreed 
there will be circumstances where ultrasound identification 
of a potentially reversible cause of cardiac arrest or ‘pseudo’ 
pulseless electrical activity may be useful.
Knowledge Gaps
It remains unclear if the addition of ultrasound during ACLS 
improves outcomes:
•	 All data are from OHCA. All data are from non-VF 
patients, primarily assessing pulseless electrical activity.
•	 A systematic review of the diagnostic utility of ultra-
sound should be done. There are some articles investi-
gating whether ultrasound findings predict probability of 
survival.
•	 Pretest probability (suspicion of an ultrasound-detect-
able etiology) is important for choosing to do ultra-
sound, because ultrasound will interfere to some extent 
with CPR.
•	 It is unknown if the findings of ultrasound during CPR 
are correctly interpreted, because images are compared 
with findings from patients with pulse (eg, right ven-
tricular dilation occurs in all cardiac arrest, separate 
from PE).
•	 It remains unclear if the addition of ultrasound dur-
ing CPR improves outcomes. The vast majority of lit-
erature on ultrasound during cardiac arrest has focused 
on the prognostic value of cardiac ultrasound findings. 
Randomized trials investigating whether use of ultra-
sound during CPR has an effect on patient outcomes are 
needed.
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Drugs During CPR
In 2010, ILCOR reduced routine drug administration in adult 
cardiac arrest to vasopressor and antiarrhythmic drugs. The 
science was insufficient to comment on critical outcomes such 
as survival to discharge and survival to discharge with good 
neurologic outcome with either vasopressors or antiarrhyth-
mic drugs. There was also insufficient evidence to comment 
on the best time to give drugs to optimize outcome. The task 
force made a decision to include only RCTs in this systematic 
review and meta-analysis. Where the number of RCTs was 
few, we looked for recent published systematic reviews or 
where there were no recent reviews, expanded the search to 
include observational studies.
Epinephrine Versus Placebo (ALS 788)
Among adults who are in cardiac arrest in any setting (P), does 
the use of epinephrine (I), compared with placebo or not using 
epinephrine (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Introduction
Since 2010, there have been 2 randomized drug trials in car-
diac arrest: one compared drugs with no drugs110 and another 
compared epinephrine with placebo.111 The Olasveengen trial 
compared a bundle of drugs given intravenously to a control 
group of patients randomized to no intravenous access and, 
therefore, no drugs. A post hoc subgroup analysis of the trial 
comparing those patients who did or did not receive epineph-
rine112 revealed an advantage with epinephrine for admission 
to hospital but suggested an association with harm for the out-
comes of survival to discharge and functional survival as mea-
sured by CPC. The Olasveengen original trial110 was excluded 
from our review; however, the post hoc subgroup analysis was 
included in the systematic review of observational and ran-
domized trials, which we have used to comment on the body 
of work defined by adjusted and unadjusted observational 
studies.113
Consensus on Science
For all 4 long-term and short-term outcomes, we found 1 
underpowered RCT that provided low-quality evidence 
(downgraded for selection and ascertainment bias) comparing 
SDE with placebo111 in 534 subjects.
For the critical outcome of survival to discharge, there 
was uncertain benefit or harm of SDE over placebo (RR, 2.12; 
95% CI, 0.75–6.02; P=0.16; absolute risk reduction [ARR], 
2.14%; 95% CI, −0.91% to 5.38%, or 21 more patients/1000 
survived with epinephrine [95% CI, 9 fewer patients/1000 to 
54 more patients/1000 survived with epinephrine]).
For the critical outcome of survival to discharge with 
good neurologic outcome (defined as CPC of 1–2), there 
was uncertain benefit or harm of SDE over placebo (RR, 1.73; 
95% CI, 0.59–5.11; P=0.32; ARR, 1.4%; 95% CI, −1.5% to 
4.5%, which translates to 14 more patients/1000 survived with 
a CPC score of 1 or 2 with epinephrine [95% CI, 15 fewer 
patients/1000 to 45 more patients/1000 survived with a CPC 
score of 1 or 2 when given epinephrine]).
For the important outcome of survival to admission, 
patients who received SDE had higher rates of survival to 
admission (RR, 1.95; 95% CI, 1.34–2.84; P=0.0004; ARR, 
12%; 95% CI, 5.7%–18.9%, which translates to 124 more 
patients/1000 survived to admission with epinephrine [95% 
CI, 57–189 more patients/1000 survived to admission]).
For the important outcome of ROSC in the prehospi-
tal setting, 151 more patients/1000 achieved ROSC with 
epinephrine (95% CI, 90–212 more patients/1000 achieved 
ROSC with epinephrine) when compared with those who 
received placebo (RR, 2.80; 95% CI, 1.78–4.41; P<0.000 01; 
ARR, 15%; 95% CI, 9%–21%).
While observational studies were excluded from the pri-
mary evidence evaluation, the task force did make some com-
parison of the randomized trial data with prior conclusions 
drawn from large observational data sets. Using the analysis 
published by Patanwala113 in 2014 when the Jacobs trial111 is 
compared with adjusted observational trials114,115 for the criti-
cal outcome of survival to discharge and functional sur-
vival with a CPC of 1 or 2, in settings with very low survival 
rates after cardiac arrest, 4.7% OHCA114 and 14% IHCA,115 
in the OHCA setting, the use of epinephrine was associated 
with worse outcomes for survival to discharge (5.4% with 
epinephrine versus 4.7% without epinephrine; unadjusted 
OR, 1.15; 95% CI, 1.07–1.53; adjusted OR, 0.46; 95% CI, 
0.42–0.51) and for functional survival (1.4% with epinephrine 
versus 2.2% without epinephrine; unadjusted OR, 0.61; 95% 
CI, 0.53%–0.71%; adjusted OR, 0.31; 95% CI, 0.26–0.36).114 
In the in-hospital setting, the use of epinephrine was not sig-
nificantly associated with either survival to discharge (OR, 
1.16; 95% CI, 0.52–2.58) or functional survival (CPC, 1–2; 
OR, 0.43; 95% CI, 0.08–2.29).
Treatment Recommendation
We suggest SDE be administered to patients in cardiac arrest 
(weak recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
We make this statement after considering the observed benefit in 
short-term outcomes (ROSC and admission to hospital) and our 
uncertainty about the benefit or harm on survival to discharge 
and neurologic outcome given the limitations of the observa-
tional studies. Our statement is not intended to change current 
practice until there are high-quality data on long-term outcomes. 
We have considered 1 mg to be the standard dose of epinephrine.
Knowledge Gaps
•	 Dose response and placebo-controlled efficacy trials 
are needed to evaluate the use of epinephrine in cardiac 
arrest. We are aware of an ongoing randomized study of 
epinephrine (adrenaline) versus placebo for OHCA in 
the United Kingdom (PARAMEDIC 2: The Adrenaline 
Trial, ISRCTN73485024).
Epinephrine Versus Vasopressin (ALS 659)
Among adults who are in cardiac arrest in any setting (P), does 
use of epinephrine (I), compared with vasopressin (C), change 
survival to 30 days with good neurologic outcome, survival to 
30 days, survival to hospital discharge with good neurologic 
outcome, survival to hospital discharge, ROSC (O)?
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Consensus on Science
A single RCT116 (n=336) of low quality (downgraded for high 
risk of bias) compared multiple doses of SDE with multiple 
doses of standard-dose vasopressin in the ED after OHCA. 
Much of the methodology is unclear, and there was 37% post-
randomization exclusion. The primary outcome measure was 
a CPC score of 1 or 2; however, neither the sample size esti-
mate nor power calculation were included in the article.
For the critical outcome of survival to discharge with 
favorable neurologic outcome (CPC 1 or 2), there was no 
advantage with vasopressin (RR, 0.68; 95% CI, 0.25–1.82; 
P=0.44 or ARR, −1.6; 95% CI, −6 to 2.4, which translates 
to 16 fewer patients/1000 surviving with CPC 1 or 2 with 
vasopressin [95% CI, 60 fewer patients/1000 to 24 more 
patients/1000 survive with CPC 1 or 2]).
For the critical outcome of survival to discharge, RR 
was 0.68 (95% CI, 0.25–1.82; P=0.44 or ARR, 1.8%; 95% 
CI, −3.1 to 6.7, which translates to 18 more patients/1000 
surviving to discharge with vasopressin [95% CI, 31 fewer 
patients/1000 surviving to discharge with vasopressin to 67 
more patients/1000 surviving to discharge]).
For the important outcome of ROSC, there was no 
observed advantage with vasopressin (RR, 0.93; 95% CI, 
0.66–1.31; P=0.67).
Treatment Recommendations
We suggest vasopressin should not be used instead of epi-
nephrine in cardiac arrest (weak recommendation, low-quality 
evidence).
We suggest that those settings already using vasopressin 
instead of epinephrine can continue to do so (weak recom-
mendation, low-quality evidence).
Values, Preferences, and Task Force Insights
The recommendation considers the fact that vasopressin is 
already used in some settings, and the available data do not indi-
cate any reason to stop using vasopressin if current treatment 
protocols already include vasopressin instead of epinephrine. 
Conversely, there is also no evidence to indicate that settings 
that use epinephrine should switch to using vasopressin.
Knowledge Gaps
•	 Until high-quality, adequately powered trials are com-
pleted comparing epinephrine with placebo, trials 
involving vasopressin are not required unless as a third 
arm against epinephrine and placebo.
Epinephrine Versus Vasopressin in Combination 
With Epinephrine (ALS 789)
Among adults who are in cardiac arrest in any setting (P), does 
use of both vasopressin and epinephrine (I), compared with 
using epinephrine alone (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 days, 
180 days, and/or 1 year; survival only at discharge, 30 days, 
60 days, 180 days, and/or 1 year; ROSC (O)?
Consensus on Science
For the critical outcome of survival to hospital discharge 
with CPC of 1 or 2, we found very-low-quality evidence 
(downgraded for very serious bias and serious imprecision) 
from 3 RCTs117–119 (n=2402) comparing SDE with vasopressin 
and epinephrine combination therapy that showed no supe-
riority with vasopressin and epinephrine combination (RR, 
1.32; 95% CI, 0.88–1.98 and ARR, 0.5%; 95% CI, −0.2% to 
1.3%, which translates to 5 more patients/1000 [95% CI, 2 
fewer patients/1000 to 13 more/1000] surviving to hospital 
discharge with a CPC of 1 or 2 with vasopressin in combina-
tion with epinephrine).
For the critical outcome of survival to hospital dis-
charge, we found very-low-quality evidence (downgraded for 
very serious bias and serious imprecision) from 5 RCTs117–
121
 (n=2438) comparing SDE to vasopressin and epineph-
rine combination therapy that did not show superiority with 
vasopressin and epinephrine combination therapy in sur-
vival to discharge (RR, 1.12; 95% CI, 0.84–1.49; P=0.45 
and ARR, −0.17%; 95% CI, −1.3 to 1, which translates to 2 
fewer patients/1000 [95% CI, 13 fewer patients/1000 to 10 
more/1000] surviving to hospital discharge with vasopressin 
in combination with epinephrine).
For the important outcome of survival to admission, 
we found moderate-quality evidence (downgraded for seri-
ous bias) from 5 RCTs117–121 (n=2438) showing no significant 
differences in survival to hospital admission with vasopres-
sin and epinephrine combination therapy (RR, 0.88; 95% CI, 
0.73–1.06; P=0.17).
For the important outcome of ROSC, we found moder-
ate-quality evidence (downgraded for serious bias) from 6 
RCTs117–122 showing no ROSC advantage with vasopressin 
and epinephrine combination therapy (RR, 0.96; 95% CI, 
0.89–1.04; P=0.31).
Treatment Recommendation
We suggest against adding vasopressin to SDE during cardiac 
arrest (weak recommendation, moderate-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we preferred to avoid the 
additional expense and implementation issues required to add 
a drug (vasopressin) that has no evidence of additional benefit 
for patients.
Knowledge Gaps
•	 Until high-quality, adequately powered trials are completed 
comparing epinephrine with placebo, trials involving vaso-
pressin in combination with epinephrine are not required 
unless as a third arm against epinephrine and placebo.
SDE Versus HDE (ALS 778)
In adult patients in cardiac arrest in any setting (P), does HDE 
(at least 0.2 mg/kg or 5 mg bolus dose) (I), compared with 
SDE (1 mg bolus dose) (C), change survival to 180 days with 
good neurologic outcome, survival to 180 days, survival to 
hospital discharge with good neurologic outcome, survival to 
hospital discharge, ROSC (O)?
Consensus on Science
For the critical outcome of survival to hospital discharge 
with CPC 1 or 2, we found very-low-quality evidence (down-
graded for very serious indirectness and serious imprecision) 
from 2 RCTs comparing SDE with HDE123,124 (n=1920) and 
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cumulative RR that did not show any CPC 1 or 2 survival to 
discharge advantage with HDE (RR, 1.2; 95% CI, 0.74–1.96; 
ARR, −0.4%, 95% CI, −1.2 to 0.5, which translates to 3 fewer 
patients/1000 surviving to discharge with a CPC score of 1 
or 2 [95% CI, 12 fewer to 5 more patients/1000 surviving to 
discharge with a CPC score of 1–2]).
For the critical outcome of survival to hospital discharge, 
we found very-low-quality evidence (downgraded for very 
serious indirectness and serious imprecision) from 5 RCTs 
comparing SDE with HDE123–127 (n=2859) that did not show 
any survival to discharge advantage with HDE (RR, 0.97; 95% 
CI, 0.71–1.32; ARR, −0.1%; 95% CI, −0.1 to 0.7, which trans-
lated to 1 fewer patient/1000 surviving to discharge with HDE 
[95% CI, 10 fewer patients/1000 to 7 more patients/1000]).
For the important outcome of survival to hospital 
 admission, we found low-quality evidence (downgraded for 
very serious indirectness) from 4 RCTs comparing SDE with 
HDE123–125,128 (n=2882) showing a survival to hospital admis-
sion advantage with HDE (RR, 1.15; 95% CI, 1.0–1.32).
For the important outcome of ROSC, we found low-qual-
ity evidence (downgraded for very serious indirectness) from 
6 RCTs comparing SDE with HDE123–128 (n=3130) showing a 
ROSC advantage with HDE (RR, 1.17; 95% CI, 1.03–1.34).
Treatment Recommendation
We suggest against the routine use of HDE in cardiac arrest 
(weak recommendation, low-quality evidence).
Values, Preferences, and Task Force Insights
In making this statement, we acknowledge that HDE improves 
short-term outcomes but note that the low-quality evidence 
failed to show an improvement in the critical outcomes of 
survival and neurologic outcome. The absolute magnitude 
of effects of HDE versus SDE on ROSC (RR, 1.17; 95% CI, 
1.03–1.34) and admission to hospital (RR, 1.15; 95% CI, 1.0–
1.32) are modest. These HDE studies were published in the 
1990s, and since then care and outcomes for cardiac arrest 
have changed dramatically, making it hard to interpret the rel-
evance of these results for current care.
Knowledge Gaps
•	 Until high-quality, well-powered trials are completed com-
paring epinephrine with placebo, trials addressing dose 
response of epinephrine are not required except as a third 
arm embedded in an epinephrine-versus-placebo trial.
Timing of Administration of Epinephrine (ALS 784)
Among adults who are in cardiac arrest in any setting (P), does 
early epinephrine delivery by IV or IO route (eg, less than 10 
minutes after the beginning of resuscitation) (I), compared with 
delayed timing of epinephrine delivery (eg, more than 10 min-
utes after the beginning of resuscitation) (C), change survival 
with favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Consensus on Science
In-Hospital Cardiac Arrest
For IHCA, for the critical outcome of survival to hospital 
discharge, there was 1 observational study129 of low quality 
(downgraded for serious risk of bias and upgraded for dose-
response effect) in 25 095 IHCA patients with a nonshockable 
rhythm that showed an improved outcome with early admin-
istration of adrenaline: compared with reference interval of 1 
to 3 minutes, adjusted OR for survival to discharge was 0.91 
(95% CI, 0.82–1.00) when epinephrine was given after 4 to 
6 minutes, 0.74 (95% CI, 0.63–0.88) when given after 7 to 9 
minutes, and 0.63 (95% CI, 0.52–0.76) when given at more 
than 9 minutes after onset of arrest.
For IHCA, for the critical outcome of neurologically 
favorable survival at hospital discharge (assessed with 
CPC 1 or 2), there was 1 observational study129 of low qual-
ity (downgraded for serious risk of bias and upgraded for 
dose-response effect) in 25 095 patients with IHCA with a 
nonshockable rhythm that showed an improved outcome from 
early administration of adrenaline: compared with reference 
interval of 1 to 3 minutes, adjusted OR was 0.93 (95% CI, 
0.82–1.06) with epinephrine given after 4 to 7 minutes, 0.77 
(95% CI, 0.62–0.95) when given after 7 to 9 minutes, and 0.68 
(95% CI, 0.53–0.86) when given at more than 9 minutes after 
onset of arrest.
For IHCA, for the important outcome of ROSC, there 
was 1 observational study129 of low quality (downgraded for 
serious risk of bias and upgraded for dose-response effect) in 
25 095 patients with IHCA with a nonshockable rhythm that 
showed an improved outcome from early administration of 
adrenaline: adjusted OR compared with reference interval of 
1 to 3 minutes of 0.90 (95% CI, 0.85–0.94) when given after 
4 to 7 minutes, 0.81 (95% CI, 0.74–0.89) when given after 7 
to 9 minutes, and 0.70 (95% CI, 0.61–0.75) when given after 
9 minutes.
No studies were identified that looked specifically at the 
effect of timing on administration of epinephrine after IHCA 
with an initial shockable rhythm.
Out-of-Hospital Cardiac Arrest
For the critical outcome of neurologically favorable sur-
vival at hospital discharge (assessed with CPC 1 or 2), there 
was very-low-quality evidence (downgraded for risk of bias, 
inconsistency, indirectness, and imprecision) from 4 obser-
vational studies130–133 involving more than 262 556 OHCAs, 
showing variable benefit from early administration of epineph-
rine. One study of 1556 OHCAs who had achieved ROSC130 
demonstrated an association between the administration of 
epinephrine and worse CPC, but shorter times of administra-
tion were associated with less negative effects: adjusted OR 
of 0.54 (95% CI, 0.32–0.91) for good CPC with epinephrine 
at less than 9 minutes versus no prehospital epinephrine, and 
adjusted OR of 0.17 (95% CI, 0.09–0.34) for epinephrine at 
more than 22 minutes.
Another study enrolling 209 577 OHCAs131 did not show 
any significant difference in 1-month CPC 1 or 2 with epi-
nephrine given in less than 9 minutes compared with no epi-
nephrine (OR, 0.71; 95% CI, 0.54–0.92 and OR, 0.95; 95% 
CI, 0.62–1.37).
Another study enrolling 3161 subjects132 showed an 
association with improved 1-month neurologic outcome in 
VF/pVT OHCA with early epinephrine (at 10 minutes or 
less from EMS call to administration) compared with no 
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epinephrine (OR, 6.34; 95% CI, 1.49–27.02). A fourth study 
enrolling more than 49 000 cases133 demonstrated a nonsignifi-
cant association with improved neurologic survival with early 
epinephrine (less than 10 minutes from EMS-initiated CPR): 
OR of 1.39 (95% CI, 1.08–1.78) versus OR of 2.01 (95% CI, 
0.96–4.22).
For the critical outcome of survival to hospital discharge 
after OHCA, there was very-low-quality evidence (down-
graded for risk of bias, inconsistency, indirectness, and impre-
cision), from 4 observational studies127,131,133,134 enrolling more 
than 420 000 OHCAs that showed variable effect from early 
administration of adrenaline. Goto131 showed no significant 
difference in 1-month survival for shockable rhythms, but 
improved 1-month survival for shockable rhythms with epi-
nephrine at less than 9 minutes (OR, 0.95; 95% CI, 0.77–1.16 
and OR, 1.78; 95% CI, 1.5–2.1). Another study133 showed an 
association with improved survival with early epinephrine 
(less than 10 minutes from EMS CPR): for arrests of cardiac 
origin: OR, 1.73 (95% CI, 1.46–2.04); for noncardiac origin: 
OR, 1.89 (95% CI, 1.37–2.61). A third study134 did not show 
any overall survival benefit for early epinephrine compared 
with late (epinephrine at more or less than 10 minutes): OR, 
0.91 (95% CI, 0.35–2.37).
For the important outcome of ROSC, there was 
very-low-quality evidence (downgraded for risk of bias, 
indirectness, and imprecision) from 4 observational stud-
ies127,131,134,135 of more than 210 000 OHCAs showing an 
association with improved outcome and early administra-
tion of adrenaline. One study135 showed increased ROSC for 
patients receiving the first vasopressor dose early (less than 
10 versus more than 10 minutes after EMS call): OR, 1.91 
(95% CI, 1.01–3.63).
Another study131 showed an association with improved 
ROSC for epinephrine given at less than 9 minutes after arrest 
versus none (for nonshockable rhythms: OR, 8.83; 95% CI, 
8.01–9.73; for shockable rhythms: OR, 1.45; 95% CI, 1.20–
1.75). A third study134 showed an association with improved 
ROSC for early epinephrine versus late (more or less than 10 
minutes after EMS call): OR, 1.78 (95% CI, 1.15–2.74).
The design flaws for most of the observational OHCA 
studies included the use of a “no epinephrine” control group 
as the comparator, thus not allowing for actual estimates of 
the effect of timing, and the lack of known timing of epineph-
rine administration upon arrival in the ED. The relationship of 
timing of defibrillation to timing of epinephrine is unknown 
for studies including shockable rhythms. These design issues 
make the question of timing of epinephrine difficult to inter-
pret in the OHCA setting despite attempts to control for other 
confounders.
Treatment Recommendation
For cardiac arrest with an initial nonshockable rhythm, we 
suggest that if epinephrine is to be administered, it is given 
as soon as feasible after the onset of the arrest (weak recom-
mendation, low-quality evidence).
For cardiac arrest with an initial shockable rhythm, we 
found insufficient evidence to make a treatment sugges-
tion regarding the timing of administration of epinephrine, 
particularly in relation to defibrillation, and the optimal 
timing may vary for different groups of patients and different 
circumstances.
Values, Preferences, and Task Force Insights
In making the recommendation for nonshockable rhythms, we 
place a higher value on being able to modify a current (stan-
dard) treatment at minimal cost.
For shockable rhythms, we place a higher value on early 
defibrillation than on administration of epinephrine but did 
not think there is sufficient evidence to make a treatment rec-
ommendation. Although we acknowledge that the pathophysi-
ology of IHCA and OHCA is likely to be different, we were 
confident that the same recommendations could apply to both 
settings.
Knowledge Gaps
•	 Until high-quality, well-powered trials are completed 
comparing epinephrine with placebo, trials addressing 
the timing of epinephrine doses are not required except 
as a third arm embedded in an epinephrine-versus-pla-
cebo trial.
Steroids for Cardiac Arrest (ALS 433)
Among adults who are in cardiac arrest in any setting (P), 
does corticosteroid or mineralocorticoid administration dur-
ing CPR (I), compared with not using steroids (C), change 
survival with favorable neurologic/functional outcome at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; survival 
only at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC (O)?
Introduction
We identified studies that assessed the use of methylpredniso-
lone, hydrocortisone, or dexamethasone during CPR. Studies 
usually bundled the steroid with other vasoactive drugs. All 
studies examined either IHCA or OHCA. Because the patho-
physiology and epidemiology of IHCA and OHCA are so dif-
ferent, we considered these situations separately.
Consensus on Science
In-Hospital Cardiac Arrest
For the critical outcome of survival to discharge with favor-
able neurologic outcome, there was low-quality evidence 
(downgraded for indirectness and for imprecision) from 1 
RCT136 in 268 patients with IHCA that showed improved out-
come with methylprednisolone, vasopressin, and epinephrine 
during cardiac arrest, and hydrocortisone in those with post-
ROSC shock compared with only epinephrine and placebo 
(18/130 [13.9%] versus 7/138 [5.1%]; RR, 2.94; 95% CI, 
1.16–6.50, which translates to 98 more/1000 surviving with 
good neurologic outcome [95% CI, from 8–279 more/1000 
surviving with good neurologic outcome]).
For the critical outcome of survival to discharge, there 
was low-quality evidence (downgraded for indirectness and 
for imprecision) from 1 RCT137 of 100 patients with IHCA 
that showed improved outcome with the combination of meth-
ylprednisolone, vasopressin, and epinephrine during cardiac 
arrest and hydrocortisone after ROSC for those with shock, 
compared with the use of only epinephrine and placebo (9/48 
[19%] versus 2/52 [4%]; RR, 4.87; 95% CI, 1.17–13.79, which 
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translates to 149 more/1000 surviving to discharge [95% CI, 
7–492 more/1000 surviving to discharge]).
For the important outcome of ROSC, there was low-qual-
ity evidence (downgraded for indirectness and imprecision) 
from 2 RCTs136,137 involving 368 patients with IHCA showing 
improved outcome with the use of methylprednisolone and 
vasopressin in addition to epinephrine, compared with the use 
of placebo and epinephrine alone (combined RR, 1.34; 95% 
CI, 1.21–1.43, which translates to 130–267 more achieving 
ROSC with the combination of methylprednisolone, vasopres-
sin, and epinephrine during cardiac arrest, compared with the 
use of only epinephrine and placebo [95% CI, 130–267 more 
achieving ROSC]).
Out-of-Hospital Cardiac Arrest
For the critical outcome of survival to discharge, there was 
very-low-quality evidence (downgraded for risk of bias, indi-
rectness, and imprecision) from 1 RCT and 1 observational 
study138,139 showing no association with benefit with the use 
of steroids. Paris had no long-term survivors and Tsai showed 
survival to discharge in 8% (3/36) receiving hydrocortisone 
compared with 10% (6/61) receiving placebo (P=0.805).
For the important outcome of ROSC, we found very-low-
quality evidence from 1 RCT138 and 1 observational study139 
with a combined total of 183 patients. The RCT138 showed no 
improvement in ROSC (and ICU admission) with dexametha-
sone given during cardiac arrest compared with placebo (5.4% 
[2/37] versus 8.7% [4/46]), but the observational study139 
showed an association with improved ROSC with hydrocor-
tisone compared with no hydrocortisone (58% versus 38%; 
P=0.049).
Treatment Recommendation
For IHCA, the task force was unable to reach a consensus 
recommendation for or against the use of steroids in cardiac 
arrest.
We suggest against the routine use of steroids during 
CPR for OHCA (weak recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this recommendation for IHCA, it was noted that 
there were no studies assessing the effect of the addition of 
steroids alone to standard treatment for IHCA. Also, although 
the triple-agent drug regimen appears to suggest an association 
with improved outcome, the population studied had very rapid 
ALS, a high incidence of asystolic cardiac arrest, and low base-
line survival compared with other IHCA studies, so some of the 
observed effects might be peculiar to the population studied.
In making this recommendation for OHCA, we considered 
the cost and distraction from the addition of treatments for 
which there is very low confidence in any effect. The differ-
ent recommendation for OHCA and IHCA was influenced by 
the physiological differences between these conditions, such 
as the incidence of sepsis, adrenal insufficiency from critical 
illness, and cardiovascular etiologies.
Knowledge Gaps
•	 It is unclear which aspect of bundled treatments such 
as epinephrine, vasopressin, and steroids are related to 
any observed treatment effect. The alternative possibil-
ity is that bundled treatments require synergistic action, 
because other studies with each agent (vasopressin and 
steroids) have failed to find the same effect.
•	 Confidence in the treatment effects from bundled treat-
ments will increase if confirmed in further studies.
Antiarrhythmic Drugs for Cardiac Arrest (ALS 428)
Among adults who are in cardiac arrest in any setting (P), 
does administration of antiarrhythmic drugs (eg, amioda-
rone, lidocaine, other) (I), compared with not using antiar-
rhythmic drugs (no drug or placebo) (C), change survival 
with favorable neurologic/functional outcome at discharge, 
30 days, 60 days, 180 days, and/or 1 year; survival only 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC (O)?
Introduction
Antiarrhythmic drugs can be used during cardiac arrest for 
refractory ventricular dysrhythmias. Refractory VF/pVT is 
defined differently in many trials but generally refers to failure 
to terminate VF/pVT with 3 stacked shocks, or with the first 
shock. In an ongoing clinical trial from which results are not 
yet available, refractory VF refers to “persistent or recurrent 
VF/pVT after 1 or more shocks.”140
Consensus on Science
Comparative data on the use of antiarrhythmic drugs were 
identified for amiodarone, lidocaine, magnesium, and nifeka-
lant. The data reviewed for magnesium only addressed the use 
of this drug for undifferentiated VF/pVT and not the treatment 
of torsades de pointes or known hypomagnesemic patients. 
Nifekalant is only available in certain regions.
Amiodarone (I) Versus No Amiodarone (C)
For the critical outcome of survival with favorable neu-
rologic/functional outcome at discharge, there was mod-
erate-quality evidence (downgraded due to serious risk of 
indirectness) from 1 RCT involving 504 OHCA patients, 
which detected no difference with administration of amioda-
rone (300 mg after 1 mg of adrenaline) compared with no drug 
(7.3% versus 6.6%; P=not significant [NS]; RR, 1.11; 95% 
CI, 0.59–2.10).141
For the critical outcome of survival at discharge, there 
was moderate-quality evidence (downgraded due to seri-
ous risk of indirectness) from 1 RCT involving 504 OHCA 
patients that detected no difference with the administration 
of amiodarone (300 mg after 1 mg of adrenaline) compared 
with no drug (13.4% versus 13.2%; P=NS; RR, 1.02; 95% CI, 
0.65–1.59).141
For the important outcome of ROSC, there was moderate-
quality evidence (downgraded due to serious risk of indirect-
ness) from 1 RCT involving 504 OHCA patients that showed 
higher ROSC with administration of amiodarone (300 mg 
after 1 mg of adrenaline) compared with no drug (64% versus 
41%; P=0.03; RR, 1.55; 95% CI, 1.31–1.85).141
Lidocaine (I) Versus No Lidocaine (C)
For the critical outcome of survival at discharge, there was 
very-low-quality evidence (downgraded for very serious risk 
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of bias and serious indirectness) from 2 retrospective observa-
tional studies that did not detect a difference with treatment. 
In 290 OHCA patients, rates of survival with administration of 
lidocaine (50 mg, repeatable up to 200 mg) or with no drug did 
not differ (14% versus 8%; P=NS).142 In 116 OHCA patients, 
survival with administration of lidocaine (100 mg) compared 
with no drug did not differ (11% versus 2%; P=NS).143
For the important outcome of ROSC, there was very-low-
quality evidence (downgraded for very serious risk of bias 
and serious indirectness) from 2 retrospective observational 
single-center studies, which showed conflicting results. In 
290 OHCA patients, rates of ROSC were not different after 
administration of lidocaine (50 mg, repeatable up to 200 mg) 
compared with no drug (45% versus 23%; P<0.001).142 In 
116 OHCA patients who had OHCA with VF refractory to 3 
shocks, a similar rate of ROSC was documented with admin-
istration of lidocaine (100 mg) compared with no drug (55% 
versus 54%; P=NS).143
Magnesium (I) Versus No Magnesium (C)
For the critical outcome of survival with favorable neuro-
logic/functional outcome at discharge, there was low-quality 
evidence (downgraded for serious risk of imprecision and indi-
rectness) from 1 single-center RCT of 156 IHCA patients with 
all initial rhythms (50% in VF/pVT), which showed similar 
survival with favorable neurologic outcome with administra-
tion of magnesium (2 g [8 mmol] bolus followed by infusion of 
8 g [32 mmol] in 24 hours) compared with no drugs (favorable 
return to independent living 14.5% versus 7.5%; P=NS; RR, 
1.93; 95% CI, 0.75–4.96; median Glasgow Coma Scale [GCS] 
score at hospital discharge 15 [interquartile range, 15–15] ver-
sus 15 [interquartile range, 15–15]; P=NS).144
For the critical outcome of survival at discharge, there 
was low-quality evidence (downgraded for serious risk of 
imprecision and indirectness) from 4 RCTs, which showed 
no differences in outcome with treatment. One single-center 
RCT of 156 IHCA patients with all initial rhythms (50% in 
VF/pVT) showed similar survival with administration of 
magnesium (2 g [8 mmol] bolus followed by infusion of 8 g 
[32 mmol] in 24 hours) compared with no drugs (21% versus 
21%; P=NS; adjusted OR, 1.22; 95% CI, 0.53–2.81).144 One 
single-center trial of 67 OHCA patients with all rhythms and 
ongoing CPR at ED arrival detected no difference with admin-
istration of magnesium (5 g [20 mmol] bolus) compared with 
no drugs (1 versus 0 patients; P=0.46).145
A multicenter study of 109 OHCA patients with VF did not 
detect a difference in survival with administration of magne-
sium (2 g [8 mmol] bolus) compared with no drugs (3.6% ver-
sus 3.7%; P=1.0; unadjusted RR of increased survival, 0.98; 
95% CI, 0.53–2.81).146 A single-center trial of 105 OHCA 
patients with VF did not detect a difference in survival with 
administration of magnesium (2 g [8 mmol] bolus, repeatable 
once) compared with no drugs (4% versus 2%; P=0.99).147
For the important outcome of ROSC, there was low-qual-
ity evidence (downgraded for serious risk of imprecision and 
indirectness) from 3 RCTs that did not detect a difference with 
treatment. One single-center trial of 67 OHCA patients with 
all rhythms and ongoing CPR at ED arrival detected no differ-
ence with administration of magnesium (5 g [20 mmol] bolus) 
compared with no drugs (23% versus 22%; P=0.97).145 A mul-
ticenter study of 109 OHCA patients with VF did not detect 
difference in ROSC rates with administration of magnesium 
(2 g [8 mmol] bolus) compared with no drugs (25% versus 
19%; P=0.39).146 A single-center trial of 105 OHCA patients 
with VF did not detect a difference in ROSC rates with admin-
istration of magnesium (2 g [8 mmol] bolus, repeatable once) 
compared with no drugs (17% versus 13%; P=0.56).147
Nifekalant (I) Versus No Nifekalant (C)
For the critical outcome of survival at discharge, there was 
very-low-quality evidence (downgraded for very serious risk 
of bias, very serious indirectness, and imprecision) from 1 
retrospective single-center observational study of 63 patients 
with cardiac arrest upon or during hospitalization, which found 
improved survival with administration of nifekalant (loading 
dose 0.27 mg/kg followed by infusion of 0.26 mg/kg/h) com-
pared with no drug in historic controls (OR for cardiac death, 
0.26; 95% CI, 0.07–0.95; P=0.041).148
Treatment Recommendations
We suggest the use of amiodarone in adult patients with 
refractory VF/pVT to improve rates of ROSC (weak recom-
mendation, moderate-quality evidence).
We suggest the use of lidocaine or nifekalant as an alterna-
tive to amiodarone in adult patients with refractory VF/pVT 
(weak recommendation, very-low-quality evidence).
We recommend against the routine use of magnesium in 
adult patients (strong recommendation, low-quality evidence).
Values, Preferences, and Task Force Insights
In making these recommendations, we considered the reported 
beneficial effects of amiodarone on the important outcome of 
survival to hospital admission. We acknowledged that there 
was the uncertainty about any beneficial or harmful effects of 
these drugs on the critical outcomes of survival or favorable 
neurologic survival. Although the evidence supporting their 
use is weaker, in making a recommendation for lidocaine and 
nifekalant as alternatives to amiodarone, the task force rec-
ognized that amiodarone is not available or currently used in 
some countries. The small quantity of new data made the task 
force place value on not changing current clinical practice.
Knowledge Gaps
•	 There is a need for sufficiently powered RCTs to detect 
a difference in survival to hospital discharge or favorable 
neurologic outcomes.
•	 A potential source of bias reducing confidence in prior 
trials of amiodarone is use of the polysorbate solvent for 
the drug. This solvent is known to reduce blood pressure, 
and its use as placebo may have created a bias for worse 
outcomes in placebo groups. Future studies should 
account for this effect or use other solvents.
•	 There is an ongoing trial comparing amiodarone to lido-
caine and to placebo designed and powered to evaluate 
for functional survival.140
•	 No data address how to select a second-line agent when 
VF/pVT is refractory to the first drug.
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2010 CoSTR Topics Not Reviewed in 2015
•	 IV fluids during cardiac arrest
•	 Drugs for atrial fibrillation
•	 Drugs for narrow complex tachycardia
•	 Drugs for monomorphic wide complex tachycardia
•	 Drugs for undifferentiated stable wide complex tachycardia
•	 Drugs for polymorphic wide complex tachycardia
•	 Drugs for torsades de pointes
•	 Drugs for bradycardia
•	 Atropine for cardiac arrest
•	 Calcium for cardiac arrest
•	 Fibrinolytics for cardiac arrest
•	 Buffering agents for cardiac arrest
Cardiac Arrest in Special Circumstances
There are numerous special circumstances where additional 
interventions and/or modifications to ALS may be required. 
The ILCOR ALS Task Force prioritized 5 topics for review: 
(1) cardiac arrest during pregnancy, (2) lipid therapy for car-
diac arrest associated with overdose, (3) opioid toxicity, (4) 
cardiac arrest caused by PE, and (5) cardiac arrest during cor-
onary catheterization.
Cardiac Arrest During Pregnancy (ALS 436)
Among pregnant women who are in cardiac arrest in any set-
ting (P), do any specific interventions (I), compared with stan-
dard care (usual resuscitation practice) (C), change survival 
with favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Introduction
The aim of this PICO review was to assess whether commonly 
applied additions to the standard practice of resuscitation led 
to improved outcomes in pregnant women. Specific empha-
sis was placed on uterine displacement for the purpose of 
decreasing aortocaval compression, and perimortem cesarean 
delivery as interventions to improve outcome in the mother 
and newborn.
Consensus on Science
There were no comparative studies of uterine displacement for 
women in cardiac arrest before delivery. No studies compared 
different maneuvers (eg, manual displacement versus left pel-
vic tilt) to achieve optimal uterine displacement for women in 
cardiac arrest before delivery.
Physiologic reviews and studies of uterine displacement 
maneuvers in nonarrest pregnant women support that uterine 
displacement might be physiologically beneficial for women 
in cardiac arrest.149 Any benefit would have to be weighed 
against the potential interference or delay with usual resus-
citation care.
For the critical outcomes of survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year, and survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year, and 
the important outcomes of ROSC, we found 3 observa-
tional studies of 154 subjects collectively150–152 that provided 
very-low-quality evidence (downgraded for very serious risk 
of bias and imprecision, and serious inconsistency) compar-
ing cardiac arrest resuscitation with or without perimortem 
cesarean delivery. The procedures to ascertain cases and 
controls in these studies were significantly different so that 
the pooled comparison of any of the assigned outcomes is 
considered inappropriate.
Treatment Recommendations
We suggest delivery of the fetus by perimortem cesarean deliv-
ery for women in cardiac arrest in the second half of preg-
nancy (weak recommendation, very-low-quality evidence).
There is insufficient evidence to define a specific time 
interval by which delivery should begin. High-quality usual 
resuscitation care and therapeutic interventions that target the 
most likely cause(s) of cardiac arrest remain important in this 
population.
There is insufficient evidence to make a recommendation 
regarding the use of left lateral tilt and/or uterine displacement 
during CPR in the pregnant patient.
Values, Preferences, and Task Force Insights
In making this statement, we place value on maternal and 
neonatal survival, on the absence of data on left lateral tilt 
and uterine displacement in women with cardiac arrest, and 
on our uncertainty about the absolute effect of either uterine 
displacement or perimortem delivery during CPR on any of 
the assigned outcomes. The task force thought not making a 
recommendation for or against the use of left lateral tilt or 
uterine tilt is unlikely to change current practice or guidelines.
Knowledge Gaps
•	 Research in the area of maternal resuscitation is lacking 
because cardiac arrest in pregnancy is rare. Most evi-
dence is extrapolated from nonpregnant people, manikin 
or simulation studies, and case reports.
•	 The heterogeneous nature of the etiologies of maternal 
cardiac arrest, variations in gestational age and body 
mass index of the cases, variations in the location (eg, 
out-of-hospital, ED, obstetric unit), and context of arrest 
and personnel available to immediately respond, and 
absence of information about the quality of usual resus-
citation care all further hamper interpretation of the lim-
ited available data.
•	 Systematic data collection in pregnant women who 
have experienced cardiac arrest will require a national 
or international registry and/or coordinated prospective 
population-level surveillance to compile a sufficiently 
large and robust data set to evaluate the effect of either 
uterine displacement or perimortem delivery on mater-
nal ROSC, maternal survival, functionally intact mater-
nal survival, neonatal survival, and functionally intact 
neonatal survival.
•	 A particular emphasis on cardiovascular etiologies of 
arrest is warranted given increasing numbers of women 
with congenital heart conditions having children, the 
increasing prevalence of cardiomyopathy among preg-
nant and postpartum women, and the preponderance of 
cardiovascular disease evident in maternal mortality sur-
veillance reports.153
 by guest on N
ovem
ber 29, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
S108  Circulation  October 20, 2015
Lipid Therapy for Cardiac Arrest (ALS 834)
In adult patients with cardiac arrest due to suspected drug 
toxicity (eg, local anesthetics, tricyclic antidepressants, oth-
ers) (P), does administration of IV lipid (I), compared with 
no IV lipid (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Introduction
Lipid therapy for cardiac arrest associated with drug toxicity, and 
in particular local anesthetic toxicity, is becoming increasingly 
common. Based on laboratory and preclinical data showing that 
IV administration of lipid solutions can absorb lipid-soluble 
drugs, studies examined whether this therapy would be useful 
for cardiac arrest related to drug overdose. We set out to identify 
studies comparing outcomes with IV lipids to no IV lipids.
Consensus on Science
We identified no human comparative studies in cardiac arrest 
and periarrest states relevant to the PICO question. Many case 
reports and case series described resuscitation that included 
administration of lipid.
Treatment Recommendation
We are unable to make any evidence-based treatment recom-
mendation about the use of IV lipid emulsion to treat toxin-
induced cardiac arrest.
Values, Preferences, and Task Force Insights
Although there are many case reports and case series of 
patients who were resuscitated after administration of IV 
lipid, the absence of any comparative data made it impossible 
to determine anything besides temporal association of the 
therapy with outcome. Despite the paucity of data, we do not 
wish to discourage the use of an antidote with some theoreti-
cal basis in a dire clinical situation.
Knowledge Gaps
•	 Comparisons are needed of patients with similar clini-
cal characteristics who were treated and who were not 
treated with IV lipids after suspected drug toxicity.
Opioid Toxicity (ALS 441)
Among adults who are in cardiac arrest or respiratory arrest 
due to opioid toxicity in any setting (P), does any specific ther-
apy (eg, naloxone, bicarbonate, or other drugs) (I), compared 
with usual ALS (C), change survival with favorable neuro-
logic/functional outcome at discharge, 30 days, 60 days, 180 
days, and/or 1 year; survival only at discharge, 30 days, 60 
days, 180 days, and/or 1 year; ROSC (O)?
Introduction
Opioid toxicity is associated with respiratory depression 
that can lead to cardiorespiratory arrest. This is becoming an 
increasingly common cause of death in many countries.154 
The specific role of education and availability of naloxone 
for those with a high risk of opioid overdose is addressed in 
“Part 3: Adult Basic Life Support and Automated External 
Defibrillation.” Here we address whether any specific 
modifications to ALS are required when cardiac arrest is pre-
cipitated by opioid toxicity.
Cardiac arrest and respiratory arrest were considered sep-
arately. We sought evidence that compared results with any 
changes in usual resuscitation sequences or interventions in 
the setting of opioid overdose. Administration of the opioid 
antagonist naloxone was the only intervention for which lit-
erature was identified.
Consensus on Science
For the important outcome of survival with favorable neuro-
logic outcome at discharge, 30 days, 60 days, 180 days, and/or 
1 year, survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year, ROSC, after opioid-induced cardiac arrest, we 
found no study with comparative data beyond standard ALS care.
For the important outcome of survival with favorable 
neurologic outcome at discharge, 30 days, 60 days, 180 
days, and/or 1 year, survival only at discharge, 30 days, 60 
days, 180 days, and/or 1 year, ROSC, after opioid-induced 
respiratory arrest, we found no comparative studies. There 
were 12 studies of which 5 compared intramuscular and 
intranasal routes of naloxone administration (2 RCT,156,157 3 
non-RCT,158–160 and 7 assessed the safety of naloxone use or 
were observational studies of naloxone use).161–169, These stud-
ies report that naloxone is safe and effective in treatment of 
opioid-induced respiratory depression, that complications are 
rare and dose related, and that mortality is rare when patients 
refuse transfer after initial naloxone administration.
Treatment Recommendation
We recommend the use of naloxone by IV, intramuscular, 
subcutaneous, IO, or intranasal routes in respiratory arrest 
associated with opioid toxicity (strong recommendation, very-
low-quality evidence). The dose of naloxone required will 
depend on the route.
We can make no recommendation regarding the modifica-
tion of standard ALS in opioid-induced cardiac arrest.
Values, Preferences, and Task Force Insights
In making these recommendations, we place a high value on 
the potential of the opioid antagonist naloxone to reverse opi-
oid-induced respiratory depression.
Knowledge Gaps
•	 There are no data on the use of any additional ALS thera-
pies in opioid-induced cardiac arrest. In respiratory arrest, 
there is only evidence for the use of naloxone—no other 
adjuncts or changes in sequence of interventions. Studies 
of naloxone use in respiratory arrest were observational, 
looked at safety, or compared routes of administration.
Cardiac Arrest Associated With PE (ALS 435)
Among adults who are in cardiac arrest due to PE or suspected 
PE in any setting (P), does any specific alteration in treatment 
algorithm (eg, fibrinolytics, or any other) (I), compared with 
standard care (according to 2010 treatment algorithm) (C), 
change survival with favorable neurologic/functional outcome 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; sur-
vival only at discharge, 30 days, 60 days, 180 days, and/or 1 
year; ROSC (O)?
 by guest on N
ovem
ber 29, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Callaway et al  Part 4: Advanced Life Support  S109
Introduction
The possible treatments for massive PE include fibrinolytic 
therapy, surgical embolectomy, and percutaneous mechanical 
thrombectomy. Most retrospective studies do not make subgroup 
analysis of patients with suspected or confirmed PE. These treat-
ments were assessed separately as therapies during cardiac arrest 
as a consequence of PE. The reported outcomes and follow-up 
of patients is very heterogeneous between studies.
Consensus on Science
Fibrinolysis
For the critical outcome of survival with favorable neu-
rologic status at 30, 90, or 180 days, there was very-low-
quality evidence (downgraded for serious imprecision) from 
1 RCT comparing fibrinolytics versus placebo during car-
diac arrest.170 In this double-blinded RCT, 37 of the 1050 
patients randomized to receive either fibrinolytic treatment 
(tenecteplase) or placebo during CPR had confirmed PE as 
primary cause of cardiac arrest. However, this study was not 
powered to reach significance in this small subgroup. Patients 
in whom PE was suspected were furthermore subject to use 
of open-label fibrinolysis and were not included in the trial at 
all. The 30-day survival in this subgroup was not statistically 
different (P=0.31; RR, 7.19; 95% CI, 0.37–139.9) between 
tenecteplase (2/15, 13.3%) and placebo (0/22, 0%).
For the important outcome of survival to hospital dis-
charge, very-low-quality evidence (downgraded for very 
serious risk of bias and imprecision) from 2 retrospective obser-
vational studies showed there was no difference in discharge 
rates: 9.5% fibrinolysis versus 4.8% control171 and 19.4% fibri-
nolysis versus 6.7% control (RR, 2.9; 95% CI, 0.75–13.8).172
For the important outcome of ROSC, very-low-quality 
evidence from 2 studies (downgraded for very serious risk of 
bias) showed benefit for the use of fibrinolytic drugs compared 
with controls in patients with PE: ROSC was reported to be sig-
nificantly higher in a retrospective analysis (81.0% fibrinolysis 
versus 42.9% control; P=0.03).171 In a separate study, ROSC 
(66.7% in fibrinolysis group versus 43.3% in control group; RR, 
1.5; 95% CI, 0.8–8.6) was not different, but 24-hour survival 
(52.8% fibrinolysis versus 23.3% control; RR, 2.3; 95% CI, 1.1–
4.7) showed favorable results for the use of fibrinolytic drugs.172
Surgical Embolectomy
We found very-low-quality evidence (downgraded for very 
serious risk of publication bias) from 2 case series173,174 with 
no control groups and a total of 21 patients requiring CPR 
with a 30-day survival rate of 12.5% and 71.4%, respectively.
Percutaneous Mechanical Thrombectomy
For the important outcome of ROSC, very-low-quality evi-
dence (downgraded for very serious risk of bias and very serious 
imprecision) from 1 case series of 7 patients with cardiac arrest 
with no control group,175 ROSC was achieved in 6 of 7 patients 
(85.7%) treated with percutaneous mechanical thrombectomy.
Treatment Recommendations
We suggest administering fibrinolytic drugs for cardiac arrest 
when PE is the suspected cause of cardiac arrest (weak recom-
mendation, very-low-quality evidence).
We suggest the use of fibrinolytic drugs or surgical embo-
lectomy or percutaneous mechanical thrombectomy for car-
diac arrest when PE is the known cause of cardiac arrest (weak 
recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making these recommendations, we acknowledge the use 
of thrombolytic drugs, surgical embolectomy or percutaneous 
mechanical thrombectomy, or a combination for known PE in 
non–cardiac arrest patients. We acknowledge the potential risk 
of bleeding after fibrinolysis and place value in the choice of 
intervention taking into account location, availability of inter-
ventions, and contraindications to fibrinolysis.
Knowledge Gaps
•	 There is a paucity of data on the topic of pulmonary 
embolus and its diagnosis and management during car-
diac arrest. Further high-quality studies are required.
Cardiac Arrest During Coronary Catheterization 
(ALS 479)
Among adults who have a cardiac arrest in the cardiac catheter-
ization laboratory (P), does any special intervention or change in 
care (eg, catheterization during CPR, cardiopulmonary bypass, 
balloon pump, different timing of shocks) (I), compared with 
standard resuscitation care (eg, CPR, drugs, and shocks accord-
ing to 2010 treatment algorithm) (C), change survival with 
favorable neurologic/functional outcome at discharge, 30 days, 
60 days, 180 days, and/or 1 year; survival only at discharge, 30 
days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Introduction
We examined the literature for any studies comparing novel 
treatments during cardiac arrest that occurs during cardiac 
catheterization in addition to standard ALS approaches (eg, 
defibrillation) to cardiac arrest. The search was intended to 
find studies about any changes in sequence of interventions or 
about routine use of advanced circulatory support techniques.
Consensus on Science
There were no comparative studies evaluating the survival 
benefit of mechanical CPR; however, individual noncompara-
tive case series reported variable survival rates.
For the critical outcomes of survival with favorable neu-
rologic/functional outcome at discharge, 30 days, 60 days, 
90 days, 180 days, and 1 year, and the outcomes of survival 
at 30 days, 60 days, 90 days, and 180 days, and 1 year, no 
studies were identified.
For the critical outcomes of survival to discharge and 
survival to 6 months, and the important outcome of ROSC, 
very-low-quality evidence (downgraded for very serious 
imprecision and risk of bias) from 1 observational study176 
compared ECLS with intra-aortic balloon pump and medi-
cal therapy for cardiogenic shock during PCI for ST-segment 
elevation myocardial infarction. There were 21 subjects with 
cardiac arrest during PCI, and all survivors were in the ECLS 
group.
Treatment Recommendation
We suggest the use of ECLS as a rescue treatment when initial 
therapy is failing for cardiac arrest that occurs during coronary 
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catheterization (weak recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this weak recommendation, the task force puts a 
higher value on usual ALS measures such as defibrillation.
We have not made a specific recommendation here regarding 
the use of automated mechanical chest compressions, because we 
found no studies that addressed this question. We have suggested 
previously that automated mechanical chest compression devices 
are a reasonable alternative to high-quality manual chest com-
pressions in situations where sustained high-quality manual chest 
compressions are impractical or compromise provider safety. This 
earlier weak recommendation could, therefore, apply to cardiac 
arrest during coronary catheterization. ECLS encompasses ECPR. 
We have already suggested ECPR is a reasonable rescue therapy 
for selected patients with cardiac arrest when initial conventional 
CPR is failing in settings where this can be implemented.
Knowledge Gaps
•	 There is a lack of data about specific interventions to 
treat cardiac arrest during coronary catheterization.
2010 CoSTR Topics Not Reviewed in 2015
•	 Anaphylaxis and cardiac arrest
•	 Asthma and cardiac arrest
•	 Post-op cardiothoracic surgery cardiac arrest
•	 Cardiac tamponade
•	 Noncardiac etiology cardiac arrest
•	 Benzodiazepine toxicity
•	 β-blocker toxicity
•	 Calcium channel blocker toxicity
•	 Carbon monoxide toxicity
•	 Cocaine toxicity
•	 Cyanide toxicity
•	 Tricyclic antidepressant toxicity
•	 Digoxin toxicity
•	 Electrolyte disturbances
•	 Avalanche victims
Postresuscitation Care
Since 2010, there has been a considerable quantity of data 
published with the domain of postresuscitation care. The 
ILCOR ALS Task Force prioritized 9 topics for review: (1) 
oxygen dose after ROSC, (2) post-ROSC ventilation strategy, 
(3) hemodynamic support, (4) antiarrhythmic drugs, (5) TTM, 
(6) post–cardiac arrest seizures, (7) glucose control, (8) prog-
nostication, and (9) organ donation.
Oxygen Dose After ROSC in Adults (ALS 448)
Among adults who have ROSC after cardiac arrest in any 
setting (P), does an inspired oxygen concentration titrated to 
oxygenation (normal oxygen saturation or partial pressure of 
oxygen) (I), compared with the use of 100% inspired oxy-
gen concentration (C), change survival to 30 days with good 
neurologic outcome, survival to hospital discharge with good 
neurologic outcome, improve survival, survival to 30 days, 
survival to hospital discharge (O)?
Introduction
Previous preclinical work suggests that hyperoxia may be 
injurious in the post–cardiac arrest period. However, whether 
these findings apply to humans remains unclear. This PICO 
question evaluated whether titration of oxygen in post–cardiac 
arrest patients alters outcome.
Consensus on Science
30% Versus 100% Inspired Oxygen for 60 Minutes After 
ROSC
For the critical outcome of survival to hospital discharge 
with favorable neurologic outcome (CPC 1 or 2), 1 RCT 
enrolling 32 OHCA (of which 4 excluded) patients (very-low-
quality evidence, downgraded for serious risk of bias, indi-
rectness, and imprecision)177 showed no difference between 
30% inspired oxygen for 60 minutes after ROSC versus 100% 
inspired oxygen for 60 minutes after ROSC (8/14 versus 6/14; 
unadjusted RR for survival, 1.33; 95% CI, 0.63–2.84).
For the critical outcome of survival to hospital dis-
charge, 1 RCT (very-low-quality evidence, downgraded for 
small numbers, lack of blinding, indirectness, misallocation of 
patients)177 showed no difference between 30% inspired oxy-
gen for 60 minutes after ROSC and 100% inspired oxygen for 
60 minutes after ROSC (10/14 versus 10/14; unadjusted RR 
for survival, 1.0; 95% CI, 0.63–1.60).
Hyperoxia Versus Normoxia
For the critical outcome of survival to 12 months with favor-
able neurologic outcome (CPC 1 or 2), 1 study178 of very-
low-quality evidence (downgraded for very serious risk of 
bias and indirectness) showed no harmful effect associated 
with hyperoxia during the first 24 hours of ICU care.
For the critical outcome of survival to hospital discharge 
with favorable neurologic outcome (CPC 1 or 2), 5 low-
quality (downgraded as very serious bias and serious incon-
sistency, indirectness, confounding) observational studies 
showed conflicting results.179–183 Two studies showed hyper-
oxia was worse than normoxia.179,181
Three studies reported favorable neurologic outcome as 
CPC 1 or 2. Very-low-quality evidence (downgraded because 
of very serious bias and serious inconsistency, indirectness, 
confounding) from a single-center study of 170 ICU patients 
treated with therapeutic hypothermia showed that the maxi-
mum Pao2 in the first 24 hours after arrest was associated with 
a worse outcome (poor neurologic status at hospital discharge; 
adjusted OR, 1.485; 95% CI, 1.032–2.136).181 Very-low-quality 
evidence (downgraded because of very serious bias and serious 
inconsistency, indirectness, confounding) from a single-center 
study of 193 ICU patients showed that the first Pao2 after 
ROSC was not associated with outcome (hyperoxia adjusted 
OR for poor neurologic outcome, 1.05; 95% CI, 0.45–2.42).182 
Very-low-quality evidence (downgraded because of very seri-
ous bias and serious inconsistency, indirectness, confounding) 
from a single-center study of 184 ICU patients showed that 
oxygen exposure over first 24 hours of ventilation was not 
associated with outcome with unadjusted and adjusted out-
comes (effect size cannot be estimated from data).183
Two studies used surrogate measures of favorable neu-
rologic outcome. Very-low-quality evidence (downgraded 
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because of very serious bias and serious inconsistency, indi-
rectness, confounding) from an observational study179 showed 
worse independent functional survival at hospital discharge 
(hyperoxia versus normoxia, 124/1156 versus 245/1171 [29% 
versus 38%]; unadjusted OR, 0.45; 95% CI, 0.36–0.58). Very-
low-quality evidence (downgraded because of very serious 
bias and serious inconsistency, indirectness, confounding) 
from an observational study180 showed no difference in dis-
charge to home (hyperoxia versus normoxia [27 versus 34%]; 
effect size cannot be estimated from data).
For the critical outcome of survival to discharge (or sur-
vival to 30 days), very-low-quality evidence (downgraded 
because of very serious bias and serious inconsistency, indi-
rectness, confounding) from 7 observational studies showed 
conflicting results.179–181,183–186 Four studies showed hyperoxia 
worse than normoxia.179,181,183,184
One study showed a worse outcome with hyperoxia versus 
normoxia based on the first ICU Pao2 (in-hospital mortality 
63% versus 45%; adjusted OR hyperoxia exposure, 1.8; 95% 
CI, 1.5–2.2).179 Another study showed a 100 mm Hg increase 
in Pao2 was associated with a 24% increase in mortality risk 
(OR, 1.24; 95% CI, 1.18–1.31).184 One study showed no asso-
ciation between hyperoxia versus normoxia (based on the 
worse Pao2 in first 24 hours on ICU; adjusted OR for hospital 
mortality, 1.2; 95% CI, 1.0–1.5).180 A single-center study of 
170 ICU patients treated with therapeutic hypothermia docu-
mented that the maximum Pao2 in the first 24 hours after arrest 
was associated with a worse outcome.181 Survivors had lower 
maximum Pao2 (198 mm Hg; interquartile range, 152.5–282) 
versus nonsurvivors (254 mm Hg; interquartile range, 172–
363); adjusted OR—higher Pao2 increased in-hospital mortal-
ity (OR, 1.439; 95% CI, 1.028–2.015). In a data linkage study 
of worse Pao2 (highest/lowest) in first 24 on ICU, hyperoxia 
was not associated with outcome (hospital mortality 47% ver-
sus 41%; adjusted OR hyperoxia versus normoxia, 1.2; 95% 
CI, 0.51–2.82).185 Another study of 122 ICU patients showed 
no difference between patients with hyperoxia (Pao2 greater 
than 300 mm Hg in first 24 hours after arrest) and normoxia 
(22/49 versus 25/70; unadjusted OR, 0.68; 95% CI, 0.32–1.44) 
for 30-day survival or survival to discharge (20/49 versus 
24/70; unadjusted OR, 0.76; 95% CI, 0.36–1.61).186 In another 
study of 184 ICU patients, the 36% with severe hyperoxia had 
a mortality of 54%, and the presence of severe hyperoxia was 
associated with decreased survival in both unadjusted and 
adjusted analysis (adjusted OR for survival, 0.83 per hour 
exposure; 95% CI, 0.69–0.99).183
For the important outcome of survival to ICU discharge, 
very-low-quality evidence (downgraded because of very seri-
ous bias, serious indirectness, confounding) from 2 observa-
tional studies showed no harm from hyperoxia.185,186 In a data 
linkage study of worse Pao2 (highest/lowest) in first 24 on 
ICU, hyperoxia was not associated with outcome (ICU mor-
tality 35% versus 32% for hyperoxia versus normoxia; unad-
justed OR, 1.16; 95% CI, 0.56–2.40).185 One observational 
study enrolling 122 ICU admissions patients showed no dif-
ference in survival to 30 days between patients with hyperoxia 
(Pao2 greater than 300 mm Hg in first 24 hours after arrest) 
and normoxia (ICU discharge 53% versus 46%; adjusted OR, 
0.75; 95% CI, 0.36–1.55).186
Hypoxia Versus Normoxia
For the critical outcome of survival to discharge (or survival 
to 30 days), very-low-quality evidence (downgraded because 
of very serious bias and serious indirectness, confounding) 
from 2 of 3 observational studies showed worse outcomes 
with hypoxia.179,180,185 One study showed a worse outcome with 
hypoxia versus normoxia based on the first ICU Pao2 (57% 
versus 45%; adjusted OR hypoxia exposure, 1.3; 95% CI, 1.1–
1.5).179 Another study documented that hypoxia versus nor-
moxia (based on the worse Pao2 in first 24 hours on ICU) was 
associated with higher hospital mortality of 60% versus 47% 
(OR, 1.2; 95% CI, 1.1–1.4) but no difference in discharge to 
home (hypoxia/poor oxygen exchange versus normoxia 26% 
versus 24%).180 In a data linkage study of worse Pao2 (high-
est/lowest) in first 24 hours on ICU, there was no difference 
in outcome between hypoxia and normoxia (for in-hospital 
mortality, 51% versus 41%; adjusted OR hypoxia versus nor-
moxia, 0.93; 95% CI, 0.47–1.87).185
For the important outcome of survival to ICU discharge, 
very-low-quality evidence (downgraded because of very seri-
ous bias, serious indirectness, and confounding) from 1 obser-
vational study showed hypoxia was associated with a worse 
outcome.185 Worse Pao2 (highest/lowest) in first 24 hours in 
ICU was associated with a worse unadjusted outcome (ICU 
mortality 49% versus 32% for hypoxia versus normoxia; 
unadjusted OR, 2.15; 95% CI, 1.23–3.77; RR, 0.74; 95% CI, 
0.56–0.96).
Treatment Recommendations
We recommend avoiding hypoxia in adults with ROSC after 
cardiac arrest in any setting (strong recommendation, very-
low-quality evidence).
We suggest avoiding hyperoxia in adults with ROSC after 
cardiac arrest in any setting (weak recommendation, very-
low-quality evidence).
We suggest the use of 100% inspired oxygen until the arte-
rial oxygen saturation or the partial pressure of arterial oxygen 
can be measured reliably in adults with ROSC after cardiac 
arrest in any setting (weak recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making these recommendations, we think, despite the very-
low-quality evidence, there is likely to be far greater actual 
harm from hypoxia and, therefore, make a strong recommen-
dation that hypoxia should be avoided. The evidence for harm 
associated with hyperoxia is of very low quality and inconsis-
tent, hence the weak recommendation.
Knowledge Gaps
•	 There is a lack of clinical trials evaluating titration of 
oxygen after ROSC.
•	 Observational data vary considerably on definitions 
of hyperoxia and the optimal timing and mechanisms 
for measurement (arterial oxygenation versus oxygen 
saturation).
•	 Future studies are necessary to define the optimal 
approach to titration of oxygen in post–cardiac arrest 
patients taking into account measurement as well as 
timing/duration.
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Postresuscitation Ventilation Strategy (ALS 571)
Among adults with ROSC after cardiac arrest in any set-
ting (P), does ventilation to a specific Paco2 goal (I), com-
pared with no specific strategy or a different Paco2 goal (C), 
change survival at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/or 1 
year (O)?
Introduction
Post–cardiac arrest patients often have pulmonary injury and/
or aspiration, and also have the added concern of ischemia-
reperfusion injury to the brain. Thus, the post–cardiac arrest 
ventilator management may need to consider both brain and 
lung injury when determining specific strategies for mechani-
cal ventilation. This PICO question addressed whether 
mechanical ventilation after cardiac arrest to achieve any spe-
cific Paco2 goal was superior to any other Paco2 goal.
Consensus on Science
No studies have specifically randomized patients to ventila-
tion to a specific Paco2 goal.
Hypocapnia
For the critical outcome of neurologically favorable sur-
vival, 2 very-low-quality cohort studies182,187 with a total of 
8376 patients (downgraded for very serious concerns about 
risk of bias and imprecision) showed hypocapnia (less than 
3.0 kPa and less than 4.7 kPa, respectively) was associated 
with a worse outcome. For the critical outcome of death (or 
failure to be discharged home), 1 very-low-quality cohort 
study188 of 6881 patients (downgraded for very serious con-
cerns about risk of bias and imprecision) showed hypocapnia 
(less than 4.7 kPa) was associated with a worse outcome.
Hypercapnia
For the critical outcome of neurologically favorable sur-
vival, 3 observational cohort studies showed inconsistent 
associations between hypercapnia and outcome (very-low-
quality evidence, downgraded for very serious concerns about 
risk of bias, imprecision, and inconsistency). One study182 
with a total of 123 patients showed worse outcome in patients 
ventilated to hypercapnia (Paco2 greater than 6.7 kPa). One 
study187 with a total of 850 patients showed no difference in 
outcome for patients ventilated to hypercapnia (Paco2 greater 
than 6.0 kPa). One study178 with a total of 409 patients showed 
better outcome for patients ventilated to hypercapnia (Paco2 
5.1–10.1 kPa).
For the critical outcome of death (or failure to be dis-
charged home), 2 cohort studies showed uncertain associa-
tions with outcome (downgraded for very serious concerns 
about risk of bias and imprecision). One study188 with a total of 
16 542 patients, showed no difference in outcome for patients 
ventilated to hypercapnia (Paco2 greater than 6.0 kPa). One 
study187 with a total of 850 patients showed a higher mean 
Paco2 in survivors.
Treatment Recommendation
We suggest maintaining Paco2 within a normal physiological 
range as part of a post-ROSC bundle of care (weak recom-
mendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, the task force did not find 
good evidence to suggest or recommend either hypercarbia or 
hypocarbia. In the absence of evidence to that end, combined 
with a potential suggestion of harm, we suggest maintaining 
normocarbia. Many physiological considerations may influ-
ence selection of Paco2 goals for individual patients.
Knowledge Gaps
•	 There are no randomized prospective controlled trials 
evaluating different Paco2 goals in post–cardiac arrest 
patients.
•	 Evaluation of optimal Paco2 goals may need to be deter-
mined in populations both with and without lung injury.
Postresuscitation Hemodynamic Support (ALS 570)
Among adults with ROSC after cardiac arrest in any setting 
(P), does titration of therapy to achieve a specific hemody-
namic goal (eg, MAP greater than 65 mm Hg) (I), compared 
with no hemodynamic goal (C), change survival with favor-
able neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival at discharge, 30 days, 
60 days, 180 days, and/or 1 year (O)?
Introduction
In the post–cardiac arrest period, patients often have persis-
tent tissue hypoperfusion/hemodynamic instability. The opti-
mal approach to resuscitation of patients after cardiac arrest 
remains unknown.
Consensus on Science
There are no RCTs addressing hemodynamic goals after 
resuscitation.
Titration of Therapy to Achieve a Specific Hemodynamic 
Goal (eg, MAP of More Than 65 mm Hg) Compared With No 
Hemodynamic Goal
For the critical outcome of survival with favorable neu-
rologic/functional outcome, very-low-quality evidence 
(downgraded for risk of bias and publication bias) from 1 mul-
ticenter retrospective nonintervention study including 8736 
subjects showed post–cardiac arrest SBP less than 90 mm Hg 
was associated with higher mortality (65% versus 37%) and 
diminished discharge functional status in survivors (49% ver-
sus 38%).189
For the critical outcome of survival, very-low-quality 
evidence (downgraded for risks of bias and publication bias) 
from 2 retrospective single-center studies including 2282 
patients showed reduced survival for patients with post-ROSC 
SBP less than 90 mm Hg190 and less than 100 mm Hg.191
Bundle of Therapies With a Specific Blood Pressure Target 
Compared With No Bundle
For the critical outcome of survival with favorable neuro-
logic/functional outcome, we found very-low-quality evi-
dence (downgraded for risks of bias and publication bias) 
from 7 studies that included 813 subjects. One pre-/post-
study of early goal-directed therapy of 36 patients with a 
MAP target greater than 80 mm Hg showed no difference 
in mortality or neurologic outcome at hospital discharge.192 
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One prospective observational study of 118 patients using 
historic controls showed that aiming for MAP greater than 
65 mm Hg increased survival to hospital discharge with a 
favorable neurologic outcome at 1 year in 34 of 61 (56%) 
versus 15 of 58 (26%) in the control period (OR, 3.61; CI, 
1.66–7.84; P=0.001).193 One cohort study of 148 patients 
showed no difference in neurologic outcome at hospital dis-
charge when a MAP less than 75 mm Hg was a threshold 
for intervention.194 One retrospective study of 136 patients 
identified groups with MAP greater than 100 mm Hg or less 
than 100 mm Hg after ROSC. Good neurologic recovery was 
independently and directly related to MAP measured during 
2 hours after ROSC (r2=0.26).195 One before-and-after obser-
vational study of a care bundle, including 55 subjects aiming 
for a MAP greater than 65 mm Hg within 6 hours, showed 
no change of in-hospital mortality (55.2% [bundle] versus 
69.2% [prebundle]) or CPC 1 or 2 (31% versus 12%).196 In 1 
prospective single-center observational study of 151 patients 
receiving a bundle of therapies where 44 (29%) experienced 
good neurologic outcome, a time-weighted average MAP 
threshold greater than 70 mm Hg had the strongest asso-
ciation with good neurologic outcome (OR, 4.11; 95% CI, 
1.34–12.66; P=0.014).197 One retrospective study of bundle 
therapy targeting a MAP greater than 80 mm Hg in 168 
patients showed survivors had higher MAPs at 1 hour (96 
versus 84 mm Hg), 6 hours (96 versus 90 mm Hg; P=0.014), 
and 24 hours (86 versus 78 mm Hg) when compared with 
nonsurvivors. Increased requirement for vasoactive drugs 
was associated with mortality at all time points. Among those 
requiring vasoactive drugs, survivors had higher MAPs than 
nonsurvivors at 1 hour (97 versus 82 mm Hg) and 6 hours (94 
versus 87 mm Hg).198
For the critical outcome of survival, we found very-low-
quality evidence (downgraded for risks of bias and publica-
tion bias) from 2 studies including 91 patients that assessed 
the impact of postresuscitation goal-directed/bundles of care 
(including blood pressure targets) on survival. One pre-/post-
study of early goal-directed therapy of 36 patients including 
a MAP target greater than 80 mm Hg showed no difference in 
mortality at hospital discharge.192 One pre-/postobservational 
study of a care bundle including 55 patients aiming for a MAP 
greater than 65 mm Hg within 6 hours resulted in an in-hos-
pital mortality of 55.2% (bundle) versus 69.2% (prebundle) 
(P=0.29; RR, 0.80; 95% CI, 0.53–1.21).196
Treatment Recommendations
We suggest hemodynamic goals (eg, MAP, SBP) be consid-
ered during postresuscitation care and as part of any bundle of 
postresuscitation interventions (weak recommendation, low-
quality evidence).
There is insufficient evidence to recommend specific 
hemodynamic goals; such goals should be considered on 
an individual patient basis and are likely to be influenced 
by post–cardiac arrest status and pre-existing comorbidities 
(weak recommendation, low-quality evidence).
Values, Preferences, and Task Force Insights
In making these recommendations, we place a higher value 
on the recognition that while hemodynamic goals are likely 
important to optimize outcome, specific targets remain 
unknown and likely vary depending on individual physiology 
and comorbid status.
Knowledge Gaps
•	 There are no prospective, randomized trials on spe-
cific hemodynamic targets or goals with respect to 
outcome.
•	 Comorbidities and the complexities of individual-based 
physiology should ideally be taken into account in future 
investigations into hemodynamic targets/goals.
•	 Future studies of measurement of actual blood flow and 
tissue perfusion, particularly cerebral perfusion, and the 
role of noninvasive technology are desirable.
Postresuscitation Antiarrhythmic Drugs (ALS 493)
Among adults with ROSC after cardiac arrest in any setting 
(P), do prophylactic antiarrhythmic drugs given immediately 
after ROSC (I), compared with not giving antiarrhythmic 
drugs (C), change survival with favorable neurologic/func-
tional outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; development of cardiac arrest; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; recurrence 
of VF; incidence of arrhythmias (O)?
Introduction
After ROSC from cardiac arrest, the decision to initiate or 
continue therapy with antiarrhythmic medications remains 
uncertain. Literature was found for both β-blocking medica-
tions and lidocaine. We identified no studies of magnesium, 
amiodarone, procainamide, bretylium, or nifekalant.
Consensus on Science
β-Blockers (I) Versus No β-Blockers (C)
For the critical outcome of survival at 6 months, we have 
identified very-low-quality evidence (downgraded for serious 
risk of bias, indirectness, and imprecision) from 1 observa-
tional study of 98 patients resuscitated from OHCA showing 
a higher rate of survival with administration of β-blockers 
(metoprolol or bisoprolol) for 72 hours after ROSC compared 
with no drug (55.7% versus 21.1%; P<0.001; RR, 2.65; 95% 
CI, 1.08–6.46) and after adjusting for the Utstein variables 
(specific OR data not available; P=0.002).199
Lidocaine (I) Versus No Lidocaine (C)
For the important outcome of recurrence of VF, we identi-
fied very-low-quality evidence (downgraded for serious risk 
of bias and indirectness) from 1 observational study of 1721 
patients resuscitated from OHCA showing a lower adjusted 
(adjusted by the Utstein variables and matched by propensity 
scores) rate of recurrence of VF following lidocaine bolus 
and/or continuous infusion immediately after ROSC com-
pared with no drug (OR, 0.34; 95% CI, 0.26–0.44).200
For the critical outcome of survival to hospital discharge, 
we identified very-low-quality evidence (downgraded for seri-
ous risk of bias and indirectness) from 1 observational study 
of 1721 patients resuscitated from OHCA showing a higher 
rate of survival to hospital discharge after adjusting for the 
Utstein variables (OR, 1.49; 95% CI, 1.15–1.95) but no differ-
ence after propensity-matching analysis (OR, not reported).200
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Treatment Recommendation
We make no recommendation about the routine prophylactic 
use of antiarrhythmic drugs post after ROSC (GRADE used 
for evidence evaluation and synthesis only, very low confi-
dence in effect estimate).
Values, Preferences, and Task Force Insights
The available data were too limited to have any confidence in 
any effect, and, therefore, no recommendation is made. We 
also place value on avoiding known side effects of medica-
tions when the treatment effect was unproven or unknown. 
The studies evaluated were all observational, and no causal 
relation could be determined. Moreover, they were performed 
before changes in current practice (ie, currently amiodarone is 
used during cardiac arrest more than lidocaine).
Knowledge Gaps
•	 There are no randomized trials for any antiarrhythmic 
drug in the post–cardiac arrest period.
•	 Patients resuscitated from VF/pVT who have received 
an antiarrhythmic medication during the cardiac arrest 
period are a specific population of interest.
Targeted Temperature Management (Induced 
Hypothermia)
Post–cardiac arrest ischemia-reperfusion injury to the brain 
may be attenuated by induced hypothermia. Several PICO 
questions are addressed in this section: TTM for (a) OHCA 
with shockable rhythm, (b) OHCA with nonshockable 
rhythms, and (c) IHCA with any rhythm; the optimal target 
temperature; the duration of TTM; and the timing of TTM.
Targeted Temperature Management (ALS 790)
Among patients with ROSC after cardiac arrest in any set-
ting (P), does inducing mild hypothermia (target temperature 
32°C–34°C) (I), compared with normothermia (C), change 
survival with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; sur-
vival only at discharge, 30 days, 60 days, 180 days, and/or 
1 year (O)?
Introduction
This PICO review was divided into 2 questions. The first 
question evaluated whether induced hypothermia should 
be initiated for postarrest patients. Evidence was evaluated 
separately for OHCA with shockable rhythms, OHCA with 
nonshockable rhythms, and IHCA (all rhythms). The second 
question evaluated the optimal target temperature for postar-
rest patients.
Consensus on Science
OHCA Arrest With a Shockable Rhythm
For the critical outcome of survival with favorable neu-
rologic outcome, we have identified low-quality evidence 
(downgraded for risk of bias and imprecision) from 1 RCT201 
and 1 quasi-randomized trial202 enrolling 275 and 77 patients, 
showing a benefit in patients with OHCA with VF or pVT as 
an initial rhythm. In these studies, cooling to 32°C to 34°C 
compared with no temperature management was associated 
with good neurologic outcome at 6 months (RR, 1.4; 95% CI, 
1.08–1.81) and survival to hospital discharge (OR, 2.65; 95% 
CI, 1.02–6.88). For the critical outcome of survival, 1 study201 
showed benefit in patients treated with induced hypothermia 
(RR for 180-day mortality, 0.74; 95% CI, 0.58–0.95), while 
another study found no significant difference (51% versus 
68% hospital mortality; RR, 0.76; 95% CI, 0.52–1.10).202
OHCA With Nonshockable Rhythms
We found no RCTs comparing mild induced hypothermia 
(32°C–34°C) to no temperature management in patients with 
OHCA with pulseless electrical activity or asystole (ie, non-
shockable) as the initial rhythm.
For the critical outcome of survival with favorable neu-
rologic outcome, we found 3 cohort studies including a total 
of 1034 patients, providing overall very-low-quality evidence 
(downgraded for risk of bias and imprecision) for no difference 
in poor neurologic outcome in patients with nonshockable 
OHCA (adjusted pooled OR, 0.90; 95% CI, 0.45–1.82).203–205
One additional retrospective study that used a large registry, 
including 1830 patients, provided very-low-quality evidence 
(downgraded for risk of bias and imprecision) for an increase 
in poor neurologic outcome in patients with nonshockable 
OHCA (adjusted OR, 1.44; 95% CI, 1.039–2.006).206 These 
data were not pooled with the above studies due to the lack 
of temperature data and limited patient information available.
For the critical outcome of survival, we found very-low-
quality evidence (downgraded for risk of bias and impreci-
sion) of a benefit in mortality at 6 months (OR, 0.56; 95% CI, 
0.34–0.93) from one of these studies.204
IHCA
We found no RCTs comparing mild induced hypothermia 
(32°C–34°C) to no temperature management in patients with 
IHCA. For the critical outcome of survival to hospital dis-
charge, we found very-low-quality evidence (downgraded for 
risk of bias and imprecision) in 1 retrospective cohort study 
including 8316 patients that showed no benefit in patients 
with IHCA of any initial rhythm who were treated with TTM 
versus no active temperature management (OR, 0.9; 95% CI, 
0.65–1.23).207
For the critical outcome of neurologically favorable sur-
vival, we found very-low-quality evidence (downgraded for 
risk of bias and imprecision) from the same observational 
study showing no benefit (OR, 0.93; 95% CI, 0.65–1.32). 
Although we found numerous before-and-after studies on 
the implementation of temperature management, these data 
are extremely difficult to interpret in light of other changes 
in post–cardiac arrest care that accompanied implementation, 
making it impossible to isolate the effect of temperature on 
outcomes after cardiac arrest. For this reason, we excluded 
all before-and-after studies. Other observational studies with 
concurrent controls also represent low-quality evidence due to 
residual confounding and other factors. We, therefore, did not 
include these in the consensus on science, except for specific 
patient populations lacking higher quality (ie, RCT) evidence.
Target Temperature
For the critical outcomes of survival and survival with 
favorable neurologic outcome, we found moderate-quality 
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evidence (downgraded for imprecision) from 1 RCT including 
939 patients. This study compared cooling to 33°C compared 
with tight temperature control at 36°C in adult patients with 
OHCA of any initial rhythm except unwitnessed asystole, and 
found no benefit (HR for mortality at end of trial, 1.06; 95% 
CI, 0.89–1.28; RR for death or poor neurologic outcome at 
6 months, 1.02; 95% CI, 0.88–1.16).208
For the critical outcome of survival with favorable neu-
rologic outcome, we found low-quality evidence (down-
graded for risk of bias and imprecision) in 1 additional small 
pilot RCT enrolling 36 patients comparing 32°C with 34°C 
in patients with OHCA VF/pVT or asystole. This study 
found no benefit (neurologically intact survival 44.4% ver-
sus 11.1%; P=0.12), although with only 36 patients it was 
underpowered.
Treatment Recommendations
We recommend selecting and maintaining a constant target 
temperature between 32°C and 36°C for those patients in 
whom temperature control is used (strong recommendation, 
moderate-quality evidence). Whether certain subpopulations 
of cardiac arrest patients may benefit from lower (32°C–34°C) 
or higher (36°C) temperatures remains unknown, and further 
research may help elucidate this.
We recommend TTM as opposed to no TTM for adults 
with OHCA with an initial shockable rhythm who remain unre-
sponsive after ROSC (strong recommendation, low-quality 
evidence).
We suggest TTM as opposed to no TTM for adults with 
OHCA with an initial nonshockable rhythm who remain unre-
sponsive after ROSC (weak recommendation, very-low-qual-
ity evidence).
We suggest TTM as opposed to no TTM for adults with 
IHCA with any initial rhythm who remain unresponsive after 
ROSC (weak recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making these recommendations, we place a higher value 
on the potential for increased survival with good neurologic 
outcome as compared with the possible risks (which appear 
to be minimal) and the cost of TTM. We emphasize that the 
mortality after cardiac arrest is high and the treatment options 
are limited. Although the evidence for TTM compared with 
no temperature management is of low quality, it is the only 
post-ROSC intervention that has been found to improve sur-
vival with good neurologic outcome. We have, therefore, 
made our recommendation strong in spite of the low-quality 
evidence.
Knowledge Gaps
•	 There is no high-quality evidence to support or refute 
the use of TTM in adults with OHCA and nonshock-
able initial rhythm, or adults with IHCA and any initial 
rhythm.
•	 There is no evidence to support or refute specific tem-
perature targets tailored to individual patients based on 
post–cardiac arrest injury severity.
•	 Studies including more detailed neurocognitive evalua-
tions to determine outcome in a more granular fashion 
are also needed.
Duration of TTM (ALS 791)
In patients with ROSC after cardiac arrest in any setting (P), 
does induction and maintenance of hypothermia for any dura-
tion other than 24 hours (I), compared with induction and main-
tenance of hypothermia for a duration of 24 hours (C), change 
survival with favorable neurologic/functional outcome at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year; survival only 
at discharge, 30 days, 60 days, 180 days, and/or 1 year (O)?
Introduction
The hypothermia trials published in 2002 used 12 hours 
and 24 hours of cooling,201,202 which was adopted in subse-
quent guidelines.209 The optimal duration for TTM remains 
unknown.
Consensus on Science
We found no human trials comparing different durations of 
TTM after cardiac arrest.
For the critical outcome of favorable neurologic out-
come, very-low-quality evidence (downgraded for risk of bias 
and imprecision) from 2 observational trials found no differ-
ence in duration of hypothermia210 and no difference in mortal-
ity or poor neurologic outcome with 24 hours compared with 
72 hours of hypothermia.211 Previous trials treated patients 
with 12 to 28 hours of TTM.201,202,208 One trial provided strict 
normothermia (less than 37.5°C) after hypothermia until 72 
hours after ROSC.208
Treatment Recommendations
We suggest that if TTM is used, duration should be at least 
24 hours, as done in the 2 largest previous RCTs201,208 (weak 
recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we place a high value on not 
changing current clinical practice, which most commonly is 
a TTM duration of 24 hours. We further note that the 2 larg-
est trials related to TTM both used at least 24 hours, one of 
which found an outcome benefit when compared with not 
using TTM.
Knowledge Gaps
•	 There is no direct evidence to support or refute any spe-
cific duration of TTM.
•	 Controlled, randomized, human trials to evaluate dura-
tion of TTM are needed.
Timing of Induced Hypothermia (ALS 802)
Among patients with return of pulses after cardiac arrest in 
any setting (P), does induction of hypothermia before some 
time point (eg, 1 hour after ROSC or before hospital arrival) 
(I), compared with induction of hypothermia after that time 
point (C), change survival with favorable neurologic/func-
tional outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 180 
days, and/or 1 year (O)?
Introduction
Prior recommendations suggest that cooling should be initi-
ated as soon as possible after ROSC, but this recommendation 
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was based only on preclinical data and rational conjecture.209 
This question addressed whether early cooling was superior 
to delayed cooling. Early cooling was defined as prehospital 
cooling before hospital arrival. Because multiple trials were 
available, only RCTs were included.
Consensus on Science
Five RCTs212–216 used cold IV fluids after ROSC to induce 
hypothermia, 1 trial used cold IV fluid during resuscitation,217 
and 1 trial used intra-arrest intranasal cooling.218 The volume 
of cold fluid ranged from 20 to 30 mL/kg and up to 2 L, though 
some patients did not receive the full amount before hospital 
arrival. One small feasibility trial was not included.219 All 7 tri-
als suffered from the unavoidable lack of blinding of the clini-
cal team, and 3 also failed to blind the outcomes assessors.
For the critical outcome of favorable neurologic out-
come, 5 trials with a total of 1867 subjects with OHCA213–216,218 
provided overall moderate-quality evidence (downgraded for 
risk of bias), showing that neurologic outcomes did not dif-
fer after initiation of induced hypothermia in the prehospital 
environment compared with later initiation (RR, 1.00; 95% 
CI, 0.95–1.06).
For the critical outcome of mortality, 7 trials with a total 
of 2237 subjects provided moderate-quality evidence (down-
graded for risk of bias), showing no overall difference in mor-
tality for patients treated with prehospital cooling (RR, 0.98; 
95% CI, 0.92–1.04) compared with those who did not receive 
prehospital cooling. No individual trial found an effect on 
either poor neurologic outcome or mortality.
For the outcome of rearrest, 4 RCTs provided low-
quality evidence (downgraded for risk of bias and inconsis-
tency) for an increased risk among subjects who received 
prehospital induced hypothermia (RR, 1.22; 95% CI, 1.01–
1.46).212,213,215,216 This result was driven by data from the largest 
trial.216
For the outcome of pulmonary edema, 3 trials reported 
no pulmonary edema in any group. Two small pilot trials212,217 
found no difference between groups, and 1 trial showed an 
increase in pulmonary edema in patients who received pre-
hospital cooling (RR, 1.34; 95% CI, 1.15–1.57).216 These trials 
provided overall low-quality evidence (downgraded for risk of 
bias and inconsistency).
Treatment Recommendations
We recommend against routine use of prehospital cooling 
with rapid infusion of large volumes of cold IV fluid immedi-
ately after ROSC (strong recommendation, moderate-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we place high value on not 
recommending an intervention with no proven benefit despite 
a large number of patients studied. We further note that the 
meta-analysis driven by the results from the largest study 
found also noted an increased risk of rearrest with prehospital 
induction of mild hypothermia using rapid infusion of cold 
IV fluid.216 This recommendation is specific to the prehospital 
setting after ROSC, and we acknowledge that cold IV fluid 
might still be used in patients who have been further evaluated 
or in other settings.
Knowledge Gaps
•	 Early cooling strategies, other than rapid infusion of large 
volumes of cold IV fluid, and cooling during CPR in the 
prehospital setting have not been studied adequately.
•	 Whether certain patient populations (eg, patients for 
whom transport time to a hospital is longer than aver-
age) might benefit from early cooling strategies remains 
unknown.
Prevention of Fever After Cardiac Arrest (ALS 879)
Among adults with ROSC after cardiac arrest in any setting 
(P), does prevention of fever to maintain strict normothermia 
(I), compared with no fever control (C), change survival with 
favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year (O)?
Introduction
Fever is associated with poor outcome in many critical ill-
nesses with neurologic injury. Increased temperature may 
aggravate ischemia-reperfusion injury and neuronal damage 
through increased metabolic activity. We examined whether 
fever prevention improves outcomes in patients not receiving 
TTM and in patients after the use of TTM.
No interventional or observational studies were identified 
addressing whether fever prevention (or treatment) after car-
diac arrest improves outcome. We, therefore, included studies 
that examined the association between fever and outcomes.
Consensus on Science
Fever After ROSC Without TTM
For the critical outcomes of survival with good neurologic/
functional outcome and/or survival only, we found very-
low-quality evidence from 5 observational studies (down-
graded for risk of bias and indirectness) that fever after ROSC 
is associated with poor outcome when TTM is not used.221–225
Fever After TTM
For the critical outcomes of survival with good neurologic/
functional outcome and/or survival only, we found very-
low-quality evidence from 6 observational studies (n=856) 
(downgraded for risk of bias and indirectness) that fever after 
TTM is not associated with outcome.225–230 For the same criti-
cal outcomes, we also found very-low-quality evidence from 
2 observational studies (n=411) (downgraded for risk of bias, 
inconsistency, and indirectness) that fever after TTM is asso-
ciated with poor outcome.231,232
Treatment Recommendation
We suggest prevention and treatment of fever in persistently 
comatose adults after completion of TTM between 32°C and 
36°C (weak recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we recognize that TTM 
always should be used in comatose patients after cardiac 
arrest, and that fever will not occur during this time. Thus, 
fever management is primarily a concern after TTM has been 
completed. Despite substantial limitations of the included 
studies, expert opinion within the task force combined with 
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the fact that fever prevention is common practice for other 
neurologic injuries in the ICU and the relative low risk of 
harm associated with fever prevention prompted us to recom-
mend in favor of fever prevention.
Knowledge Gaps
•	 In the absence of RCTs, whether the prevention or treat-
ment of fever after cardiac arrest is beneficial remains 
unclear.
•	 It is unclear how long fever prevention is necessary, and 
what technique (eg, external, internal, pharmacologic) is 
best.
•	 Data to date cannot distinguish whether fever causes 
increased neurologic injury or severe neurologic injury 
causes temperature dysregulation.
Postresuscitation Seizure Prophylaxis (ALS 431)
Among adults with ROSC after cardiac arrest in any setting 
(P), does seizure prophylaxis (I), compared with no prophy-
laxis (C), reduce the incidence of seizures, or improve survival 
with favorable neurologic/functional outcome at discharge, 30 
days, 60 days, 180 days, and/or 1 year; survival only at dis-
charge, 30 days, 60 days, 180 days, and/or 1 year (O)?
Introduction
Seizures, and particularly status epilepticus (SE), are asso-
ciated with poor outcomes in comatose post–cardiac arrest 
patients. While seizure and SE can be the result of severe brain 
injury caused by cardiac arrest, these disorders also have the 
potential to exacerbate brain injury caused by cardiac arrest. 
We examined whether seizure prophylaxis or effective sei-
zure management improve outcomes of post–cardiac arrest 
patients.
Consensus on Science
For the critical outcome of survival with favorable neu-
rologic/functional outcome, moderate-quality evidence 
(downgraded for indirectness) from 2 prospective double-
blinded randomized clinical trials involving a total of 312 sub-
jects233,234 and 1 nonrandomized prospective clinical trial that 
used historic controls with 107 subjects235 detected no benefit 
of seizure prophylaxis.
In 1 block randomized trial,234 OHCA patients with ROSC 
received either placebo, diazepam, magnesium sulfate, or 
diazepam plus magnesium sulfate. The percentage of patients 
independent at 3 months was 25.3% (19/75) in the placebo 
group, 34.7% (26/75) in the magnesium group, 17.3% (13/75) 
in the diazepam group, and 17.3% (13/75) in the diazepam 
plus magnesium group (for magnesium: RR, 1.22; 95% CI, 
0.81–1.83). After adjusting for baseline imbalances, outcomes 
did not differ between groups. In a trial of thiopental versus 
placebo within 1 hour of ROSC,233 1-year survival with good 
cerebral function was 15% (20/131) in the placebo group and 
18% (24/131) in the thiopental group (RR, 1.20; 95% CI, 
0.70–2.06). After multivariate adjustment, groups did not dif-
fer (OR, 1.18; 95% CI, 0.76–1.84). A nonrandomized clinical 
trial235 showed no benefit of barbiturate therapy in comatose 
post–cardiac arrest patients using a combination of thiopental 
and phenobarbital when compared with historic controls. In 
this study, survival to hospital discharge with favorable neuro-
logic outcome was 38% (20/53) in the barbiturate group and 
26% (14/54) in the historic control group (ARR, 11.8%; 95% 
CI, −5.8 to 28.5; or 118 more patients/1000; 95% CI, 58 fewer 
to 285 more patients/1000). One case series showed that 9 of 
10 patients with anesthesia-associated cardiac arrest survived 
with good neurologic outcome when single-dose phenytoin 
was administered early after ROSC.236
For the important outcome of seizure prevention, we 
identified low-quality evidence downgraded for indirectness 
from 2 prospective double-blinded RCTs233,234 showing no 
benefit of seizure prophylaxis. In 1 trial of thiopental treat-
ment,233 21% (28/131) of control subjects and 13% (17/131) 
of thiopental-treated subjects had seizures (ARR, −8.4%; 95% 
CI, −17.5 to 0.8; 84 fewer patients/1000; 95% CI, 175 fewer 
to 8 more patients/1000). The incidence of seizures in a sec-
ond trial234 was 11.9% in all treatment groups (double placebo, 
magnesium plus placebo, diazepam plus placebo, and diaz-
epam plus magnesium).
Treatment Recommendation
We suggest against routine seizure prophylaxis in post–car-
diac arrest patients (weak recommendation, very-low-quality 
evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, the task force acknowledged 
the lack of confidence in a treatment effect on the critical out-
come of survival with good neurologic function treatment. The 
task force also considered that seizure prophylaxis in other 
forms of acute brain injuries is not associated with improved 
outcomes, and that most drugs have significant side effects.
Knowledge Gaps
•	 Standardized definitions for diagnosing seizures in 
comatose post–cardiac arrest patients have not been 
used.
•	 The utility of continuous electroencephalogram (EEG) 
versus intermittent EEG monitoring versus no EEG in 
the diagnosis and treatment of seizures in comatose 
post–cardiac arrest patients remains controversial due to 
resource utilization and lack of evidence for improved 
outcomes.
•	 There are no RCTs designed to evaluate the impact of 
seizure prophylaxis after ROSC on incidence of seizures 
and neurologic outcome.
•	 There are inadequate data regarding the timing, duration, 
dosing, and choice of antiepileptic drugs for seizure pro-
phylaxis in comatose post–cardiac arrest patients.
Seizure Treatment (ALS 868)
Among adults with ROSC after cardiac arrest in any setting 
(P), does effective seizure treatment (I), compared with no sei-
zure control (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year (O)?
Consensus on Science
There are no RCTs addressing this question.
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For the critical outcome of survival with favorable neuro-
logic outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year, very-low-quality evidence (downgraded for lack of 
concurrent comparative data) from 3 case series237–239 showed 
only 1/47 post–cardiac arrest patient treated for seizures or 
SE survived with good neurologic function. The antiepileptic 
drugs used were widely variable (phenytoin, levetiracetam, 
sodium valproate, clonazepam, propofol, and midazolam); 
included general anesthetics; and the drug, dose, and timing 
of therapy were not consistently reported. In these reports, no 
post–cardiac arrest patients with seizures were left untreated, 
providing no insight into the impact of antiepileptic drug ther-
apy on survival or neurologic outcome. In 1 study, effective sei-
zure control was achieved in 4/5 patients treated for seizures, 
and 0/5 survived with good neurologic function.239 In 1 study, 
effective seizure control was achieved in 0/24 patients with SE, 
and 1/24 patients survived with good neurologic function.237
Treatment Recommendation
We recommend the treatment of seizures in post–cardiac arrest 
patients (strong recommendation, very-low-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we acknowledge very low 
confidence in the estimated treatment effect. However, ongo-
ing seizures have the potential to worsen brain injury, and 
treatment of recurrent seizures and SE is the standard of care 
in other patient populations.
Knowledge Gaps
•	 Standardized definitions for diagnosing seizures in 
comatose post–cardiac arrest patients have not been 
used.
•	 The utility of continuous EEG versus intermittent EEG 
monitoring versus no EEG in the diagnosis and treat-
ment of seizures in comatose post–cardiac arrest patients 
remains controversial due to resource utilization and 
lack of evidence for improved outcomes.
•	 There are no RCTs designed to evaluate the impact of 
seizure prophylaxis after ROSC on incidence of seizures 
and neurologic outcome.
•	 There are inadequate data regarding the timing, duration, 
dosing, and choice of antiepileptic drugs for seizure pro-
phylaxis in comatose post–cardiac arrest patients.
•	 The threshold for treating epileptiform activity other 
than convulsive seizures (eg, generalized epileptiform 
discharges) is poorly defined.
Glucose Control After Resuscitation (ALS 580)
Among adults with ROSC after cardiac arrest in any setting 
(P), does a specific target range for blood glucose manage-
ment (eg, strict 4–6 mmol/L) (I), compared with any other 
target range (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year (O)?
Introduction
Glycemic control with insulin is now common for critically ill 
patients, and hyperglycemia after cardiac arrest is associated 
with worse neurologic outcomes. We examined whether 
specific glucose values other than those selected for other 
critically ill patients should be targeted in patients after resus-
citation from cardiac arrest.
Consensus on Science
For the critical outcome of survival to hospital discharge, 
there was moderate-quality evidence (downgraded for risk 
of bias due to lack of blinding) from 1 RCT of 90 subjects 
showing reduced 30-day mortality (RR, 0.94; 95% CI, 
0.53–1.68) when subjects were assigned to strict (4–6 
mmol/L) versus moderate (6–8 mmol/L) glucose control.240 
One before-and-after observational study of 119 subjects pro-
vided very-low-quality evidence (downgraded for multiple 
potential confounding variables) of reduced in-hospital mor-
tality (RR, 0.46; 95% CI, 0.28–0.76) after implementation of 
a bundle of care that included defined glucose management 
(5–8 mmol/L).193 The effect of glucose management cannot be 
separated from the effects of other parts of the bundle.
Treatment Recommendation
We suggest no modification of standard glucose management 
protocols for adults with ROSC after cardiac arrest (weak rec-
ommendation, moderate-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we considered the lack of 
evidence that the approach to glucose management chosen for 
other critical care populations should be modified for the post–
cardiac arrest patients. Moreover, we noted that strict glycemic 
control is labor intensive, and in other populations, implemen-
tation of strict glycemic control is associated with increased 
episodes of hypoglycemia, which might be detrimental. 
Avoiding hypoglycemia was considered more important than 
the unproven benefits of treating moderate hyperglycemia.
Knowledge Gaps
•	 It remains unknown whether maintaining serum glucose 
within a specific range or minimizing variability in post–
cardiac arrest patients will improve survival and/or neu-
rologic outcome.
Neurologic Prognostication
In contemporary practice, many comatose post–cardiac arrest 
patients will not survive or will survive with an unfavorable 
neurologic outcome. In some regions, family and treating 
teams may limit or withdraw life-sustaining treatment when 
unfavorable neurologic outcomes are expected. Therefore, 
reliable strategies for timely prognostication are a critical 
component of any cardiac arrest system of care.
The decision to limit treatment of comatose post–cardiac 
arrest patients should never rely on a single prognostication 
element. The consensus of the task force was that a multimodal 
approach should be used in all cases, with all supplementary 
tests considered in the context of the clinical examination. The 
most reliable combination and timing for each assessment 
remain to be determined and require further research.
Reported reliability (FPR and 95% CIs) of any predictor 
of poor outcome in post–cardiac arrest patients is specific to 
the time points after cardiac arrest or rewarming when they are 
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measured. In addition, although several elements are associ-
ated with poor outcome when measured before 72 hours after 
ROSC, it is the consensus of the task force that decisions to 
limit treatments must consider that neurologic prognosis is 
uncertain before at least 72 hours after ROSC. We acknowl-
edge that other non-neurological factors may contribute to 
decisions to limit treatment.
Separate PICO questions addressed prognostication of 
comatose post–cardiac arrest patients treated with hypother-
mic TTM and patients not treated with hypothermic TTM. 
This approach was chosen because hypothermic TTM can 
alter the natural history of coma and may also delay recovery 
of CNS function. Moreover, patients may be exposed to larger 
doses and durations of pharmacologic sedation and neuromus-
cular blockade to prevent or treat shivering during TTM, and 
the metabolism of these agents may be delayed during hypo-
thermic TTM. Prognostic elements that are reliable in coma-
tose post–cardiac arrest patients not treated with hypothermic 
TTM may be less reliable at the same time point in patients 
treated with TTM.
This review identified clinical signs, neurophysiologi-
cal measurements, blood or cerebrospinal fluid markers, or 
imaging studies that had high specificity for poor neurologic 
outcome, defined as death, vegetative state, or severe cerebral 
disability (CPC 3–5). This approach was justified by the need 
to identify signs or measurements that might be used to justify 
limiting life-sustaining treatment. To quantify the specificity 
of the finding, we examined the FPR of each sign for pre-
dicting unfavorable neurologic outcome, with a goal of 0% 
FPR. The 95% CI of the FPR was calculated, and we tended 
to recommend a finding as useful if the FPR was less than 
5%, and suggest that a finding might be useful if the FPR was 
less than 10%. In most cases, clinical signs and findings were 
considered individually, because few studies considered com-
binations of clinical findings.
Prognostication in Comatose Patients Treated With 
Hypothermic TTM (ALS 450)
Among adults with ROSC who are treated with hypother-
mia (P), does any clinical variable when abnormal (eg, clini-
cal exam, EEG, somatosensory evoked potentials [SSEPs], 
imaging, other) (I), compared with any clinical variable when 
normal (C), reliably predict death or poor neurologic out-
come at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
death only at discharge, 30 days, 60 days, 180 days, and/or 
1 year (O)?
Consensus on Science
Clinical Examination
No study on clinical examination reported blinding of the 
treating team to the results of the index test.
For the critical outcome of survival with unfavorable 
neurologic status or death at discharge, we identified 
very-low-quality evidence (downgraded for very serious risk 
of bias and imprecision) from 4 studies on corneal reflex, 
pupillary reflex, motor response, GCS, or myoclonus (295 
patients).238,241–243
For the critical outcome of survival with unfavor-
able neurologic status or death at 90 days, we identified 
very-low-quality evidence (downgraded for very serious risk 
of bias and very serious imprecision) from 5 studies on corneal 
reflex, pupillary reflex, motor response, brainstem reflexes, or 
myoclonus (388 patients).244–248
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified low- or 
very-low-quality evidence (downgraded for very serious risk 
of bias and serious or very serious imprecision) from 4 studies 
on corneal reflex, pupillary reflex, motor response, brainstem 
reflexes, or myoclonus (642 patients).249–252
Corneal Reflex. In patients who are comatose after resusci-
tation from cardiac arrest and are treated with TTM, bilater-
ally absent corneal reflexes at 72 to 120 hours from ROSC 
predicted poor outcome, with 2 (0–7)% FPR and 25 (18–
32)% sensitivity241,248,251,253 (301 subjects; very-low-quality 
evidence).
Pupillary Reflex. Bilaterally absent pupillary light reflexes 
(PLR) on hospital admission predicted poor outcome, with 
32 (19–48)% FPR and 86 (71–95)% sensitivity242,254 (86 
patients; very-low-quality evidence). Bilaterally absent PLR 
at 72 to 108 hours from ROSC predicted poor outcome, with 
1 (0–3)% FPR and 19 (14–25)% sensitivity241,248,249,251,254 (5 
studies, 383 subjects; low-quality evidence downgraded for 
very serious bias).
Motor Response to Pain. On hospital admission, bilaterally 
absent or extensor motor responses, corresponding to a motor 
score 1 or 2 (M1–2) of the GCS, predicted a poor outcome, 
with 53 (36–68)% FPR and 92 (75–99)% sensitivity242 (66 
patients; very-low-quality evidence). At 36 to 108 hours from 
ROSC, an M1–2 predicted a poor outcome, with 70 (65–74)% 
sensitivity and 10 (7–15)% FPR245,247–251 (635 subjects; very-
low-quality evidence).
One study248 indicated that both absent corneal reflexes 
and motor response to pain at 72 hours predicted poor out-
come (CPC 4–5) more accurately in patients who did not 
receive any sedative drugs 12 hours or less before neurologic 
assessment than in those who did.
Combination of Clinical Signs. Bilateral absence of 1 or 
more brainstem reflexes (pupillary, corneal, or oculocephalic) 
at 36 to 72 hours from arrest predicted a poor outcome, with 
8 (4–14)% FPR and 56 (48–63)% sensitivity (3 studies; 304 
patients; very-low-quality evidence).246,247,255 In 1 study (103 
subjects; very-low-quality evidence), the combined absence 
of corneal reflex, PLR, and M1–2 at 72 hours from ROSC 
predicted poor outcome, with 0 (0–8)% FPR and 15 (7–26)% 
sensitivity.245 In that study, the index test was used as a crite-
rion for withdrawal of life-sustaining treatment. A GCS of 4 
or less at 96 hours from ROSC predicted poor outcome, with 
5 (1–15)% FPR and 46 (28–66)% sensitivity243 (72 subjects; 
very-low-quality evidence).
Myoclonus and Status Myoclonus. Presence of myoclo-
nus within 72 hours from ROSC predicted a poor outcome, 
with 5 (3–8)% FPR and 39 (35–44)% sensitivity (6 stud-
ies,238,246,247,249,250,252 845 subjects; very-low-quality evidence). 
In 1 study245 (103 subjects; very-low-quality evidence), 
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presence of myoclonus within 7 days after ROSC predicted 
poor outcome, with 11 (3–26)% FPR and 54 (41–66)% 
sensitivity.
In 3 studies241,248,256 (215 patients; low-quality evidence) 
presence of status myoclonus (defined as a continuous pro-
longed and generalized myoclonus) within 72 to 120 hours 
from ROSC predicted poor outcome, with 0 (0–4)% FPR and 
16 (11–22)% sensitivity. However, reports of good neuro-
logic recovery despite an early-onset, prolonged, and gen-
eralized myoclonus have been published.252,257–259 In some of 
these cases,252,257 myoclonus persisted after awakening and 
evolved into a chronic action myoclonus (Lance-Adams 
syndrome).
Electrophysiology
For the critical outcome of survival with unfavorable neu-
rologic status or death at discharge, we identified very-low-
quality evidence (downgraded for very serious bias and very 
serious imprecision) from 8 studies on short-latency SSEPs, 
EEG, or Bispectral Index (BIS; 571 subjects).238,241,254,256,260–262
For the critical outcome of survival with unfavorable neu-
rologic status or death at 30 days, we identified 1 study on 
SSEPs (77 subjects; very-low-quality evidence, downgraded 
for serious bias and very serious imprecision).263 For the criti-
cal outcome of survival with unfavorable neurologic status 
or death at 60 days, we identified 1 study on brainstem audi-
tory evoked potentials (26 subjects; very-low-quality evidence 
downgraded for serious bias and very serious imprecision).264
For the critical outcome of survival with unfavorable 
neurologic status or death at 90 days, we identified 5 stud-
ies on SSEPs or EEG (362 subjects; low- or very-low-quality 
evidence, downgraded for serious or very serious bias and/or 
very serious imprecision).245–248,265
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified 10 
studies on SSEPs, EEG, or BIS (566 subjects; moderate-, 
low-, or very-low-quality evidence downgraded for serious or 
very serious bias and/or very serious imprecision).249–251,266–272
For the critical outcome of survival with unfavorable 
neurologic status or death at 1 year, we identified 1 study 
on EEG (106 subjects; very-low-quality evidence).252
Short Latency SSEPs. In most prognostication studies, absence 
of the N20 wave after rewarming has been used—alone or in 
combination—as a criterion for deciding on withdrawal of life-
sustaining treatment, with a consequent risk of self-fulfilling 
prophecy.
In patients who are comatose after resuscitation from 
cardiac arrest and who are treated with TTM, a bilaterally 
absent N20 SSEP wave during TTM predicted poor outcome, 
with 2 (0–4)% FPR and 28 (22–34)% sensitivity249,263,266,271 
(424 subjects; moderate-quality evidence, downgraded for 
serious bias). A bilaterally absent N20 SSEP wave after 
rewarming predicted poor outcome, with 1 (0–3)% FPR (9 
studies,245–251,254,261,265 629 subjects; very-low-quality evidence 
downgraded for very serious bias and serious inconsistency) 
and 45 (41–50)% sensitivity.
SSEP recording is prone to electrical interference. In 
1 study,249 3 subjects with a bilaterally absent N20 during 
TTM rapidly recovered consciousness after rewarming and 
ultimately had a good outcome. In a post hoc assessment, 2 
experienced neurophysiologists reviewed blindly the original 
tracings and concluded that the SSEP recordings were unde-
terminable because of excessive noise.
EEG. Definitions of burst suppression were inconsistent 
among studies. Definitions of epileptiform activity, electro-
graphic seizures, and SE were inconsistent among studies.
Absence of Background Reactivity. Absence of back-
ground reactivity on the EEG recorded during TTM predicted 
poor outcome, with 2 (1–7)% FPR and 63 (54–72)% sensitiv-
ity (3 studies,238,246,247 249 subjects; very-low-quality evidence 
downgraded for very serious bias and serious imprecision). 
Absence of background reactivity on the EEG recorded after 
rewarming predicted poor outcome, with 0 (0–3)% FPR and 
62 (53–70)% sensitivity (3 studies,238,247,250 223 subjects; very-
low-quality evidence downgraded for very serious bias and 
serious imprecision). One group of investigators provided 3 
of the 4 prognostication studies on absent EEG reactivity after 
cardiac arrest.
Burst Suppression. Presence of burst suppression on ini-
tial EEG immediately after induction of TTM predicted poor 
outcome, with 0 (0–5)% FPR and 31 (19–44)% sensitiv-
ity (2 studies,267,268 119 subjects; very-low-quality evidence 
downgraded for very serious bias and serious inconsistency). 
Presence of burst suppression on EEG during TTM predicted 
poor outcome, with 6 (1–15)% FPR and 70 (56–82)% sensi-
tivity (2 studies,247,266 107 patients; very-low-quality evidence 
downgraded for very serious bias, serious inconsistency, and 
very serious imprecision). In 1 study268 (95 subjects; very-low-
quality evidence) presence of burst suppression on EEG after 
rewarming predicted poor outcome, with 0 (0–5)% FPR and 
18 (8–34)% sensitivity.
Epileptiform Activity. Presence of epileptiform discharges 
on EEG during TTM262 (38 subjects) or after rewarming250 
(108 patients) predicted poor outcome, with 8 (0–39)% and 
12 (3–31)% FPR, respectively. Quality of evidence was very 
low in both studies, downgraded for very serious bias and very 
serious imprecision. Presence of electrographic seizures with 
nonreactive EEG background during TTM247 (61 patients), 
electrographic seizures during TTM262 (38 subjects), or elec-
trographic seizures both during TTM and after rewarming238 
(54 subjects) predicted poor outcome, with 0% FPR (95% CIs, 
0–10, 0–22, and 0–9, respectively; very-low-quality evidence 
downgraded for very serious bias and serious or very serious 
imprecision).
Presence of SE during TTM273 (51 subjects) or after 
rewarming272 (30 subjects) predicted poor outcome, with 0% 
FPR (95% CIs, 0–22 and 0–13, respectively). However, in 
another study,252 the presence of an SE within 72 hours from 
ROSC was associated with good outcome in 2 cases (FPR 
6 [1–21]%). In both those patients, SE was first recorded 
at 40 hours or greater from ROSC (shortly after rewarm-
ing), and the EEG was reactive (very-low-quality evidence, 
downgraded for serious or very serious bias and very serious 
imprecision).
In 1 study268 (95 subjects), presence of electrographic SE 
on a burst suppression pattern was associated with an invari-
ably poor outcome (CPC 4–5; FPR 0 [0–5]%), while an 
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electrographic SE on a continuous background was still com-
patible with recovery of consciousness (FPR 4 [0–12]%; very-
low-quality evidence downgraded for very serious bias and 
very serious imprecision).
Flat or Low-Amplitude EEG. In 1 study266 (46 subjects), 
a flat or low-amplitude (less than 20 mcV) EEG during TTM 
at 24 hours from cardiac arrest predicted poor outcome, with 
0 (0–11)% FPR and 40 (19–64)% sensitivity. In another 
study268 (95 subjects), however, a flat (less than 10 mcV) 
EEG recorded during TTM at a median of 8 hours from car-
diac arrest or immediately after rewarming was followed by 
recovery of consciousness (FPR 46 [32–59]% and 5 [1–15]%, 
respectively; very-low-quality evidence downgraded for seri-
ous or very serious bias and very serious imprecision).
Bispectral Index. In 1 study270 (45 subjects), a lowest BIS 
value of 0 during TTM, corresponding to a flat or low-ampli-
tude EEG, predicted a poor outcome, with 0 (0–6)% FPR and 
50 (31–69)% sensitivity. However, in another study269 (75 sub-
jects), a lowest BIS value of 0 during TTM predicted poor 
outcome, with 10 (3–23)% FPR. The quality of evidence was 
very low (downgraded for very serious bias and very serious 
imprecision).
EEG Grades. In 1 study238 (54 subjects; very-low-quality 
evidence), a grade 3 EEG, corresponding to 1 pattern among 
unreactive, burst suppression, focal or generalized seizures, 
generalized periodic epileptiform discharges, SE, low ampli-
tude (10 mcV or less), or alpha-theta coma, predicted poor 
outcome, with 6 (1–20)% FPR during TH and 0 (0–9)% FPR 
after rewarming.
Other Neurophysiological Tests. In 1 study264 (26 subjects; 
very-low-quality evidence), absence of brainstem auditory 
evoked potentials wave V during induction of TTM predicted 
poor outcome, with 0 (0–31)% FPR and 56 (31–78)% sensi-
tivity. In 1 pilot study265 (17 subjects; very-low-quality evi-
dence), the bilateral absence of pain-related middle-latency 
cortical evoked potentials predicted poor outcome, with 0 
(0–53)% FPR and 85 (55–98)% sensitivity.
Blood and Cerebrospinal Fluid Markers
Blood marker thresholds vary because of heterogeneous 
measurement techniques,274–276 the presence of extraneuronal 
sources of biomarkers (hemolysis, non–central nervous sys-
tem sources, and neuroendocrine tumors for neuron-specific 
enolase [NSE],277 muscle and adipose tissue breakdown for 
S100B),278 and the incomplete knowledge of the kinetics of 
their blood concentrations in the first few days after ROSC.
For the critical outcome of survival with unfavorable 
neurologic status or death at discharge, we identified 4 stud-
ies on NSE (354 subjects; low- or very-low-quality evidence 
downgraded for serious or very serious bias and very serious 
imprecision).241,279–281 For the critical outcome of survival with 
unfavorable neurologic status or death at 60 days, we identified 
1 study on NSE (73 subjects; very-low-quality evidence).282
For the critical outcome of survival with unfavor-
able neurologic status or death at 90 days, we identified 
3 studies on NSE (248 patients, very-low-quality evidence 
downgraded for serious or very serious bias and very serious 
imprecision).246–248
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified 8 studies 
on NSE or S100B (810 patients; moderate-, low-, or very-low-
quality evidence, downgraded for serious or very serious bias 
and/or serious or very serious imprecision).249,251,269,272,283–286
NSE. In comatose resuscitated patients who are treated with 
TTM, the threshold for prediction of poor outcome with 0% 
FPR varied between 49.6 mcg/L and 151.4 mcg/L at 24 hours 
from ROSC272,284,285,287 (309 subjects; very-low-quality evi-
dence, downgraded for serious or very serious bias and very 
serious imprecision), between 25 mcg/L and 151.5 mcg/L at 
48 hours251,272,279,281,282,284–287 (10 studies, 919 subjects; moder-
ate- to very-low-quality evidence downgraded for serious or 
very serious bias and very serious imprecision), and between 
57.2 mcg/L and 78.9 mcg/L at 72 hours280–282 (193 subjects; 
low- or very-low-quality evidence).
Limited evidence282,284,288 suggests that not only the NSE 
absolute concentrations but also their trends over time may 
have predictive value. Limited evidence284,288 suggests that the 
discriminative value of NSE levels at 48 to 72 hours is higher 
than at 24 hours.
S100B. For S100B, the documented thresholds for a 0% FPR 
were 0.18 and 0.21 mcg/L at 24 hours after ROSC283,285 (2 stud-
ies, total 66 subjects; very-low-quality evidence downgraded 
for serious or very serious bias and very serious imprecision) 
and 0.3 mcg/L at 48 hours (1 study, 75 subjects; very-low-
quality evidence downgraded for serious or very serious bias 
and very serious imprecision).
Imaging
All studies on prognostication after cardiac arrest using imag-
ing have a small sample size with a consequent low precision 
and are prone to selection bias, because the imaging studies 
were performed at discretion of treating physician, which may 
have caused a selection bias and overestimated their perfor-
mance. Imaging studies depend partly on subjective human 
decision in identifying the region of interest to be studied and 
in the interpretation of results.
For the critical outcome of survival with unfavorable 
neurologic status or death at discharge, we identified 3 
studies on computed tomography (CT; 273 subjects; low- or 
very-low-quality evidence downgraded for serious or very 
serious bias and serious or very serious imprecision).241,279,289
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified 6 stud-
ies on CT or magnetic resonance imaging (MRI; 246 subjects; 
very-low-quality evidence downgraded for serious or very 
serious bias and very serious imprecision).251,287,290–293
CT Scan. The main CT finding of global anoxic-ischemic 
cerebral insult after cardiac arrest is cerebral edema,294 which 
appears as a reduction in the depth of cerebral sulci (sulcal 
effacement) and an attenuation of the gray matter/white matter 
(GM/WM) interface, due to a decreased density of the GM. 
This attenuation has been quantitatively measured as the ratio 
(GWR) between the GM and the WM densities.
In 4 studies254,279,289,290 (total 276 subjects; low- or very-
low-quality evidence downgraded for serious or very seri-
ous bias and very serious imprecision), a reduced GWR at 
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the level of the basal ganglia on brain CT performed within 
2 hours from ROSC predicted an almost invariably poor out-
come (FPR from 0% to 8%). Measurement techniques and 
thresholds for GWR varied among studies.
In 1 study241 (102 subjects; low-quality evidence down-
graded for serious bias and serious imprecision), a global 
cerebral edema on brain CT at a median of 1 day after cardiac 
arrest predicted poor outcome, with 0 (0–5)% FPR.
MRI. The main MRI finding of anoxic-ischemic cerebral 
injury is a hyperintensity in diffusion weighted imaging 
(DWI) sequences due to cytotoxic edema. Presence of DWI 
abnormalities in cortex or basal ganglia (1 study, 21 subjects; 
very-low-quality evidence) or both (2 studies, 30 subjects; very-
low-quality evidence) between 2 and 6 days from ROSC was 
associated with poor outcome (FPR, 0%–9%). Precision of pre-
diction, however, was very low, due to the small size of these 
studies.
Postischemic DWI abnormalities can be quantified using 
apparent diffusion coefficient (ADC). ADC values between 
700 and 800×10−6 mm2/s are considered normal. In 1 study293 
(22 subjects; very-low-quality evidence downgraded for very 
serious bias and very serious imprecision), presence of more 
than 10% of brain volume with ADC less than 650×10−6 
mm2/s predicted poor outcome, with 0 (0–28)% specificity. In 
another study,295 a low ADC at the level of putamen, thalamus, 
or occipital cortex also predicted poor outcome, with 0% FPR 
(95% CIs, 0–24%). The ADC thresholds varied according to 
the brain area studied.
Treatment Recommendations
We suggest against the use of clinical criteria alone before 72 
hours after ROSC to estimate prognosis (weak recommenda-
tion, low-quality evidence).
We suggest that multiple modalities of testing (clini-
cal exam, neurophysiological measures, imaging, or blood 
markers) be used to estimate prognosis instead of relying on 
single tests or findings (weak recommendation, low-quality 
evidence).
Clinical Examination
We recommend using bilaterally absent PLRs or the com-
bined absence of both pupillary and corneal reflexes at least 
72 hours after ROSC to predict poor outcome in patients who 
are comatose after resuscitation from cardiac arrest and who 
are treated with TTM (strong recommendation, low-quality 
evidence).
We suggest against using an absent (M1) or extensor motor 
response to pain (M2) alone to predict poor outcome, given its 
high FPR. However, due to its high sensitivity, this sign may 
be used to identify the population with poor neurologic status 
needing prognostication or to predict poor outcome in combi-
nation with other more robust predictors (weak recommenda-
tion, very low-quality evidence).
We suggest against the use of myoclonus during the first 
72 hours from ROSC as a predictor for prognosticating a poor 
neurologic outcome (weak recommendation, low-quality 
evidence).
We suggest that the presence of a status myoclonus during 
the first 72 hours from ROSC be considered at 72 hours after 
ROSC (in combination with other factors) as a predictor for 
prognosticating a poor neurologic outcome (weak recommen-
dation, low-quality evidence).
We suggest prolonging the observation of clinical signs 
when interference from residual sedation or paralysis is 
suspected, so that the possibility of obtaining false-pos-
itive results is minimized. We recommend that the earli-
est time to prognosticate a poor neurologic outcome is 72 
hours after ROSC, and should be extended longer if the 
residual effect of sedation and/or paralysis confounds the 
clinical examination (weak recommendation, low-quality 
evidence).
Electrophysiology
We recommend using bilateral absence of N20 SSEP wave 
measured at least 72 hours after ROSC to predict poor out-
come in patients who are comatose after resuscitation from 
cardiac arrest and who are treated with TTM (strong recom-
mendation, low-quality evidence).
SSEP recording requires appropriate skills and experi-
ence, and utmost care should be taken to avoid electrical inter-
ference from muscle artifacts or from the ICU environment, 
as well as confounding drugs. This test is only ordered in the 
appropriate clinical context.
We suggest using persistent absence of EEG reactivity 
to external stimuli at 72 hours or longer after ROSC (weak 
recommendation, low-quality evidence), presence of per-
sistent burst suppression after rewarming, or intractable 
and persistent SE (weak recommendation, very-low-qual-
ity evidence) to predict poor outcome in patients who are 
comatose after resuscitation from cardiac arrest and who are 
treated with TTM.
We recommend against using BIS to predict poor outcome 
during TTM in patients who are comatose after resuscitation 
from cardiac arrest and are treated with TTM (strong recom-
mendation, very-low-quality evidence).
Blood Markers
We suggest using utmost care and preferably sampling at mul-
tiple serial time points (24–72 hours) when assessing NSE, 
to avoid false-positive results due to hemolysis (weak recom-
mendation, very-low-quality evidence).
We suggest using serial high-serum values of NSE at 48 
to 72 hours from ROSC in combination with other predic-
tors for predicting poor neurologic outcome in patients who 
are comatose after cardiac arrest and who are treated with 
TTM (weak recommendation, very-low-quality evidence). 
However, no threshold-enabling prediction with 0 FPR can be 
recommended, and NSE levels are insufficiently specific to be 
used alone for estimating prognosis.
Imaging
We suggest using brain imaging studies for prognostication 
only in centers where specific experience is available (weak 
recommendation, very-low-quality evidence).
We suggest using the presence of a marked reduction of 
the GM/WM ratio on brain CT within 2 hours after ROSC or 
the presence of extensive diffusion restriction on brain MRI 
at 2 to 6 days after ROSC in combination with other predic-
tors for prognosticating a poor neurologic outcome in patients 
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who are comatose after cardiac arrest and who are treated with 
TTM (weak recommendation, very-low-quality evidence). 
Early imaging markers of poor prognosis should not prevent 
support for a sufficient period of time to observe other clinical 
features, although some extreme CT scan findings are consis-
tent with herniation and brain death.
Knowledge Gaps
Clinical Examination
•	 Prospective studies are needed to investigate the pharma-
cokinetics of sedative drugs and neuromuscular block-
ing drugs in post–cardiac arrest patients, especially those 
treated with controlled temperature.
•	 Studies are needed to investigate the reproducibility 
of clinical signs used to predict outcome in comatose 
postarrest patients.
•	 There is no universally accepted definition of status 
myoclonus. A recently proposed definition296 suggests 
using the term status myoclonus to indicate a continuous 
and generalized myoclonus persisting for 30 minutes in 
comatose survivors of cardiac arrest.
Electrophysiology
•	 In most prognostication studies, results of SSEPs were 
not blinded and were used as a criterion for limitation 
or suspension of life-sustaining treatment. Blinded stud-
ies on SSEPs are needed to assess the relevance of self-
fulfilling prophecies for SSEPs.
•	 Definitions of EEG-based predictors are inconsistent 
among prognostication studies. Future studies should 
comply with recently recommended definitions.297
•	 The stimulation modalities for eliciting EEG reactivity 
have not been standardized.
Blood Markers
•	 There is a need for standardization of the measur-
ing techniques for NSE and S100 in cardiac arrest 
patients.
•	 Little information is available on the kinetics of the 
blood concentrations of biomarkers in the first few days 
after cardiac arrest.
Imaging
•	 Prospective studies in unselected patient populations are 
needed for evaluating the prognostic accuracy of imag-
ing studies in comatose patients resuscitated from car-
diac arrest.
Prognostication in Absence of TTM (ALS 713)
Among adults who are comatose after cardiac arrest and 
are not treated with TTM (P), does any clinical finding 
when normal (eg, clinical exam, EEG, SSEPs, imaging, 
other) (I), compared with any clinical finding when abnor-
mal (C), reliably predict death or poor neurologic outcome 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
death only at discharge, 30 days, 60 days, 180 days, and/
or 1 year (O)?
Consensus on Science
No study on clinical examination reported blinding of the 
treating team to the results of the index test. Blinding of the 
treating team is very difficult to achieve for predictors based 
on clinical examination, which implies a risk of self-fulfilling 
prophecy.
For the critical outcome of survival with unfavor-
able neurologic status or death at discharge, we identi-
fied 2 studies on pupillary reflex and motor response or 
oculocephalic reflex (151 patients; very-low-quality evi-
dence downgraded for very serious bias and very serious 
imprecision).298,299
For the critical outcome of survival with unfavorable 
neurologic status or death at 30 days, we identified 1 study 
on GCS (97 patients; very-low-quality evidence downgraded 
for very serious bias and very serious imprecision).300
For the critical outcome of survival with unfavorable 
neurologic status or death at 90 days, we identified 2 studies 
on corneal reflex, pupillary reflex, motor response, oculoves-
tibular reflex, GCS, or myoclonus (97 patients; very-low-qual-
ity evidence downgraded for serious or very serious bias and 
serious or very serious imprecision).301,302
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified 4 stud-
ies on brainstem reflexes, motor response, or myoclonus (650 
patients; very-low-quality evidence downgraded for serious or 
very serious bias and very serious imprecision).303–306
For the critical outcome of survival with unfavor-
able neurologic status or death at 1 year, we identified 
3 studies on brainstem reflexes, motor response, GCS, or 
myoclonus (172 patients; very-low-quality evidence down-
graded for serious or very serious bias and very serious 
imprecision).307–309
Clinical Examination
Pupillary Reflex. In 1 study299 (98 patients; very-low-qual-
ity evidence), an absent PLR on hospital admission pre-
dicted poor outcome, with 8 (1–25)% FPR and 56 (43–67)% 
sensitivity. At 24 hours298,302,306 (3 studies, 496 patients), 48 
hours298,303,306 (3 studies, 403 patients), and 72 hours298,306 
(2 studies, 382 patients) from ROSC, the FPRs of PLR for 
prediction of poor outcome were 9 (4–18)%, 4 (0–12)%, 
and 0 (0–8)%, respectively. Sensitivity ranged from 18 
(15–23)% to 21 (17–25)%; (very-low-quality evidence, 
downgraded for serious or very serious bias and very seri-
ous imprecision).
Corneal Reflex. In patients who are comatose after resuscita-
tion from cardiac arrest and who are not treated with TTM, 
an absent corneal reflex at 24 and 48 hours after ROSC pre-
dicted poor outcome, with 17 (9–27)% and 7 (2–20)% FPR. 
Sensitivities were 37 (32–42)% and 30 (25–35)%, respec-
tively302,303,306 (3 studies, 497 subjects; very-low-quality evi-
dence downgraded for very serious bias, serious inconsistency, 
and very serious imprecision).
Oculovestibular Reflex. In 2 studies302,303 (65 patients; very-
low-quality evidence downgraded for very serious bias, seri-
ous inconsistency, and very serious imprecision), the bilateral 
absence of oculovestibular reflex at 24 hours from ROSC 
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predicted poor outcome, with 0 (0–18)% FPR and 38 (25–
53)% sensitivity. In 1 study303 (19 patients; very-low-quality 
evidence downgraded for very serious bias and very serious 
imprecision), the bilateral absence of oculovestibular reflex at 
48 hours from ROSC predicted poor outcome, with 0 (0–35)% 
FPR and 25 (5–57)% sensitivity.
Combination of Ocular Reflexes. In 1 study306 (386 
patients; very-low-quality evidence downgraded for very 
serious bias and very serious imprecision), the combined 
absence of both pupillary and corneal reflexes at 24, 48, 
and 72 hours from ROSC predicted a poor outcome, with 
5 (1–17)%, 3 (0–17)%, and 0 (0–15)% FPR, respectively, 
and 13% to 14% sensitivity. In 1 study307 (60 patients; very-
low-quality evidence downgraded for serious bias and very 
serious imprecision), the absence of more than 1 among 
pupillary, corneal, and oculocephalic reflex at 6 to 12, 24, 
and 48 hours from ROSC predicted poor outcome, with 0 
(0–22)% FPR.
Motor Response to Pain. At 24 hours from ROSC, an absent 
or extensor motor response, corresponding to a motor score 
1 or 2 (M1–2) of the GCS, predicted a poor outcome, with 
27 (12–48)% FPR and 76 (71–80)% sensitivity302,306 (2 stud-
ies, 462 patients; very-low-quality evidence downgraded for 
serious bias, serious inconsistency, and serious imprecision). 
At 72 hours from ROSC, an M1–2 predicted a poor outcome, 
with 15 (5–31)% FPR and 39 (33–44)% sensitivity301,306 (2 
studies, 322 patients; very-low-quality evidence downgraded 
for serious bias, serious inconsistency, and very serious 
imprecision).
An absent extensor or abnormal flexion to pain (M1–3) 
predicted a poor outcome at 12, 24, and 48 hours from ROSC 
with 57 (37–76)%, 35 (21–52)%, and 10 (3–24)% FPR, 
respectively298,303,307 (3 studies, 120 patients; very-low-quality 
evidence downgraded for very serious bias, serious inconsis-
tency, and very serious imprecision). At 72 hours, the FPR 
of this sign was 6 (0–29)%298 (1 study, 27 patients; very-low-
quality evidence downgraded for very serious bias and very 
serious imprecision).
GCS. A GCS of 4 or less on admission, at 24 hours, and at 48 
hours from ROSC predicted poor outcome, with 40 (19–64)%, 
25 (5–57)%, and 0 (0–22)% FPR, respectively307,308 (2 stud-
ies, 119 patients; very-low-quality evidence downgraded for 
serious bias and very serious imprecision). Sensitivity ranged 
from 54 (37–71)% to 74 (58–86)%. A GCS of 5 or less at 72 
hours from ROSC predicted poor outcome, with 75 (63–86)% 
sensitivity and 7 (1–24)% FPR.
Myoclonus and Status Myoclonus. Presence of myoclonus 
on admission305 (1 study, 107 patients; very-low-quality evi-
dence) or at 24 hours from ROSC302 (1 study, 75 patients; 
very-low-quality evidence) predicts a poor outcome, with 0 
(0–14)% and 0 (0–5)% FPR, respectively. A status myoclo-
nus within 24 hours, at 36 to 48 hours, and 72 hours from 
ROSC predicted a poor outcome, with 0 (0–7)%, 0 (0–5)%, 
and 0 (0–14)% FPR, respectively304,306 (2 studies, 464 
patients; very-low-quality evidence downgraded for very 
serious bias and serious imprecision). Sensitivity ranged 
from 2% to 29%.
Electrophysiology
For the critical outcome of survival with unfavorable neuro-
logic status or death at discharge, we identified 2 studies on 
short-latency SSEPs (63 patients; very-low-quality evidence 
downgraded for very serious bias and very serious impreci-
sion)310,311 and 3 studies on EEG (46 patients; very-low-quality 
evidence, downgraded for very serious bias and very serious 
imprecision).312–314
For the critical outcome of survival with unfavor-
able neurologic status or death at 30 days, we identi-
fied 2 studies on SSEPs (80 patients; very-low-quality 
evidence downgraded for very serious bias and very serious 
imprecision).315,316
For the critical outcome of survival with unfavor-
able neurologic status or death at 60 days, we iden-
tified 2 studies on EEG (54 patients; very-low-quality 
evidence downgraded for very serious bias and very serious 
imprecision).317,318
For the critical outcome of survival with unfavor-
able neurologic status or death at 90 days, we identified 
2 studies on SSEPs or EEG (102 patients; very-low-quality 
evidence downgraded for very serious bias and very serious 
imprecision).302,319
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified 6 stud-
ies on SSEPs or EEG (733 patients; very-low-quality evidence 
downgraded for serious or very serious bias and serious or 
very serious imprecision).271,303,320–323
For the critical outcome of survival with unfavorable 
neurologic status or death at 1 year, we identified 6 stud-
ies on SSEPs or EEG (829 patients; low- or very-low-quality 
evidence downgraded for serious or very serious bias and very 
serious imprecision).306,307,324–327
Short-Latency SSEPs. Bilateral absence of the N20 wave 
of short-latency SSEPs predicted death or vegetative state, 
with 0 (0–12)% FPR as early as 8 hours from cardiac arrest. 
An FPR of 0% was also confirmed at 24, 48, and 72 hours 
after ROSC (95% CIs from 0–3 to 0–9) with consistent sen-
sitivity (43%–46%). Among all patients in whom N20 SSEP 
wave was absent in the first 7 days from cardiac arrest, 
there was only 1 case of false-positive result.302 Quality 
of evidence was very low in all but 1 study, downgraded 
for serious or very serious bias and serious or very serious 
imprecision.
Studies assessing the predictive value of a delayed or 
absent N70 SSEP from 24 hours to 72 hours after ROSC 
reported a false-positive prediction from 1 (0–7)% to 58 (28–
85)%302,306,320,321,324 (5 studies, 657 subjects; very-low-quality 
evidence downgraded for serious or very serious bias and seri-
ous or very serious imprecision).
Blinding of SSEP results, along with criteria for with-
drawal of life-sustaining treatment, was not reported in most 
prognostication studies in resuscitated patients who were not 
treated with TTM.
Electroencephalography. In 1 study303 (26 patients; very-low-
quality evidence downgraded for serious bias and very serious 
imprecision), an EEG grade 3 to 5 at 24 and 48 hours predicted 
poor outcome (CPC 3–5), with 0% FPR (95% CIs, 0–22 and 
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0–24, respectively). An EEG grade 4 to 5 at 72 hours or less 
from ROSC predicted poor outcome, with 0 (0–11)% FPR 
and 44 (34–54)% sensitivity307,313,315 (3 studies, 125 patients; 
very-low-quality evidence downgraded for very serious bias 
and very serious imprecision). EEG grading systems were not 
consistent among studies.
Presence of burst suppression within 48 hours from 
ROSC was compatible with recovery of consciousness (FPR 
5 [0–26]%302; 1 study, 72 patients; very-low-quality evidence 
downgraded for very serious bias and very serious impreci-
sion), while a burst suppression at 72 hours from ROSC pre-
dicted poor outcome, with 0 (0–11)% FPR306 (1 study, 277 
patients; very-low-quality evidence downgraded for very seri-
ous bias and very serious imprecision).
A low-voltage EEG (20–21 mcV or less) predicted a poor 
outcome, with 0 (0–15)% FPR within 48 hours from ROSC302 
(1 study, 72 patients; very-low-quality evidence downgraded 
for very serious bias and very serious imprecision) and with 0 
(0–11)% FPR at 72 hours from ROSC306 (1 study, 283 patients; 
very-low-quality evidence downgraded for very serious bias 
and very serious imprecision). Sensitivity was 15 (7–28)% 
and 31 (25–37)%, respectively.
Presence of alpha coma within 72 hours or from 1 to 7 
days after ROSC was not consistently associated with poor 
outcome (positive predictive value, 96 [80–100]% and 88 [74–
96]%)303,312,314,318,325,326 (6 studies, 68 patients; very-low-quality 
evidence downgraded for very serious bias and very serious 
imprecision).
Blood Markers
In patients who are comatose after resuscitation from car-
diac arrest and who are not treated with TTM, high concen-
trations of biomarkers predict a poor outcome. Advantages 
of biomarkers over other predictors such as EEG and 
clinical examination include quantitative results and likely 
independence from the effects of sedatives. However, the 
thresholds associated with 0% FPR vary between studies, 
and S100B thresholds are less well documented than NSE 
thresholds.
The main reasons for the observed variability in biomark-
ers’ thresholds include the use of heterogeneous measurement 
techniques,274–276 the presence of extraneuronal sources of bio-
markers (hemolysis and neuroendocrine tumors for NSE,277 
muscle and adipose tissue breakdown for S100B),278 and the 
incomplete knowledge of the kinetics of their blood concen-
trations in the first few days after ROSC.
For the critical outcome of survival with unfavorable 
neurologic status or death at discharge, we identified 2 
studies on S100B (99 patients; low- or very-low-quality evi-
dence downgraded for very serious bias and/or very serious 
imprecision)328,329 and 1 study on NSE (73 patients; very-low-
quality evidence downgraded for serious bias and very serious 
imprecision).280
For the critical outcome of survival with unfavor-
able neurologic status or death at 90 days, we identified 
1 study on NSE (32 patients; very-low-quality evidence 
downgraded for very serious bias and very serious impreci-
sion)248 and 1 study on S100B (27 patients; very-low-quality 
evidence downgraded for very serious bias and very serious 
imprecision).319
For the critical outcome of survival with unfavorable 
neurologic status or death at 180 days, we identified 3 
studies on NSE or S100B (618 patients; moderate-, low-, or 
very-low-quality evidence downgraded for serious bias and/or 
serious or very serious imprecision).285,323,330
For the critical outcome of survival with unfavorable 
neurologic status or death at 1 year, we identified 2 stud-
ies on NSE or S100B (86 patients; very-low-quality evi-
dence downgraded for very serious bias and very serious 
imprecision).331,332
Neuron-Specific Enolase. In resuscitated patients with poor 
neurologic outcome, the blood levels of NSE are higher than 
those in patients with good neurologic outcome. However, the 
threshold for prediction of poor outcome with 0% FPR varied 
between 13.3 and 47.6 mcg/L at 24 hours from ROSC285,306,319 
(3 studies, 332 patients; very-low-quality evidence), between 
8.8 and 65 mcg/L at 48 hours285,319,330,331 (4 studies, 277 patients; 
moderate- to very-low-quality evidence), and between 15 and 
90.9 mcg/L at 72 hours280,319,331 (3 studies, 301 patients; low- or 
very-low-quality evidence).
S100B. For S100B, the documented thresholds for 0% 
FPR ranged between 0.19 and 5.2 mcg/L at 24 hours after 
ROSC285,319 (2 studies, total 60 patients; very-low-quality evi-
dence) and between 0.12 and 0.8 mcg/L at 48 hours285,319,329,331 
(4 studies, 158 patients; very-low-quality evidence). In 1 
study (27 patients; very-low-quality evidence), the threshold 
for prediction of poor outcome with 0% FPR at 72 hours was 
0.5 mcg/L.
Imaging
All prognostication studies on imaging have a small sample 
size, and in all of them, imaging was performed at the discre-
tion of the treating physician, which may have caused a selec-
tion bias and overestimated the performance of index tests. 
Another limitation is that these methods depend partly on sub-
jective human decision in identifying the region of interest to 
be studied and in the interpretation of results.
 For the critical outcome of survival with unfavor-
able neurologic status or death at discharge, we iden-
tified 3 studies on CT (113 patients; very-low-quality 
evidence)294,333,334 and 2 studies on MRI (40 patients; very-
low-quality evidence).316,335 For the critical outcome of sur-
vival with unfavorable neurologic status or death at 90 
days, we identified 2 studies on MRI (61 patients; low- or 
very-low-quality evidence).301,336 For the critical outcome of 
survival with unfavorable neurologic status or death at 
180 days, we identified 3 studies on MRI (34 patients; very-
low-quality evidence).292,293,337
CT Scan. The main CT finding of global anoxic-ischemic 
cerebral insult after cardiac arrest is cerebral edema,294 which 
appears as a reduction in the depth of cerebral sulci (sulcal 
effacement) and an attenuation of the GM/WM interface, due 
to a decreased density of the GM. This attenuation has been 
quantitatively measured as the GWR between the GM and the 
WM densities.
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In 2 studies333,334 (total 60 patients; very-low-quality evi-
dence), a GWR between the caudate nucleus and the posterior 
limb of internal capsule (CN/PIC) below 1.22 within 24 hours 
or below 1.18 within 48 hours from ROSC predicted poor out-
come, with 0 (0–28)% and 17 (0–64)% FPR, respectively. At 
72 hours from ROSC, the presence of diffuse brain swelling 
on CT predicts a poor outcome, with 0 (0–45)% FPR and 52 
(37–67)% sensitivity294 (1 study, 53 patients; very-low-quality 
evidence).
MRI. The main MRI finding of anoxic-ischemic cerebral 
injury is a hyperintensity in DWI sequences due to cytotoxic 
edema. In a small study subpopulation292 (12 patients; very-
low-quality evidence), presence of diffuse DWI abnormalities 
in cortex or brainstem at a median of 80 hours from ROSC 
predicted poor outcome, with 0 (0–35)% FPR. In another 
small study337 (12 patients; very-low-quality evidence), pres-
ence of extensive (cortex, basal ganglia, and cerebellum) DWI 
changes predicted poor outcome, with 0 (0–45)% FPR.
Postischemic DWI abnormalities can be quantified 
by using ADC. ADC values between 700 and 800×10−6 
mm2/s are considered normal.335 In 1 study338 (80 patients; 
very-low-quality evidence), a whole-brain ADC less than 
665×10−6 mm2/s predicted poor outcome, with 0 (0–21)% 
FPR and 40 (28–53)% sensitivity. In a small subset of 
another study293 (10 patients; very-low-quality evidence), 
presence of more than 10% of brain volume with ADC 
less than 650×10−6 mm2/s predicted poor outcome, with 
88 (47–100)% sensitivity and 0 (0–78)% FPR. In another 
study, an ADC below various thresholds at the level of 
putamen, thalamus, or occipital cortex at less than 120 
hours from ROSC also predicted poor outcome, with 0 
(0–31)% FPR. Finally, in 2 studies301,335 (total 24 patients; 
very-low-quality evidence), the presence of extensive cor-
tical global DWI or fluid-attenuated inversion recovery 
changes within 7 days from arrest predicted poor outcome, 
with 0 (0–78)% FPR.
Treatment Recommendations
Clinical Examination
We recommend using the absence of PLR (or the combined 
absence of both pupillary and corneal reflexes) at 72 hours or 
greater from ROSC to predict poor outcome in patients who 
are comatose after resuscitation from cardiac arrest and who 
are not treated with TTM (strong recommendation, very-low-
quality evidence).
We suggest against using an absent or extensor motor 
response to pain (M≤2) alone to predict poor outcome, given 
its high FPR (weak recommendation, very-low-quality evi-
dence). However, due to its high sensitivity, this sign may be 
used to identify the population with poor neurologic status 
needing prognostication or to predict poor outcome in combi-
nation with other more-robust predictors.
We suggest using the presence of myoclonus or status 
myoclonus within 72 hours from ROSC in combination with 
other predictors to predict poor outcome in comatose survi-
vors of cardiac arrest (weak recommendation, very-low-qual-
ity evidence).
We suggest prolonging the observation of clinical signs 
when interference from residual sedation or paralysis is 
suspected, so that the possibility of obtaining false-positive 
results is minimized (weak recommendation, very-low-qual-
ity evidence).
Electrophysiology
We recommend using bilateral absence of the N20 SSEP 
wave within 72 hours from ROSC to predict poor outcome 
in patients who are comatose after cardiac arrest and who are 
not treated with TTM (strong recommendation, very-low-
quality evidence). SSEP recording requires appropriate skills 
and experience, and utmost care should be taken to avoid 
electrical interference from muscle artifacts or from the ICU 
environment.
We suggest using the presence of burst suppression on 
EEG at 72 hours from ROSC in combination with other pre-
dictors for prognosticating a poor neurologic outcome in 
patients who are comatose after cardiac arrest and who are not 
treated with TTM (strong recommendation, very-low-quality 
evidence).
We suggest against using EEG grades for prognostication 
due to the inconsistencies in their definitions (weak recom-
mendation, very-low-quality evidence).
We suggest against using low-voltage EEG for prognos-
tication, given the potential interferences of technical factors 
on EEG amplitude (weak recommendation, very-low-quality 
evidence).
Blood Markers
We suggest using high serum values of NSE at 24 to 72 
hours from ROSC in combination with other predictors for 
prognosticating a poor neurologic outcome in patients who 
are comatose after cardiac arrest and who are treated with 
therapeutic hypothermia (weak recommendation, very-low-
quality evidence). However, no threshold-enabling predic-
tion with 0 FPR can be recommended. We suggest using 
utmost care and preferably sampling at multiple time points 
when assessing NSE, to avoid false-positive results due to 
hemolysis.
Imaging
We suggest using the presence of a marked reduction of the 
GM/WM ratio on brain CT within 48 hours after ROSC or the 
presence of extensive reduction in diffusion on brain MRI at 
2 to 6 days after ROSC only in combination with other more-
established predictors for prognosticating a poor neurologic 
outcome in patients who are comatose after resuscitation from 
cardiac arrest and who are not treated with TTM (weak rec-
ommendation, very-low-quality evidence).
We suggest using brain-imaging studies for prognostica-
tion only in centers where specific experience is available 
(weak recommendation, very-low-quality evidence).
Knowledge Gaps
Clinical Examination
•	 Prospective studies are needed to investigate the pharma-
cokinetics of sedative drugs and neuromuscular blocking 
drugs in post–cardiac arrest patients, independently from 
treatment with TTM.
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•	 Clinical studies are needed to evaluate the reproducibil-
ity of clinical signs used to predict outcome in comatose 
postarrest patients.
•	 There is no universally accepted definition of status 
myoclonus. A recently proposed definition suggests 
using the term status myoclonus to indicate a continuous 
and generalized myoclonus persisting for 30 minutes or 
more in comatose survivors of cardiac arrest.
Electrophysiology
•	 Blinded studies on SSEPs are needed to assess the rel-
evance of self-fulfilling prophecy for this predictor.
•	 The definitions of low-voltage EEG and burst suppres-
sion, and the EEG grades are inconsistent among prog-
nostication studies. Future studies should comply with 
recently recommended definitions.
Blood Markers
•	 There is a need for standardization of the measuring 
techniques for NSE and S100 in cardiac arrest patients.
•	 Little information is available on the kinetics of the 
blood concentrations of biomarkers in the first few days 
after cardiac arrest.
Imaging
•	 Prospective studies in unselected patient populations and 
including evaluation of inter-rater agreement are needed 
to determine the prognostic accuracy of imaging studies 
in comatose patients resuscitated from cardiac arrest.
2010 CoSTR Topics Not Reviewed in 2015
•	 Postresuscitation hemofiltration
•	 IV fluids following cardiac arrest
•	 Neuroprotective drugs
•	 Postresuscitation treatment protocol
Organ Donation (ALS 449)
In adults and children who are receiving an organ transplant 
in any setting (P), do organs retrieved from a donor who has 
had CPR (I), compared with organs retrieved from a donor 
who did not have CPR (C), have improved immediate graft 
function (30 days), 1-year graft function, or 5-year graft func-
tion (O)?
Introduction
Resuscitation from cardiac arrest is not always successful, 
and many patients who are initially resuscitated from cardiac 
arrest will subsequently die in the hospital. Whether these 
nonsurviving patients can become organ donors has been 
debated because of the potential injury to organs during the 
initial cardiac arrest.
The committee reviewed experience about donation from 
this population that has accumulated in recent years. Two situ-
ations were separately considered. In the first, an individual 
who dies after being resuscitated by successful CPR may 
become an organ donor after brain death or having withdrawal 
of life-sustaining treatment. In the second situation, an indi-
vidual may die because of unsuccessful CPR in a center with 
a rapid response system that allows procurement of organs 
after unsuccessful CPR. For kidney transplants, the primary 
outcomes were graft function, because recipients can survive 
with renal replacement therapy even with graft failure. For 
other organs, recipient death was considered equivalent to 
graft failure. Only studies that allowed comparison of organs 
procured in these situations with other organs from non-CPR 
donors were selected for review.
Consensus on Science
Donors With Prior CPR
Two nonrandomized studies provided low-quality evi-
dence that the mean yield of organs procured from donors 
who had been resuscitated by CPR before donation was 
3.9339 or 2.9.340
For the important outcome of immediate graft sur-
vival, low-quality evidence from nonrandomized studies 
did not detect any worse outcome when donors have had 
CPR and resuscitation for adult hearts (3239 organs340–347), 
pediatric hearts (557 organs, 4 studies), adult lungs (1031 
organs340,345,348), pediatric lungs (105 organs340), adult kidneys 
(5000 organs340,349), pediatric kidneys (1122 organs340,350), adult 
livers (2911 organs340,341), pediatric livers (689 organs340,350), 
adult intestines (25 organs340,351), and pediatric intestines (79 
organs340).
For the important outcome of graft survival for 1 year, 
low-quality evidence from nonrandomized studies did not 
detect any worse outcome when donors have had CPR and 
resuscitation for adult hearts (3230 organs340–342,344–347), pedi-
atric hearts (1605 organs340,350,352,353), adult lungs (1031 
organs340,345,348), pediatric lungs (105 organs340), adult kidneys 
(5000 organs340,341), pediatric kidneys (1122 organs340), adult 
livers (2911 organs340,341), pediatric livers (689 organs340), 
adult intestines (25 organs340,351), and pediatric intestines (79 
organs340).
For the important outcome of graft survival for 5 years, 
low-quality evidence from nonrandomized studies did not 
detect any worse outcome when donors have had CPR and 
resuscitation for adult hearts (3230 organs340–342,344–347), 
pediatric hearts (1537 organs340,353,354), adult lungs (1031 
organs340,345,348), pediatric lungs (105 organs340), adult kidneys 
(5000 organs340,341), pediatric kidneys (1122 organs340), adult 
livers (2911 organs340,341), pediatric livers (689 organs340), 
adult intestines (25 organs340), and pediatric intestines (79 
organs340).
Donors With Ongoing CPR (Uncontrolled Non–Heart-
Beating Donors or Uncontrolled Donation After Circulatory 
Death)
Two nonrandomized studies provided low-quality evidence 
that the mean number of organs procured from donors with 
ongoing CPR was 1.5355 and 3.2.356
For the important outcome of immediate graft survival, 
low-quality evidence from nonrandomized studies did not 
detect any worse outcome when organs were recovered from 
non–heart-beating donors with ongoing CPR compared with 
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other types of donors for adult kidneys (203 organs357–360) or 
adult livers (64 organs355,358,361,362).
For the important outcome of graft survival for 1 year, 
low-quality evidence from nonrandomized studies did not 
detect any worse outcome when organs were recovered from 
non–heart-beating donors with ongoing CPR compared with 
other types of donors for adult kidneys (199 organs357,358,360) or 
adult livers (60 organs355,358,361).
For the important outcome of graft survival for 5 years, 
low-quality evidence from nonrandomized studies did not 
detect any worse outcome when organs were recovered from 
non–heart-beating donors with ongoing CPR compared with 
other types of donors for adult kidneys (177 organs357,360) or 
adult livers (34 organs355).
Treatment Recommendation
We recommend that all patients who have restoration of cir-
culation after CPR and who subsequently progress to death be 
evaluated for organ donation (strong recommendation, low-
quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we consider the absence of 
any evidence of worse graft function from donors with ante-
cedent CPR, the desirability of providing more organs to 
waiting recipients, and the absence of any risk to the donor. 
As in all organ donations, the function of the donated organ 
determines whether procurement and transplantation proceed. 
Therefore, there is also precaution to ensure the safety of the 
recipient.
Treatment Recommendation
We suggest that patients who fail to have restoration of circu-
lation after CPR and who would otherwise have termination 
of CPR efforts be considered candidates for kidney or liver 
donation in settings where programs exist (weak recommen-
dation, low-quality evidence).
Values, Preferences, and Task Force Insights
In making this recommendation, we consider the evidence 
that kidney grafts obtained from donors in whom CPR failed 
can function at rates comparable to kidneys obtained from 
other donors, and that recipients can safely tolerate delayed 
graft function that is common with kidneys obtained in this 
manner. We also consider the immediate lifesaving potential 
of liver grafts, which offsets the potentially greater rate of 
long-term graft failure in livers obtained from donors with 
ongoing CPR.
Knowledge Gaps
•	 The optimal methods for organ procurement after failed 
CPR are unknown.
•	 Barriers to consenting to this organ donation and the 
acceptability of these practices in different settings are 
unknown.
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Registry and Outcomes (CAIRO) 
Programme. 2013 - 2015†; 
NIHR Programme Development 
Grant (RP-DG-0612-10004) 
Improving Outcomes from Out 
of Hospital Cardiac Arrest NIHR 
Health Technology Assessment 
Programme Grant (HTA - 
12/127/126) for a randomised 
placebo controlled trial of adrenaline 
for out of hospital cardiac 
arrest*; NIHR Health Technology 
Assessment Programme Grant 
(HTA-12/167/102) for a randomised 
trial of the effectiveness of a supra-
glottic airway device versus tracheal 
intubation in the initial airway 
management of out of hospital 
cardiac arrest (AIRWAYS-2)*
None None None None None None
Kazuo Okada Resuscitation 
Council of Asia
None None None None None None None
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Brian J. O’Neil Wayne State 
University
Zoll Circulation* None None None None Bristol 
Meyers 
Squibb*
None
Edison F. Paiva Hospital das 
Clinicas
None None None None None None None
Michael J. Parr Liverpool Hospital None None None None None None None
Tzong-Luen 
Wang
Shin-Kong Wu 
Ho-Su Memorial 
Hospital
None None None None None None None
Jonathan Witt Medical Minds None None None None None None None
Consultants
Michael W. 
Donnino
Beth Israel 
Deaconess Med 
Center
American Heart Association† None None None None American 
Heart 
Association†
None
Peter T. Morley University of 
Melbourne Clinical 
School, Royal 
Melbourne Hospital
None None None None None American 
Heart 
Association†
None
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the 
Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person 
receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the 
entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*Modest.
†Significant.
CoSTR Part 4: PICO Appendix
Part Task Force PICO ID Short Title PICO Question Evidence Reviewers
Part 4 ALS ALS 428 Antiarrhythmic drugs for 
cardiac arrest
Among adults who are in cardiac arrest in any setting (P), 
does administration of antiarrhythmic drugs (eg, amiodarone, 
lidocaine, other) (I), compared with not using antiarrhythmic 
drugs (no drug or placebo) (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 30 
days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Katie Dainty, Thomas Pellis, Steve 
Lin
Part 4 ALS ALS 431 Postresuscitation Seizure 
Prophylaxis
Among adults with ROSC after cardiac arrest in any 
setting (P), does seizure prophylaxis (I), compared with 
no prophylaxis (C), reduce the incidence of seizures, or 
improve survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year (O)?
Romergryko Geocadin, William 
Stacey
Part 4 ALS ALS 433 Steroids for Cardiac Arrest Among adults who are in cardiac arrest in any setting (P), 
does corticosteroid or mineralocorticoid administration 
during CPR (I), compared with not using steroids (C), 
change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Sarah Todhunter,
Tonia Nicholson
Part 4 ALS ALS 435 Cardiac Arrest Associated 
with Pulmonary Embolism
Among adults who are in cardiac arrest due to PE 
or suspected PE in any setting (P), does any specific 
alteration in treatment algorithm (eg, fibrinolytics, or any 
other) (I), compared with standard care (according to 2010 
treatment algorithm) (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Wolfgang Wetsch, Bernd Böttiger
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Part 4 ALS ALS 436 Cardiac Arrest  
during Pregnancy
Among pregnant women who are in cardiac arrest in any 
setting (P), do any specific interventions (I), compared 
with standard care (usual resuscitation practice) (C), 
change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Carolyn Zelop, Jill Mhyre
Part 4 ALS ALS 441 Opioid toxicity Among adults who are in cardiac arrest or respiratory 
arrest due to opioid toxicity in any setting (P), does 
any specific therapy (eg, naloxone, bicarbonate, or 
other drugs) (I), compared with usual ALS (C), change 
survival with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; ROSC (O)?
Allan Mottram, Fred Severyn, 
Mohammed Alhelail
Part 4 ALS ALS 448 Oxygen dose after  
ROSC in adults
Among adults who have ROSC after cardiac arrest in 
any setting (P), does an inspired oxygen concentration 
titrated to oxygenation (normal oxygen saturation or 
partial pressure of oxygen) (I), compared with the use of 
100% inspired oxygen concentration (C), change survival 
to 30 days with good neurologic outcome, survival 
to hospital discharge with good neurologic outcome, 
improve survival, survival to 30 days, survival to hospital 
discharge (O)?
Jasmeet Soar, Michael Donnino
Part 4 ALS ALS 449 Organ donation In adults and children who are receiving an organ 
transplant in any setting (P), do organs retrieved from 
a donor who has had CPR (I), compared with organs 
retrieved from a donor who did not have CPR (C), have 
improved immediate graft function (30 days), 1-year graft 
function, or 5-year graft function (O)?
Stephen West, Clifton Callaway
Part 4 ALS ALS 450 Prognostication in 
Comatose Patients 
Treated with Hypothermic 
TTM
Among adults with ROSC who are treated with 
hypothermia (P), does any clinical variable when 
abnormal (eg, clinical exam, EEG, somatosensory evoked 
potentials [SSEPs], imaging, other) (I), compared with any 
clinical variable when normal (C), reliably predict death or 
poor neurologic outcome at discharge, 30 days, 60 days, 
180 days, and/or 1 year; death only at discharge, 30 
days, 60 days, 180 days, and/or 1 year (O)?
Claudio Sandroni, Eyal Golan
Part 4 ALS ALS 459 ETCO2 to predict outcome 
of cardiac arrest
Among adults who are in cardiac arrest in any setting (P), 
does any ETCO2 level value, when present (I), compared 
with any ETCO2 level below that value (C), change 
survival with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; ROSC (O)?
Brian O’Neil, Edison Paiva
Part 4 ALS ALS 469 Confirmation of Correct 
Tracheal Tube Placement
Among adults who are in cardiac arrest, needing/with an 
advanced airway, in any setting (P), does use of devices 
(eg, 1. waveform capnography, 2. CO
2 detection device, 
3. esophageal detector device, or 4. tracheal ultrasound) 
(I), compared with not using devices (C), change 
placement of the ET tube between the vocal cords and 
the carina, success of intubation (O)?
Sarah Heikal, Markus Skrifvars
Part 4 ALS ALS 470 Defibrillation Strategies for 
Ventricular Fibrillation (VF) 
or Pulseless Ventricular 
Tachycardia (pVT)
Among adults who are in ventricular fibrillation or 
pulseless ventricular tachycardia in any setting (P), does 
any specific defibrillation strategy (eg, 1. energy dose, 
or 2. shock waveform) (I), compared with standard 
management (or other defibrillation strategy) (C), change 
Survival with Favorable neurological/functional outcome 
at discharge, 30 days, 60 days, 180 days and/or 1 year, 
Survival only at discharge, 30 days, 60 days, 180 days 
and/or 1 year, ROSC, termination of arrhythmia (O)?
Giuseppe Ristagno, Charles Deakin
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Part 4 ALS ALS 479 Cardiac Arrest During 
Coronary Catheterization
Among adults who have a cardiac arrest in the cardiac 
catheterization laboratory (P), does any special 
intervention or change in care (eg, catheterization 
during CPR, cardiopulmonary bypass, balloon pump, 
different timing of shocks) (I), compared with standard 
resuscitation care (eg, CPR, drugs, and shocks according 
to 2010 treatment algorithm) (C), change survival with 
favorable neurologic/functional outcome at discharge, 
30 days, 60 days, 180 days, and/or 1 year; survival only 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC (O)?
Ian Drennan, Peter Kudenchuk
Part 4 ALS ALS 493 Postresuscitation 
Antiarrhythmic Drugs
Among adults with ROSC after cardiac arrest in any 
setting (P), do prophylactic antiarrhythmic drugs given 
immediately after ROSC (I), compared with not giving 
antiarrhythmic drugs (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; development of cardiac 
arrest; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; recurrence of VF; incidence of 
arrhythmias (O)?
Thomas Pellis, Steve Lin
Part 4 ALS ALS 570 Postresuscitation 
Hemodynamic Support
Among adults with ROSC after cardiac arrest in any 
setting (P), does titration of therapy to achieve a specific 
hemodynamic goal (eg, MAP greater than 65 mm Hg) 
(I), compared with no hemodynamic goal (C), change 
survival with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival at discharge, 30 days, 60 days, 180 days, and/
or 1 year (O)?
Michael Fries, Michael Parr
Part 4 ALS ALS 571 Postresuscitation  
Ventilation Strategy
Among adults with ROSC after cardiac arrest in any 
setting (P), does ventilation to a specific Paco2 goal (I), 
compared with no specific strategy or a different Paco2 
goal (C), change survival at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year (O)?
Asger Granfeldt, Bo Lofgren
Part 4 ALS ALS 579 Impedance threshold  
device
Among adults who are in cardiac arrest in any setting 
(P), does use of an inspiratory ITD during CPR (I), 
compared with no ITD (C), change survival with 
favorable neurologic/functional outcome at discharge, 
30 days, 60 days, 180 days, and/or 1 year; survival 
only at discharge, 30 days, 60 days, 180 days, and/or 
1 year; ROSC (O)?
Peter Morley, Jasmeet Soar
Part 4 ALS ALS 580 Glucose Control After 
Resuscitation
Among adults with ROSC after cardiac arrest in any 
setting (P), does a specific target range for blood 
glucose management (eg, strict 4–6 mmol/L) (I), 
compared with any other target range (C), change 
survival with favorable neurologic/functional outcome 
at discharge, 30 days, 60 days, 180 days, and/or 1 
year; survival only at discharge, 30 days, 60 days, 180 
days, and/or 1 year (O)?
Janice Zimmerman, Jonathon 
Sullivan
Part 4 ALS ALS 656 Monitoring Physiological 
Parameters During CPR
Among adults who are in cardiac arrest in any setting 
(P), does the use of physiological feedback regarding 
CPR quality (eg, arterial lines, ETCO2 monitoring, Spo2 
waveforms, or others) (I), compared with no feedback 
(C), change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC; change in physiologic 
values by modifications in CPR (O)?
Amit Chopra, Natalie Wong
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Part 4 ALS ALS 658 Ultrasound during CPR Among adults who are in cardiac arrest in any setting 
(P), does use of ultrasound (including echocardiography 
or other organ assessments) during CPR (I), compared 
with conventional CPR and resuscitation without use of 
ultrasound (C), change survival with favorable neurologic/
functional outcome at discharge, 30 days, 60 days, 180 
days, and/or 1 year; survival only at discharge, 30 days, 
60 days, 180 days, and/or 1 year; ROSC (O)?
Katherine Berg, Lars Wiuff 
Andersen
Part 4 ALS ALS 659 Epinephrine Versus 
Vasopressin
Among adults who are in cardiac arrest in any setting (P), 
does use of epinephrine (I), compared with vasopressin 
(C), change survival to 30 days with good neurologic 
outcome, survival to 30 days, survival to hospital 
discharge with good neurologic outcome, survival to 
hospital discharge, ROSC (O)?
Laurie Morrison, Clifton Callaway, 
Steve Lin
Part 4 ALS ALS 713 Prognostication in  
Absence of TTM
Among adults who are comatose after cardiac arrest and 
are not treated with TTM (P), does any clinical finding 
when normal (eg, clinical exam, EEG, SSEPs, imaging, 
other) (I), compared with any clinical finding when 
abnormal (C), reliably predict death or poor neurologic 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; death only at discharge, 30 days, 60 days, 180 
days, and/or 1 year (O)?
Claudio Sandroni, Tobias Cronberg
Part 4 ALS ALS 714 SGAs Versus Tracheal 
Intubation
Among adults who are in cardiac arrest in any setting (P), 
does SGA insertion as first advanced airway (I), compared 
with insertion of a tracheal tube as first advanced airway 
(C), change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; survival only at discharge, 30 days, 60 
days, 180 days, and/or 1 year; ROSC; CPR parameters; 
development of aspiration pneumonia (O)?
Jerry Nolan, Charles Deakin
Part 4 ALS ALS 723 ECPR Versus Manual or 
Mechanical CPR
Among adults who are in cardiac arrest in any 
setting (P), does the use of ECPR techniques 
(including extracorporeal membrane oxygenation or 
cardiopulmonary bypass) (I), compared with manual CPR 
or mechanical CPR (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Mayuki Aibiki, Tzong-Luen Wang
Part 4 ALS ALS 778 SDE Versus HDE In adult patients in cardiac arrest in any setting (P), 
does HDE (at least 0.2 mg/kg or 5 mg bolus dose) (I), 
compared with SDE (1 mg bolus dose) (C), change 
survival to 180 days with good neurologic outcome, 
survival to 180 days, survival to hospital discharge with 
good neurologic outcome, survival to hospital discharge, 
ROSC (O)?
Laurie Morrison, Clifton Callaway, 
Steve Lin
Part 4 ALS ALS 782 Mechanical CPR Devices Among adults who are in cardiac arrest in any setting (P), 
do automated mechanical chest compression devices 
(I), compared with standard manual chest compressions 
(C), change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Steven Brooks, Laurie Morrison
Part 4 ALS ALS 783 Basic Versus Advanced 
Airway
Among adults who are in cardiac arrest in any setting 
(P), does insertion of an advanced airway (tracheal tube 
or SGA) (I), compared with basic airway (bag-mask 
device with or without oropharyngeal airway) (C), change 
survival with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; ROSC; CPR parameters; development of 
aspiration pneumonia (O)?
Jerry Nolan, Jan-Thorsten Graesner
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Part 4 ALS ALS 784 Timing of  
Administration of 
Epinephrine
Among adults who are in cardiac arrest in any setting 
(P), does early epinephrine delivery by IV or IO route (eg, 
less than 10 minutes after the beginning of resuscitation) 
(I), compared with delayed timing of epinephrine 
delivery (eg, more than 10 minutes after the beginning 
of resuscitation) (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Tonia Nicholson, Michael Donnino
Part 4 ALS ALS 788 Epinephrine Versus  
Placebo
Among adults who are in cardiac arrest in any setting (P), 
does the use of epinephrine (I), compared with placebo or 
not using epinephrine (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year; ROSC (O)?
Laurie Morrison, Clifton Callaway, 
Steve Lin
Part 4 ALS ALS 789 Epinephrine Versus 
Vasopressin in 
Combination With 
Epinephrine
Among adults who are in cardiac arrest in any setting 
(P), does use of both vasopressin and epinephrine (I), 
compared with using epinephrine alone (C), change 
survival with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; ROSC (O)?
Clifton Callaway, Laurie Morrison, 
Steve Lin
Part 4 ALS ALS 790 Targeted Temperature 
Management
Among patients with ROSC after cardiac arrest in 
any setting (P), does inducing mild hypothermia 
(target temperature 32°C–34°C) (I), compared with 
normothermia (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year (O)?
Joshua Reynolds, Katherine Berg
Part 4 ALS ALS 791 Duration of TTM In patients with ROSC after cardiac arrest in any setting 
(P), does induction and maintenance of hypothermia 
for any duration other than 24 hours (I), compared 
with induction and maintenance of hypothermia for a 
duration of 24 hours (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year (O)?
Theodoros Xanthos, Lars Wiuff 
Andersen
Part 4 ALS ALS 802 Timing of Induced 
Hypothermia
Among patients with return of pulses after cardiac arrest 
in any setting (P), does induction of hypothermia before 
some time point (eg, 1 hour after ROSC or before hospital 
arrival) (I), compared with induction of hypothermia 
after that time point (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year (O)?
Theodoros Xanthos, Michael Cocchi
Part 4 ALS ALS 808 Ventilation rate during 
continuous chest 
compression
Among adults with cardiac arrest with a secure airway 
receiving chest compressions (in any setting, and with 
standard tidal volume) (P), does a ventilation rate of 10 
breaths/min (I), compared with any other ventilation rate 
(C), change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year; ROSC (O)?
Koen Monsieurs, Jasmeet Soar, 
Gino Vissers
Part 4 ALS ALS 834 Lipid Therapy for  
Cardiac Arrest
In adult patients with cardiac arrest due to suspected 
drug toxicity (eg, local anesthetics, tricyclic 
antidepressants, others) (P), does administration of IV 
lipid (I), compared with no IV lipid (C), change survival 
with favorable neurologic/functional outcome at 
discharge, 30 days, 60 days, 180 days, and/or 1 year; 
survival only at discharge, 30 days, 60 days, 180 days, 
and/or 1 year; ROSC (O)?
Eric Lavonas, Mohammed Alhelail
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Part 4 ALS ALS 868 Seizure Treatment Among adults with ROSC after cardiac arrest in any 
setting (P), does effective seizure treatment (I), compared 
with no seizure control (C), change survival with favorable 
neurologic/functional outcome at discharge, 30 days, 60 
days, 180 days, and/or 1 year; survival only at discharge, 
30 days, 60 days, 180 days, and/or 1 year (O)?
Romergryko Geocadin, William 
Stacey
Part 4 ALS ALS 879 Prevention of Fever  
After Cardiac Arrest
Among adults with ROSC after cardiac arrest in any 
setting (P), does prevention of fever to maintain strict 
normothermia (I), compared with no fever control (C), 
change survival with favorable neurologic/functional 
outcome at discharge, 30 days, 60 days, 180 days, and/
or 1 year; survival only at discharge, 30 days, 60 days, 
180 days, and/or 1 year (O)?
Katherine Berg, Lars Wiuff 
Andersen
Part 4 ALS ALS 889 Oxygen dose during CPR In adults with cardiac arrest in any setting (P), does 
administering a maximal oxygen concentration (eg, 100% 
by face mask or closed circuit) (I), compared with no 
supplementary oxygen (eg, 21%) or a reduced oxygen 
concentration (eg, 40%–50%) (C), change survival with 
favorable neurologic/functional outcome at discharge, 
30 days, 60 days, 180 days, and/or 1 year; survival only 
at discharge, 30 days, 60 days, 180 days, and/or 1 year; 
ROSC (O)?
Anthony Lagina, Jasmeet Soar
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